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Abstract 
 
Neuroblastoma is a paediatric cancer that arises from the sympathetic ganglia and adrenal 
medulla. Tumours with MYCN amplification have the worst prognosis, and make up around 
30% of neuroblastoma diagnoses. Neuroblastoma exhibits an unusually high propensity for 
spontaneous regression, which occurs most frequently in the youngest patients (under 18 
months of age), perhaps because developmental cues still present prompt belated 
differentiation of the tumour cells. This led to the hypothesis that factors from an appropriate 
embryonic environment may be capable of activating the correct molecular switches to 
encourage the differentiation and/or apoptosis of neuroblastoma cells, reprogramming the 
tumour to a benign phenotype. 
 
To test this hypothesis, EGFP-labelled MYCN-amplified Kelly cells were injected into the 
extra-embryonic vitelline veins of embryonic day 3 (E3) and E6 chick embryos, and the 
responses of injected cells were analysed at E10 and E14. Kelly cells injected at E3 respond 
to neural crest migratory cues and integrate into neural crest-derived tissues: some neural, 
notably the sympathetic ganglia and enteric nervous system, although never the adrenal 
gland; and others non-neural, such as the meninges and tail. Cells injected at E6 do not 
show such targeting, integrating into various tissues such as the liver, kidney and meninges. 
The cells respond to their respective microenvironments, and in sympathetic ganglia some 
cells differentiate, show reduced cell division, and crucially such cells have undetectable 
MYCN expression by E10. In non-neural locations, cells form more rapidly dividing clumps 
and continue to express MYCN. The downregulation of MYCN is dependent on continuous 
and direct interaction with the sympathetic ganglion environment.  
 
Kelly cells’ morphology, behaviour and gene expression are altered by the sympathetic 
ganglia microenvironment. Taking these key observations, we speculate that the Kelly cells’ 
MYCN amplicon may likely contain the required DNA regulatory sequences to enable MYCN 
expression to be altered in response to the embryonic environment. If the factors responsible 
for MYCN repression can be elucidated, they may represent effective new therapeutic 
targets. 
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1.1. Neuroblastoma: an introduction 
 
Neuroblastoma is a paediatric cancer of the sympathetic nervous system, with tumours 
primarily arising in the paravertebral sympathetic ganglia and, more commonly, in the 
adrenal glands (Brodeur 2003; Matthay 1997; Park, Eggert & Caron 2008)  (Figure 1.1). 
Metastasis is usually to the lymph nodes, bone, bone marrow, liver and/or skin (Brodeur et 
al. 1988). Affecting 7.5 in every 100,000 children (Schwab et al. 2003), neuroblastoma is the 
most common solid tumour outside of the cranium in children and accounts for around 15% 
of all paediatric oncology deaths (Maris et al. 2007). Patients are usually diagnosed before 
the age of 5 years (90% of all cases) (Schwab et al. 2003), but can, in rarer circumstances, 
present with the disease up to 14, or even occasionally up to 19 years of age. 
Neuroblastoma is almost unheard of in adults. In the vast majority of cases, neuroblastoma 
occurs sporadically, although in 1-2% of diagnoses, the disease is inherited (Shojaei-
Brosseau et al. 2004). Familial neuroblastoma is usually diagnosed at an earlier age, often 
within the child’s first year of life (Maris et al. 1997), and multiple primary tumours at 
diagnosis is a feature much more common in those with a genetic predisposition than in 
patients with sporadic disease. Hereditary neuroblastoma is often associated with mutations 
in the ALK and Phox2b genes, which, it is postulated, may prolong the process of 
sympathetic neurogenesis during embryonic development, thus increasing the window in 
which mutational events may likely occur (Bourdeaut et al. 2005; Mosse et al. 2008; Perri et 
al. 2005). 
 
Neuroblastoma is a peculiar disease with a diverse range of clinical behaviours, ranging 
from rapid malignant progression, complete with metastasis and extremely poor prognosis, 
to tumours that (occasionally) differentiate into benign ganglioneuroblastoma or 
ganglioneuroma (Maris et al. 2007). In addition, neuroblastoma has the highest rates of 
spontaneous regression of any human cancer (Castleberry 1997). However, even with an 
increasing wealth of research into the disease, medicine is still failing those deemed “high 
risk” patients, with survival often less than 40% (De Bernardi et al. 2003) (Figure 1.1). 
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Figure 1.1. Kaplan-Meier curve to show event-free survival of patients classed as low-, 
intermediate- or high-risk. Taken from Maris et al. 2007. 
 
 
1.2. The sympathetic nervous system 
 
The human body is controlled by its extensive networks of neurons which, via the brain, 
innervate skeletal muscles to facilitate movement, sense touch, pain and temperature, 
stimulate glands to emit their secretions, allow us to taste, smell and see, and keep viscera 
like the heart functioning efficiently – to name but a few of the nervous system’s numerous 
and wide-ranging functions. The network itself can be separated into various hierarchical 
subdivisions (Figure 1.2): principally the central nervous system (CNS), composed of the 
brain and spinal cord and arising from the embryonic neural tube; and the peripheral nervous 
system (PNS), which connects the brain and spinal cord to the limbs and organs, and is 
derived from the embryonic neural crest. The PNS itself can be split into the somatic nervous 
system, responsible for voluntary bodily movements, and the autonomic nervous system 
(ANS), which operates largely at a subconscious level to control visceral functions. The ANS 
can then be split into three subdivisions: the enteric (ENS), the parasympathetic, and the 
sympathetic nervous systems. The ENS controls digestion, by regulating movement, blood 
flow and secretions in the digestive system, and exists as two plexuses: the submucosal 
(more externally) and myenteric plexuses, located in the wall of the gastrointestinal tract 
(Sasselli, Pachnis & Burns 2012). The parasympathetic nervous system, in general, is 
associated with “rest and digest” functions, for example salivary gland secretion, constriction 
of the pupil, urination and defecation. Its preganglionic neurons come from cranial nerve 
nuclei III, VII, IX and X and the sacral segments of the spinal cord, and both pre- and post-
ganglionic neurons release the neurotransmitter acetylcholine (Le Douarin 1982). The 
sympathetic division of the ANS is composed of the sympathetic ganglia and the adrenal 
medullas (often referred to as modified sympathetic ganglia), and is associated with “fight or 
flight” responses, like increasing heart rate and contractional force, bronchiole dilation, 
induction of sweat secretion, and inhibition of peristalsis in the gut. Its effects are 
complimentary (often antagonistic) to those of the parasympathetic nervous system, for 
example it functions in pupil dilation, whereas the parasympathetic acts to constrict the 
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pupils. Sympathetic neurons arise from the thoracic and lumbar regions of the spinal cord. 
The preganglionic neurons synapse within the sympathetic chains, or in plexuses nearer to 
body organs, utilising the neurotransmitter acetylcholine. Postganglionic fibres’ mediator is 
noradrenaline (Langley & Grant 1999). 
 
 
 
 
Figure 1.2. Overview of the human nervous system, split into subdivisions. 
 
 
The segmentally-arranged sympathetic ganglia, as mentioned above, are the sites where 
preganglionic sympathetic neurons synapse and from which postganglionic neurons arise. 
They lie either side of the vertebral column, and are connected by bundles of longitudinal 
nerve fibres to form the bilateral sympathetic trunks/chains. 
 
The two bilateral adrenal glands that lie superior to the kidneys are composed of an outer 
collagenous capsule, which surrounds the cortex, derived from the embryonic intermediate 
mesoderm, and the inner neural-crest-derived medulla. It is the medullary cells that can 
develop into malignant neuroblastic cells (Castleberry 1997). It has been said that the 
adrenal medulla could be considered as “a modified sympathetic ganglion whose 
postganglionic neurons lost their processes during development and became secretory cells” 
(Junqueira et al. 1986). The adrenal medulla is the only organ to be stimulated by 
preganglionic sympathetic neurons, and in response secrete either adrenaline or, like 
postganglionic sympathetic neurons, noradrenaline, with the effect of increasing the 
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metabolic rate, raising blood pressure, and other functions associated with the fight or flight 
response of the sympathetic nervous system (Le Douarin 1982). 
 
Neuroblastoma tumours can appear at any point along the length of the sympathetic ganglia, 
although a more favourable disease outcome can be expected for those patients with 
tumours in the cervical or thoracic regions than those with tumours in the abdomen: it is not 
known why this is the case (Evans, Dangio & Randolph 1971). Overall, 65% of 
neuroblastomas occur in the abdomen, and of these, over half arise from the adrenal 
medulla (Maris et al. 2007). The adrenal glands are in fact the most common site for 
neuroblastoma masses, and prognosis for these tumours depends on a number of different 
factors (see “staging”). 
 
 
1.3. The neural crest 
 
Neuroblastoma develops from cells that would/do form the sympathetic ganglia and adrenal 
medulla, as well as the extra-adrenal paraganglia such as the organ of Zuckerkandl, 
therefore, like the aforementioned structures, can be said to originate from the embryonic 
neural crest. 
 
 
  
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
Jessen, K.R. & Mirsky, R. (2005) 'The origin and development of glial cells 
in peripheral nerves', Nature Reviews Neuroscience, vol. 6, no. 9, pp. 671-
682. [Box 1] 
 
 
Figure 1.3. Illustration of neural crest formation and migration. Taken from Jessen & Mirsky 
2005. 
 
 
Early in development, embryos undergo the process of neurulation, in which the 
neuroepithelial cells that constitute the neural plate invaginate to initially form the neural 
groove, and subsequently the neural tube, following fusion of the bilateral neural folds 
(Figure 1.3). The neural tube is the primordium of the central nervous system, and as such, 
will go on to form the brain and spinal cord. The neural crest is a group of neuroectodermal 
cells that detach from the crests of the neural folds during neural tube formation. They 
transiently exist as a multipotent subpopulation of cells that, according to the signals they 
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encounter from the neural tube, migrate in two waves through the embryo: the first “wave” of 
NCCs travel along a ventromedial route, and the second follow the dorsolateral pathway 
(Erickson & Goins 1995). The formerly multipotent neural crest cells’ gene expression 
changes as they advance through the mesoderm and their fate is progressively restricted, 
until they eventually undergo terminal differentiation and become the cellular components of 
structures including the melanocytes of the skin, the dorsal root ganglia, sensory nerves, the 
sympathetic, parasympathetic and enteric nervous systems, the meninges (pia and 
arachnoid maters), the great vessels of the heart, and many of the muscular and skeletal 
structures of the head (Moore & Persaud 2003). Temporo-spatial factors are extremely 
influential in the determining the fate of these multipotent cells. Their destiny depends on 
their location along the rostro-caudal axis of the embryo – for example, the craniofacial 
cartilage comes only from cranial neural crest cells, and only the trunk neural crest cells give 
rise to the autonomic nervous system (Le Douarin 1982). In addition, their timepoints of 
migration also determine their fate – in the trunk, the earliest migrating neural crest cells 
travel more ventrally to form structures such as the sympathetic ganglia, adrenal medulla 
and DRGs, whereas those that migrate in the “second wave”, 24 hours later than the first, 
form the melanocytes (Erickson, Duong & Tosney 1992; Weston & Butler 1966). Migration 
and hence cell fate seems to be a result of factors in the cells’ local environments rather 
something that is intrinsically pre-programmed into the cells. This can be demonstrated by 
experiments in which vagal crest cells that would not normally go on to form sympathetic 
neurons, do so when transplanted into the embryonic trunk region (Le Douarin 1982), and 
another in which neural crest cells from slightly older embryos (destined to migrate more 
dorsally) were transplanted into younger embryos, where they migrated both ventrally and 
dorsally (Weston & Butler 1966). An additional experiment of interest found that the first 
wave of migrating neural crest cells tended to “fill” the ventral neural crest target locations, 
so that the later-migrating cells were unable to do so – if early neural crest migration was 
halted shortly after delamination, the later-migrating cells would then target both ventral and 
dorsal locations (Baker et al. 1997). The overriding theme of the above investigations is that 
neural crest cells show a great deal of plasticity, in that they behave according to the 
environment they find themselves in. 
 
Since neuroblastoma is a malignancy of childhood, and not often an inherited condition, one 
can conclude that it arises from a defect within normal embryonic development and/or 
neonatal growth. If we look at the multitude of genes involved in the development of the 
sympathetic nervous system, and assess which of these may be implicated in the 
pathogenesis of neuroblastoma, we can further our understanding of the disease and 
identify potential therapeutic targets. 
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1.3.1. Genes involved in neural crest specification and delamination 
 
Prior to neurulation, cells of the ectoderm are susceptible to becoming either epidermal or 
neural. High levels of bone morphogenetic proteins (BMPs) specify an epidermal fate, 
whereas inhibition of BMP signalling (by molecules such as noggin, chordin and follistatin) 
induces a neural phenotype, via initiation of expression of Sox2, Zicr-1 and Zic3 transcription 
factors, which in turn induce expression of N-CAM and N-tubulin (Mizuseki et al. 1998; 
Wilson & Hemmatibrivanlou 1995). Intermediate levels of BMPs likely result in an “initial, 
weak specification of neural crest cell fate” with “additional signals from the adjacent non-
neural ectoderm, the underlying mesoderm, or both required to enhance and maintain this 
induction” (LaBonne & Bronner-Fraser 1998b). The expression of neural plate border 
specifier genes Zic1/3, Msx1/2 and Pax3/7, precede the activation of the downstream neural 
crest specifier genes: Snail (also termed Snail1), Slug (aka Snail2), AP-2, FoxD3, Sox9, 
Sox10 and c-Myc, that are transcribed in response to Wnt, FGF and Notch signalling (Aoki et 
al. 2003; Bellmeyer et al. 2003; LaBonne & Bronner-Fraser 1998b) (Figure 1.4). All neural 
crest specifier genes are expressed in both pre-migratory and migrating neural crest cells, 
and display extensive crossregulation/interdependence (Meulemans & Bronner-Fraser 
2004). 
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Figure 1.4. Representation of factors and processes involved in preparing neural crest cells 
for delamination, and subsequent migration.  Arrow represents increasing time. Taken from 
Morales, Barbas & Nieto 2005. 
 
 
1.3.2. Neural crest delamination and migration 
 
Overexpression experiments have shown that LSox5, Slug, AP-2 and FoxD3 are heavily 
involved in the delamination of neural crest cells (Meulemans & Bronner-Fraser 2004). In 
order to delaminate from the neural folds/neural tube, the neural crest cells must undergo 
changes both in their morphology and migratory potential (for example, via downregulation 
of N-cadherin) and accomplish an epithelial to mesenchymal transition (EMT) (Duband 
Chapter One: Introduction 
 
8 
 
2000). Sox9’s key function is thought to be in neural crest specification and cell survival, as 
well as interacting with Slug in inducing EMT, whereas FoxD3 has been shown to regulate 
changes in cell adhesion molecules in order to allow delamination to occur (Cheung et al. 
2005). N-cadherin and cadherin-6B are lost from NCCs, to be replaced by cadherin-7 which 
is permissive of cell migration (Akitaya & Bronnerfraser 1992; Nakagawa & Takeichi 1995). 
The transcription factor Id3 is thought to help segregate the neural crest cells, at the same 
time stabilising this population, ready to undergo EMT (Kee & Bronner-Fraser 2005). This 
transition “involves a profound reorganisation of the cytoskeleton that may be incompatible 
with a high rate of cell division” (Meulemans & Bronner-Fraser 2004), and hence Snail 
expression prevents the cells from progressing from G1 to S phase. During this cell cycle 
arrest, alterations in expression of proteins such as cadherins and Rho GTPases (which are 
targets of the neural crest specifiers) alter neural crest cell shape and adhesion, facilitating 
the process of delamination (Fukata & Kaibuchi 2001). Cell-cell adhesions must be broken, 
and interactions between NCCs and the extracellular matrix increased (Delannet & Duband 
1992). BMP signalling (BMP2 in the cranial neural crest and BMP4 in the trunk) is thought to 
be the key trigger for delamination, and its onset is controlled by a gradient of Noggin along 
the antero-posterior axis of the trunk (Sela-Donenfeld & Kalcheim 1999). BMP4 permits the 
G1/S transition to occur in a synchronous manner, which is essential for delamination, and 
this occurs through Wnt1 signalling, which upregulates cyclin D1 (Burstyn-Cohen et al. 
2004). Delamination occurs at the same stage as somite development, i.e. occurs next to the 
epithelial somites. The earliest migrating NCCs travel between the somite and neural tube, 
following the path of the intersomitic blood vessels, but after somitic dissociation into 
dermomyotome and sclerotome, NCCs are repelled from the intersomitic spaces by 
semaphorins, and attracted into the somites by CXCR4/CXCL12 signalling (Kulesa & 
Gammill 2010). They migrate along two major pathways: what will become the melanocytes 
migrate dorsolaterally on top of the dermomyotome, 24 hours later than the prospective 
sympathetic and enteric nervous systems, DRGs and glia, which migrate ventrally through 
the rostral sclerotome (Thiery, Duband & Delouvee 1982). Ephrins prevent the first wave of 
NCCs expressing Eph receptors from entering the dermomyotome and following the 
dorsolateral pathway, but later promote migration of the primitive melanocytes along this 
route by enhancing their adhesion to fibronectin (Meulemans & Bronner-Fraser 2004; 
Santiago & Erickson 2002). In addition, ephrins help guide migration of NCCs on the 
ventromedial pathway through the somites in a segmental manner, by producing both 
migration-promoting and -inhibitory effects, depending on the class of ephrins encountered 
(Krull et al. 1997; McLennan & Krull 2002). In addition to ephrins, semaphorins prevent the 
Neuropilin-expressing NCCs from entering the posterior half of the somites (Gammill et al. 
2006), and also restrict migration of the prospective DRG cells to a more dorsal position than 
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those NCCs destined for the sympathoadrenal lineage (Roffers-Agarwal & Gammill 2009). 
Prospective SA cells are drawn out of the somites by CXCR4/CXCL12 and 
ErbB2/Neuregulin signalling, and Neuropilin/Semaphorin repulsion from the surrounding 
tissues results in aggregation at the dorsal aorta (Kulesa & Gammill 2010). This aggregation 
is not segmental as may be expected; rather the NCCs disperse along the entire length of 
the dorsal aorta. The repulsive effects of ephrinB in the mesoderm, in addition to CXCL12 
attraction and N-cadherin-mediated adhesion, results in cell condensation, thus the 
formation of segmental ganglia (Kasemeier-Kulesa et al. 2006). 
 
In post-migratory neural crest cells, i.e. once cells have reached their respective targets and 
begun to differentiate, expression of the neural crest specifier genes Id, AP-2, Slug, Snail 
and FoxD3 is switched off. As a consequence, the cells’ migratory ability and multipotency is 
lost. However, Sox9, Sox10 and LSox5, initially involved as neural crest specifiers, continue 
to be expressed and play a part in cell differentiation – Sox9 in the formation of cartilage, 
Sox10 in the differentiation of enteric neurons, melanocytes and glia, and LSox5 also in glial 
differentiation (Meulemans & Bronner-Fraser 2004). 
 
There are a multitude of genes implicated in all of the processes involved in neural crest 
development, and rather than a linear hierarchy of events, they all interact in a complex 
network to illicit sometimes multiple, often different, but nevertheless coordinated functions. 
 
 
1.3.3. Migration and early differentiation of trunk neural crest cells, destined to 
become structures of the sympathetic nervous system 
 
The sympathetic ganglia and adrenal chromaffin cells arise from the neural crest cells caudal 
to somite 5. Although their catecholaminergic phenotype, as indicated by tyrosine 
hydroxylase (TH) expression, is not apparent until they reach the vicinity of the dorsal aorta 
(around embryonic day 2.5 in the chick), the signals they encounter during their ventral 
migration, from the somites, ventral neural tube and notochord, are important for this 
adrenergic induction (Reissmann et al. 1996). The significance of the ventral neural tube and 
notochord, raises the possibility that sonic hedgehog (Shh) may be involved. However, it is 
only next to the dorsal aorta that cells begin to differentiate, and Reissmann et al. (1996) 
concluded that BMP-4 and BMP-7 from this structure were the most critical proteins for 
adrenergic differentiation. Therefore it can be said that the neural crest cells aggregate at the 
dorsal aorta to form the primary sympathetic ganglia, and in response to the BMPs 
expressed by the dorsal aorta, the cells begin to undergo neuronal and catecholaminergic 
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differentiation (Huber 2006). However, BMP signalling is also essential for differentiation of 
other neural crest derivatives, such as parasympathetic neurons, therefore other factors may 
be additionally required for specification of the sympathoadrenal lineage. One such factor, 
the EGF-like growth factor neuregulin-1, in conjunction with its tyrosine kinase receptor 
ErbB3 (which is expressed on the surface of migrating neural crest cells), is extremely 
important in migration of the neural crest cells to the mesenchyme lateral to the dorsal aorta 
(Britsch et al. 1998). Mutations in the genes of either of these proteins result in a lack of 
neural crest cells finding their way to the primary sympathetic ganglia, hence hypoplasia of 
the resultant sympathetic chain and absence of the adrenal medulla (Britsch et al. 1998). 
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Figure 1.5. A) depicts the migration of trunk neural crest cells from their origin dorsal to the 
neural tube (nt), past the notochord (no), to aggregate next to the dorsal aorta (da), where 
they form the primary sympathetic ganglia (sgp). Following BMP signalling, the cells the 
separate into the nascent sympathetic ganglia (sg) and adrenal gland (ag). B) Shows the 
genes involved in the progression from a neural crest cell into a sympathoadrenal (SA) cell. 
Taken from Huber 2006. 
 
 
1.3.4. Differentiation of neural crest sympathetic precursors 
 
Neuroblastoma may arise from impaired sympathoadrenal differentiation that results in a 
pool of rapidly proliferating cells susceptible to mutations and malignant transformation. 
Therefore an understanding of the key factors involved in normal sympathetic development 
may help determine causes of neuroblastoma pathogenesis. 
 
 
1.3.4.1. MASH-1 
 
Achaete-Scute homolog-1 (MASH-1 in rodents, hASH-1 in humans, and CASH-1 in chicks, 
but termed ‘MASH-1’ here for simplicity) is the first marker specifying a neural fate 
expressed upon the neural crest cells’ arrival at the dorsal aorta (HH stage 15 in the chick). It 
is a basic helix-loop-helix transcription factor that is essential for the proper development of 
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the autonomic nervous system and is transiently expressed in response to BMP2 signalling 
(LaBonne & Bronner-Fraser 1998a). However, high hASH-1 levels are seen in 
neuroblastoma tumours and cell lines (Soderholm et al. 1999). Phox2b, whose expression is 
also induced by BMPs, is critical for the maintenance of MASH-1 (Pattyn et al. 1999). 
MASH-1 activates Phox2a, and is necessary for gene expression of tyrosine hydroxylase 
(TH) and dopamine-β-hydroxylase (DBH), enzymes involved in the biosynthesis of 
noradrenaline (Hirsch et al. 1998). MASH-1 may also be required for the expression of 
neuronal proteins such as SCG10 and peripherin, but not for early SA proteins, as MASH-1 
inactivation had no effect on the expression of Phox2b, Hand2, c-Ret and neurofilament 
(Sommer et al. 1995). It has been concluded that MASH-1 promotes further development of 
early precursors that are already committed to a neuronal fate, allowing the transition into a 
mature sympathetic neuron or chromaffin cell (Huber 2006). 
 
 
1.3.4.2. Phox2b 
 
Phox2b is a homeodomain protein expressed in all noradrenergic neurons, both in the 
central and peripheral nervous systems. Phox2b expression occurs as soon as the migrating 
neural crest cells aggregate on either side of the dorsal aorta, driving the NCCs along the 
pathway of sympathoadrenal differentiation. All autonomic ganglia fail to form properly and 
then degenerate in mice lacking Phox2b (Pattyn et al. 1999). It is therefore absolutely 
fundamental to the development of the autonomic nervous system, even more so than 
MASH-1, as in the absence of Phox2b the only autonomic marker expressed by the neural 
crest cells aggregated at the dorsal aorta is MASH-1 – Hand2, c-Ret and the neuronal 
protein neurofilament, which were not affected by a loss of MASH-1, are absent in this 
scenario. Even MASH-1 is downregulated prematurely, indicating its dependence on Phox2b 
for maintenance (Huber 2006). As well as being necessary for the maintenance of MASH-1, 
it is required for the expression of Ret, the receptor subunit for the glial-derived neurotrophic 
factor (GDNF), which is normally expressed in early aggregating sympathoblasts (Pattyn et 
al. 1999). Phox2b also induces expression of both TH and DBH, the two enzymes needed 
for the synthesis of noradrenaline, to the extent that they are absent in the sympathetic and 
enteric progenitors and in the adrenal medulla of mice lacking Phox2b (Pattyn et al. 1999). 
The Phox2b gene has been reported to be mutated in a small proportion of familial 
neuroblastomas, and mutated Phox2b is now known to predispose an individual to 
developing neuroblastoma (Raabe et al. 2008; Trochet et al. 2004). Mutated Phox2b can 
lead to increased proliferation and dedifferentiation of sympathoadrenal cells (Reiff et al. 
2010), both of which would contribute to malignant transformation. Phox2b mutations have 
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also been detected rarely in sporadic cases of neuroblastoma (van Limpt et al. 2004), but 
overexpression of both Phox2b and Phox2a is regularly observed in both primary tumours 
and cell lines (Longo et al. 2008). The Phox2 genes are involved in the Delta-Notch 
signalling pathway to regulate sympathetic neuroblast differentiation, therefore deregulation 
of said genes may lead to disruption of the differentiation pathway and eventually 
tumourigenesis (van Limpt et al. 2005). It has also been reported that MYCN, a potent 
oncogene for neuroblastoma, promotes proliferation of the Phox2b-expressing population of 
neuronal precursors during development, preventing their further development and leading 
to hyperplasia (Alam et al. 2009). 
 
 
In SA cells, the expression of MASH-1 and Phox2b is followed by Hand2 (dHAND), Phox2a 
and GATA2/3. 
 
 
1.3.4.3. Hand2 
 
This basic helix-loop-helix transcription factor’s expression proceeds (and is dependent on) 
Phox2b, yet precedes Phox2a, and in addition, is expressed independently of MASH-1. It is 
essential for both the proliferation of sympathetic neuron precursors and their noradrenergic 
differentiation – in Hand2 knockout embryos there is a much reduced number of sympathetic 
neurons, as well as a strong decrease in TH and DBH expression in those neurons that 
developed. Schmidt and colleagues reported that in post-mitotic differentiated sympathetic 
neurons, Hand2 is required for maintenance of the noradrenergic phenotype – this was the 
conclusion of experiments where knockdown of the gene had no effect on pan-neuronal 
genes such as SCG10, TUJ-1 and HuC, but dramatically reduced the expression of TH and 
DBH (Schmidt et al. 2009). Hand2 is routinely detected in neuroblastomas, regardless of 
stage, suggesting that in these tumours, sympathetic differentiation is blocked at a relatively 
early stage in development (Gestblom et al. 1999). 
 
 
1.3.4.4. Phox2a 
 
The Phox2a homeodomain transcription factor is closely related to Phox2b. Like Phox2b, it 
is expressed throughout the entire developing autonomic nervous system, although 
Phox2a’s expression occurs a little later, and it also is directly involved in the transcription of 
DBH and TH (Longo et al. 2008). However, Phox2a is much more dispensable for SA 
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differentiation: inactivation of this gene has no effect on the majority of autonomic structures, 
only on the parasympathetic ganglia of the head (Morin et al. 1997). MASH-1 and Phox2b, 
which are activated independently of each other in sympathoblasts, are both required for 
Phox2a expression (Hirsch et al. 1998; Pattyn et al. 1999). Like Phox2b, Phox2a is highly 
expressed in neuroblastomas (Longo et al. 2008). 
 
 
1.3.4.5. GATA2/3 
 
These zinc finger transcription factors are expressed after MASH-1, Phox2b, Hand2 and 
Phox2a, but before the expression of the noradrenergic enzymes TH and DBH (Tsarovina et 
al. 2004). They are required for the manifestation of noradrenergic traits: in the absence of 
embryonic GATA3, sympathetic ganglia lack TH and DBH (Lim et al. 2000); therefore a 
function in sympathetic differentiation is implied. Chromaffin cells from GATA3-null embryos 
also showed reduced levels of MASH-1, Hand2 and Phox2b, implying that feedback from 
GATA3 is required to maintain expression of supposed upstream transcription factors 
(Moriguchi et al. 2006). In neuroblastomas, GATA3 has been shown to induce expression of 
cyclin D1, a promoter of cell cycle progression (Molenaar et al. 2010). 
 
 
Although the five transcription factors detailed above are expressed in a somewhat 
sequential manner (MASH-1 before Phox2a and Hand2; Phox2b before Phox2a, Hand2 and 
Gata3), rather than functioning in a linear cascade, they form a cross-linking regulatory 
network, with the end result being sympathoadrenal cell formation. From their location in the 
primary sympathetic ganglia, the presumptive chromaffin cells then migrate to the adrenal 
gland anlagen, and the cells destined to become sympathetic neurons travel dorsally to the 
position of the secondary sympathetic ganglia “proper” (Le Douarin 1982) (Figure 1.5 A). 
Once in their final position, their gene expression will change accordingly as the cells 
differentiate further (Figure 1.6). 
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Figure 1.6. Diagram to illustrate the fundamental differences in protein markers between 
chromaffin cells and sympathetic neurons, both of which originate from sympathoadrenal 
precursor cells. Adapted from Huber (2006). 
 
 
1.3.4.6. Differentiated sympathoadrenal cell characteristics 
 
Sympathetic neurons and chromaffin cells are similar in their ability to synthesize, store, 
release, and take up catecholamines such as tyrosine hydroxylase and dopamine β-
hydroxylase, both of which are involved in the production of noradrenaline (Figure 1.7). 
However, the two cell types are distinct in their morphologies, with sympathetic neurons 
extending axons and dendrites, and expressing neuronal markers, whereas chromaffin cells’ 
early neuronal commitment is repressed, potentially by glucocorticoids (Schober, Krieglstein 
& Unsicker 2000). Chromaffin cells are named as such because of the large chromaffin 
granules they contain (Figure 1.6). In addition, a large proportion of chromaffin cells produce 
adrenaline (Huber, Kalcheim & Unsicker 2009). 
 
 
 
 
Figure 1.7. The adrenaline/noradrenaline synthesis pathway. Enzymes that catalyse each 
step are in italics. 
 
 
1.3.4.7. The Trk neurotrophin receptors 
 
The neurotrophin family of growth factors are heavily involved in the formation of a neuronal 
phenotype, and their effects are brought about via binding to their respective receptor 
tyrosine kinases. TrkA is the high affinity receptor for NGF, TrkB for BDNF and neurotrophin-
4/5 (NT-4/5), and TrkC for neurotrophin-3 (NT-3). P75 is a low affinity receptor, capable of 
binding all neurotrophin ligands (Barbacid 1994). In normal sympathetic neuron 
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development, TrkA/NGF supports the survival and differentiation of sympathetic neurons 
(Nakagawara 2005). TrkC/NT-3 is also thought to promote the survival of sympathetic 
neuroblasts, although it is not quite as critical as TrkA (Fagan et al. 1996). TrkB/BDNF is not 
known to be required for sympathetic neuron differentiation (Pahlman & Hoehner 1996). 
 
In normal development, TrkC is the first neurotrophin receptor to be expressed, in migratory 
neural crest cells following detection of insulin-like growth factors (IGFs) and bFGF 
(Pahlman & Hoehner 1996). Stimulation with NT-3 induces expression of TrkA and p75 after 
cell aggregation at the dorsal aorta (Pahlman & Hoehner 1996). Therefore although required 
for sympathetic neuron development, NGF does not initiate differentiation of sympathetic 
neurons, but enhances an already-initiated process (Hall & Ekanayake 1991). Within the 
primary sympathetic ganglia, two subpopulations of cells can be seen: early differentiating 
neurons that express TrkA along with TrkC, and sympathoblasts that will differentiate later 
that express TrkC and TrkB (Straub, Sholler & Nishi 2007). A further increase in TrkA 
expression is then seen to coincide with a reduction in TrkC (Fagan et al. 1996), and in 
addition, during normal development, all TrkB-expressing cells eventually differentiate into 
neurons. It appears that all SA precursors have the ability to differentiate into sympathetic 
neurons, but maybe those that settle near to the dorsal aorta experience a microenvironment 
rich in NGF, facilitative of neuronal differentiation, but those that migrate to the site of the 
prospective adrenal gland encounter an environment rich in glucocorticoids but lacking in 
NGF, therefore go on to adopt a chromaffin cell endocrine phenotype (Hall & Ekanayake 
1991). 
 
In culture, addition of BDNF to TrkB-positive sympathoblasts strongly promotes cell 
proliferation, although this is not the case in vivo where only 10-20% of TrkB+ cells 
incorporate BrdU, perhaps because endogenous BDNF does not reach the threshold 
required for massive proliferation (Straub, Sholler & Nishi 2007). Nevertheless, their results 
suggest a role in development for TrkB in expanding/maintaining the sympathoblast 
population, and that if TrkB downregulation is impaired during development, this may be a 
trigger for the development of neuroblastoma. 
 
High levels of TrkA are found in many neuroblastoma tumours with a good prognosis 
(Kogner et al. 1993), often those destined to undergo spontaneous regression – in cells with 
a single MYCN copy, the presence of NGF induces cells to mature into neurons, and in its 
absence, undergo apoptosis (Nakagawara 1998). This may suggest that regressive 
neuroblastomas originate from early sympathetic neurons that expressed TrkA (Straub, 
Sholler & Nishi 2007). Conversely, TrkA is downregulated in aggressive tumours, often 
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associated with MYCN amplification. TrkB, a marker of poor prognosis, is usually expressed 
along with its preferred ligands in MYCN amplified tumours, giving cells an added growth 
advantage (Nakagawara 2005). 
 
 
1.4. The MYCN oncogene 
 
In 1983, Schwab and colleagues published a paper detailing the discovery of multiple copies 
of the MYCN oncogene in various neuroblastoma cell lines and one primary tumour (Schwab 
et al. 1983). Since then, clinical analyses have identified amplification of the MYCN gene in 
around 25-30% of newly diagnosed patients’ tumours, which invariably results in high levels 
of the protein being expressed, and this has been shown to be associated with an 
aggressive phenotype and poor prognosis (Cohn & Tweddle 2004). The MYCN gene is 
found on chromosome 2p24, and this is where it remains as a single copy, even in MYCN-
amplified cells. The amplified copies of DNA are situated at an alternate locus – either as a 
homogeneously stained region (HSR) on a different chromosome (this varies from tumour to 
tumour), or as extra-chromosomal double minutes (DMs) (Corvi et al. 1994). 
 
The MYCN basic helix-loop-helix/leucine zipper (bHLH/Zip) protein is 60-63kD transcription 
factor, located in the nucleus, with a short half life of roughly 30 minutes (Ikegaki, Bukovsky 
& Kennett 1986). It was first identified owing to its similarity to c-Myc and amplification in 
neuroblastomas (Schwab et al. 1983). Incidentally, MYCN expression is associated with low 
levels of c-Myc. The normal expression of MYCN and c-Myc differs somewhat in terms of 
location – c-Myc is expressed in a variety of tissues at all stages of the cell cycle in dividing 
cells, whereas MYCN is restricted to the CNS, PNS, kidney, spleen and lungs during 
embryonic development (Thomas et al. 2004b; Zimmerman et al. 1986). 
 
 
1.4.1. MYCN in normal development 
 
In the embryo, MYCN is critical for neural crest-derived neuronal development. MYCN-
deficient mice show a massive reduction in the number of mature neurons present in the 
sympathetic and dorsal root ganglia (Sawai et al. 1993). During normal development, MYCN 
is initially expressed rather uniformly in nuclei of the entire neural crest cell population, but 
following ganglion colonisation, its expression is turned off in those cells destined to fulfil a 
glial fate, but retained in the cells undergoing neuronal differentiation (Wakamatsu et al. 
1997). MYCN expression is then turned off in PNS neurons by E14 in the chick. It is thought 
Chapter One: Introduction 
 
17 
 
that MYCN is required for the proliferation and expansion of the population of neuronal 
progenitors, but in neural progenitor cell sphere culture, removal of growth factors EGF and 
bFGF resulted in MYCN degradation, allowing cell cycle exit and differentiation (Knoepfler, 
Cheng & Eisenman 2002). High levels of endogenous MYCN can induce early ventral neural 
crest cell migration in vivo, as well as actively promoting neuronal differentiation 
(Wakamatsu et al. 1997). Since some early-migrating neural crest cells located to the spinal 
nerve cord and formed Schwann cells rather than neurons, they concluded that although it is 
likely that high MYCN expression drives neuronal differentiation, the final cell phenotype is 
“determined within the allowance of the microenvironment”. Within the sympathetic ganglia, 
BMPs from the dorsal aorta induce expression of MASH-1, and since MASH-1 null mutant 
mice fail to express any SA markers, it is entirely possible that sympathetic neuron 
differentiation is initiated by the cooperative action of MYCN and MASH-1. 
 
MYCN is a part of the Myc/Max/Mad/Mnt network of proteins that together regulate cell 
proliferation, differentiation and apoptosis (Grandori et al. 2000; Henriksson & Luscher 
1996). MYCN can act as a transcriptional enhancer by forming a heterodimer with Max, 
which binds to E-box sequences (CACGTG) in the promoter regions of target genes. There, 
the MYCN:Max complex executes its function via recruitment of histone acetyltransferase 
enzymes (Bouchard et al. 2001; McMahon, Wood & Cole 2000). This acetylation modifies 
chromatin in gene promoter regions and enhances transcription. Mad also dimerises with 
Max, reducing the amount of Max available for MYCN binding, as well as competing with the 
MYCN:Max complexes for the same promoter E-boxes (Nikiforov et al. 2003). Mad is an 
antagonist of MYCN and a negative regulator of cell growth, usually present in differentiated 
cells (Chin et al. 1995; Larsson et al. 1994). The Mad:Max heterodimers recruit histone 
deacetylases (HDACs) through the adaptor protein Sin3, resulting in transcriptional 
repression of many MYCN target genes such as TERT and Id2 (McMahon, Wood & Cole 
2000). Mnt is another MYCN transcriptional antagonist, expressed in differentiated, but also 
proliferating cells, where it heterodimerises with Max and represses MYCN target gene 
transcription (Hurlin, Queva & Eisenman 1997). In addition, MYCN:Miz1 heterodimers can 
also inhibit transcription (Eilers & Eisenman 2008). Mad and Mnt’s transcriptional repression 
of MYCN target genes is primarily due to chromatin remodelling (Alland et al. 1997; Wolffe 
1997). The relative levels of Myc versus Mad may well determine whether a cell undergoes 
cell cycle progression to remain in a proliferative state or begins to differentiate (Ayer & 
Eisenman 1993). However in differentiating SK-N-BE(2) neuroblastoma cells, although 
MYCN is significantly downregulated (and therefore MYCN:Max DNA binging is reduced), 
expression of Mad and Mnt, and indeed their DNA binding is hardly affected (Smith et al. 
2004). When Mad or Mnt was overexpressed, cells were still able to differentiate following 
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administration of retinoic acid. This work supports the theory that downregulation of MYCN, 
rather than alterations in Mad or Mnt expression, is critical to allow differentiation of 
neuroblastoma cells. 
 
 
1.4.2. MYCN in oncogenesis 
 
Myc family members (c-Myc, MYCN, L-Myc) play fundamental roles in the control of normal 
(and oncogenic) cell proliferation, growth, metabolism, differentiation and apoptosis. Myc is 
also one of the four genes, along with Sox2, Oct4 and Klf4, required to induce “stemness” in 
fibroblastic cells (induced pluripotency stem cells) (Takahashi & Yamanaka 2006). 
Deregulation/overexpression of MYCN (e.g. by amplification) could therefore enhance 
tumourigenesis by creating a population of rapidly dividing, self-renewing cells that would be 
increasingly vulnerable to further oncogenic mutations. Indeed amplification of the MYCN 
gene has been demonstrated in a number of cancers, including glioblastoma, 
medulloblastoma, retinoblastoma, rhabdomyosarcoma, and small cell lung carcinoma (Vita & 
Henriksson 2006), but for the purpose of this project, we will focus on its occurrence in 
neuroblastomas. 
 
Consistent with its occurrence in pools of undifferentiated, proliferating cells, high MYCN 
levels are found in aggressive neuroblastomas. The highest MYCN expression is found in 
MYCN-amplified tumours. The highest expression of MYCN target genes occurs in both 
MYCN-amplified and stage 4 MYCN-non-amplified tumours, although not in those classified 
as stage 4S (a special stage which undergoes spontaneous regression) – even though 4S 
have the highest levels of MYCN in all non-amplified tumours (Westermann et al. 2008). It 
was therefore proposed “only partial activation of MYCN target genes occurs in 4S disease”. 
 
MYCN is known to have a causal role in neuroblastoma tumourigenesis, as demonstrated by 
the transgenic TH-MYCN mouse model (Weiss et al. 1997). Overexpression of MYCN was 
targeted to sympathoadrenal cell precursors by placing the gene downstream of the TH 
promoter, and consequently several months after birth, these mice developed 
neuroblastoma tumours, which were similar in location, histology and chromosomal gains 
and losses to their human counterparts. MYCN overexpression is associated with an 
aggressive phenotype, with decreased growth factor dependence and contact inhibition, as 
well as a raised metastatic potential (Lutz et al. 1996; Schweigerer et al. 1990). 
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Paradoxically, MYCN also triggers barriers to tumourigenesis, such as sensitising cells to 
apoptosis, and initiating DNA damage responses and cell senescence (Larsson & 
Henriksson 2010). Therefore, for MYCN-driven tumourigenesis to occur, mutations that 
disrupt said tumour repressor functions will be strongly selected for. 
 
 
 
 
Figure 1.8. Overview of the major genes targeted by MYCN, by means of transcriptional 
promotion or repression, and their normal functions. 
 
 
 
1.4.3. MYCN targets involved in cell cycle control 
 
1.4.3.1. CDK4/Cyclin D2/E2F1 
 
Cyclin-dependent kinase 4 (CDK4) is a direct transcriptional target of MYCN (Westermann et 
al. 2008). It facilitates the transition from G1 to S phase of the cell cycle, within its complex 
with cyclin D2 (also a MYCN target), by phosphorylating pRb, thereby dismantling the 
pRb:E2F1 complex and allowing E2F1 to activate transcription of genes involved in cell cycle 
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progression (Figure 1.8) (Alberts et al. 2010). One such gene is SKP2, which primarily 
targets negative regulators of the cell cycle for degradation, for example p27 and p21 (Muth 
et al. 2010). High SKP2 and E2F1 (which also activates MYCN expression (Strieder & Lutz 
2003)), and low p27 have all been associated with MYCN amplification in neuroblastomas 
(Bell et al. 2010), as well as tumour dedifferentiation and aggressiveness in various other 
cancers (Muth et al. 2010). 
 
 
1.4.3.2. Id2 
 
Id2 expression may be induced by MYCN in neuroblastomas. Id2 is an inhibitor of the 
tumour suppressor pRb, therefore promotes cell proliferation by interacting with this protein 
and allowing E2F1 to be released and initiate transcription of S-phase proteins (Bell et al. 
2010). Id2 also prevents differentiation by forming heterodimers with other bHLH proteins 
such as MASH-1 and HES1, and inhibiting their transcriptional function (Massari & Murre 
2000). In primary neuroblastomas, Id2 has been shown to be strongly correlated with a poor 
outcome, and maintains the malignant proliferative behaviour of tumour cells (Lasorella et al. 
2002). 
 
 
1.4.3.3. MDM2 
 
MDM2 is known as a proto-oncogene, due to its role in inactivation of the constitutively-
expressed tumour suppressor p53 by sequestration/degradation – hence inhibiting its 
apoptotic activity. However, it also functions independently of p53 to regulate genes involved 
in the cell cycle (reduces levels of p21 and pRb, and prevents ubiquitination and degradation 
of E2F) and differentiation (prevents expression of MyoD) (Fiddler et al. 1996; Ganguli & 
Wasylyk 2003). MYCN has been shown to bind to an E-box within the MDM2 promoter and 
directly induce its expression, and conversely, MYCN inhibition reduces MDM2 levels, 
stabilises p53 and leads to apoptosis (Slack et al. 2005). MDM2 has also been implicated in 
MYCN mRNA stabilisation and hence increased protein translation (Gu et al. 2012). Hence 
there are multiple ways in which MDM2 contributes to neuroblastoma progression. 
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1.4.3.4. ODC 
 
Ornithine decarboxylase (ODC) is the rate-limiting enzyme in the pathway for polyamine 
synthesis. It is a direct transcriptional target of MYCN (Lutz et al. 1996), and in addition, with 
its gene being located on chromosome 2p24-25, is amplified with MYCN in around a fifth of 
MYCN-amplified neuroblastomas (Hogarty et al. 2008). This leads to an increased 
availability of polyamines, critical for cell survival, stabilisation of the DNA structure and 
promotion of cell division. 
 
1.4.4. MYCN targets involved in apoptosis 
 
MYCN activates both proliferative and apoptotic pathways, therefore for MYCN-expressing 
neuroblastoma precursors to progress to a full-blown malignancy, the balance must be 
tipped in favour of cell proliferation. 
 
 
1.4.4.1. p53 
 
The tumour suppressor gene p53 is very rarely mutated in neuroblastomas (in less than 2% 
of tumours at diagnosis), and the p53 pathways are typically functionally active (Hosoi et al. 
1994), thus for malignant progression, inhibition of p53-mediated apoptosis is essential. p53 
is a direct transcriptional target of MYCN in neuroblastoma and is associated with high 
expression/amplification of the MYCN gene (Chen et al. 2010). It promotes a G1 phase cell 
cycle arrest upon DNA damage, by upregulating the CDK inhibitor p21, and allows the 
relevant DNA repair mechanisms to occur. However, MYCN amplification has been shown to 
correlate with failure to arrest in the G1 phase of the cell cycle following DNA damage (Bell 
et al. 2006). If growth arrest is not possible, p53 sensitises the cell to apoptosis by inducing 
genes such as Bax, Puma and Fas (Tweddle et al. 2003) (Figure 1.9). However, MYCN 
directly represses expression of p21, via its complex with Miz-1, and also promotes 
transcription of MDM2, hence overriding p53-induced cell cycle arrest. Therefore, in a highly 
MYCN-expressing neuroblastoma precursor, increased levels of MDM2 may provide that 
counterbalance to apoptosis needed for mass proliferation of a developing tumour. 
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Figure 1.9. Basic illustration identifying major p53 interactions.  
 
 
1.4.4.2. p73 
 
p73 is a member of the p53 family of tumour suppressor proteins, which are involved in 
growth arrest and/or apoptosis in neuronal cells (Pozniak et al. 2000). p73 is not a MYCN 
target gene, rather it is a regulator of MYCN – p73 directly activates transcription of the 
MYCN gene, but can also post-transcriptionally inhibit the stability of MYCN mRNA 
(Horvilleur et al. 2008). p73 has been mapped to chromosome 1p36, a region often 
associated with loss of heterozygosity in neuroblastomas, but when present, it is thought that 
the protein, along with p53, is involved in apoptosis of TrkA-expressing neurons upon NGF 
withdrawal (Nakagawara 2005). 
 
 
1.4.4.3. BCL-2 
 
MYCN also represses anti-apoptotic proteins such as BCL-2, which allows Bax to act and 
eventually trigger a caspase cascade that will kill the cell (Bell et al. 2010). 
 
 
1.4.4.4. ALK 
 
Anaplastic lymphoma receptor tyrosine kinase (ALK), of the insulin receptor superfamily, is a 
protein which plays a role in the developing CNS and PNS (including synaptogenesis of the 
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sympathetic ganglia), but in adults its presence is restricted to within only a few cells in the 
CNS (Iwahara et al. 1997). In the presence of its ligands (e.g. pleiotrophin), ALK has an anti-
apoptotic role, and is involved in processes such as differentiation and axon guidance. 
However, with no ligand binding the ALK receptor is cleaved by caspases, exposing its pro-
apoptotic domain (Mourali et al. 2006). It has been implicated in the development of human 
cancers such as anaplastic large-cell lymphoma, non-small-cell lung cancer and 
neuroblastoma. Germline mutations in ALK have been discovered in the majority of familial 
neuroblastoma cases, and point mutations have been found in 7-10% of somatic tumours. 
Constitutive ALK signalling is thought to contribute to oncogenic transformation via control of 
cell cycle progression, survival, cell shaping and cell migration (Carpenter & Mosse 2012). 
The ALK gene is located on chromosome 2p23, and although this is only amplified in around 
2% of neuroblastomas, unsurprisingly, this almost always occurs alongside MYCN 
amplification (whose gene is located at 2p24) (Azarova, Gautam & George 2011). No 
associations between these activating ALK mutations alone and disease stage or survival 
have yet been established. However one of the most potent ALK mutations, F1174 (which 
appears mostly in tumours with amplification of MYCN), when coupled with MYCN 
amplification, is associated with a poor prognosis in humans, a fact that is supported by 
recent animal models. When mice overexpressing the F1174 mutation were crossed with the 
MYCN transgenic mice, their progeny developed aggressive neuroblastomas with increased 
penetrance, an early onset, and decreased overall survival (Berry et al. 2012). Likewise, 
coexpression of these two aberrations in zebrafish increased the frequency of tumours and 
accelerated tumour onset, compared to MYCN alone (Zhu et al. 2012). It should be noted 
that animals carrying the ALK mutation alone, without increased MYCN expression did not 
form tumours, suggesting that ALK accelerates MYCN-driven tumourigenesis. It is thought 
that ALK regulates the stability of the MYCN protein, as ALK:MYCN tumours display an 
increased intensity of MYCN staining, and in the Kelly cell line, which overexpresses both 
ALK and MYCN, ALK knockdown results in decreased MYCN protein levels and the half-life 
of the MYCN protein being reduced (Berry et al. 2012). These authors also discovered that 
although proliferation levels in ALK:MYCN versus MYCN tumours were similar, apoptosis 
was massively reduced in the mouse tumours with elevated ALKF1174 and MYCN 
coexpression – a feature that was confirmed in human neuroblastomas. They propose that 
this reduction in apoptosis is mediated by increased expression of BCL-2, and lowered 
expression of pro-apoptotic genes such as Bax, and since this is in contrast with MYCN’s 
repression of anti-apoptotic proteins (see section 1.4.4.3), concluded that an evasion of 
MYCN-induced apoptosis may be ALK’s key role in MYCN-driven tumourigenesis. 
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1.4.4.5. Bmi-1 
 
Bmi-1 is an oncogene belonging to the polycomb group of proteins, which tend to suppress 
genes by means of chromatin remodelling, i.e. in an epigenetic manner. Bmi-1 knockout 
mice have suggested a role for the protein in haematopoiesis and development of the central 
and peripheral nervous systems, as defects in all of these areas are observed in the 
absence of Bmi-1 (Vanderlugt et al. 1994). A role in self-renewal of neural crest stem cells 
has also been documented, although it is not required for their survival or differentiation 
(Molofsky et al. 2003). High levels are routinely found in both primary neuroblastomas and 
cell lines, and in Weiss’ TH-MYCN transgenic mouse model, the tumours formed have high 
Bmi-1 expression. Bmi-1 inhibits the apoptotic activity of MYCN, as cells of the SHEP cell 
line forced to overexpress both MYCN and Bmi-1 were highly resistant to a variety of 
apoptosis-inducing agents, compared to cells with high MYCN expression alone, which were 
extremely sensitive to apoptotic induction (Cui et al. 2007). These apoptosis-resistant Bmi-1-
expressing SHEP cells showed a reduction in p53 protein, which would probably have been 
repressed indirectly, via MDM2 binding and subsequent degradation – Bmi-1 represses the 
expression of p14ARF, an MDM2 inhibitor, so high levels of Bmi-1 would result in an increase 
in MDM2 protein. Other groups have shown that Bmi-1 downregulates p53 and helps drive 
tumour progression by reducing levels of apoptosis of damaged cells (Alajez et al. 2009; 
Chatoo et al. 2009). Bmi-1 directly binds to p53 in a complex and results in increased p53 
ubiquitination and degradation (Calao et al. 2012). Since Bmi-1 is also highly expressed in 
neuroblastomas without MYCN amplification, a more general, yet essential role in 
tumourigenesis seems likely, possibly in the maintenance/self-renewal of tumour cells, in 
addition to it helping override MYCN-expressing cells’ tendency to undergo apoptosis. And 
indeed, Bmi-1 knockdown impaired the ability of neuroblastoma cells to form tumours in 
immunodeficient mice (Cui et al. 2007). 
 
 
1.4.4.6. Survivin 
 
Survivin (SVV) is an inhibitor of apoptosis, which binds to caspase and inhibits its function 
(Tamm et al. 1998). It probably has a vital role during development, where there is an 
ongoing readdressing of the critical balance between proliferation and apoptosis, to allow 
proper structural formation of the various organs. SVV is highly expressed in most 
embryonic tissues, as well as in most human cancers, but it is absent in terminally 
differentiated cells (Adida et al. 1998b; Pina-Oviedo et al. 2007). This in theory could make 
SVV an exciting therapeutic target, in the hope that cancer cells would be targeted, but 
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normal cells unaffected. Its gene has been mapped to chromosome 17q, in a region 
frequently gained in neuroblastoma, and consistent with this, high levels of SVV are 
associated with MYCN amplification and a poor prognosis (Adida et al. 1998a). Pro-
apoptotic p53 represses SVV transcription, however in vitro studies have shown that SVV 
overexpression (potentially akin to that in MYCN-amplified neuoblastomas) inhibits p53-
mediated apoptosis induced by DNA damage (Hoffman et al. 2002). 
 
 
MYCN generally favours induction of apoptotic pathways in response to DNA damage, over 
the initiation of cell senescence (Larsson & Henriksson 2010). Although apoptosis seems to 
defeat the object of tumourigenesis, if overexpression of MYCN can override this default (by 
the ways described above) and allow cell cycle progression in just a few DNA-damaged 
cells, this could lead to neuroblastoma tumourigenesis. 
 
 
1.4.5. Other MYCN targets that may contribute to tumour progression 
 
1.4.5.1. TERT 
 
MYCN is able to bypass cell senescence by inducing expression of the TERT subunit of 
telomerase. This prevents the erosion of chromosomal telomeres, resulting in cell 
immortalisation. Telomerase is found in almost all neuroblastomas and is associated with 
MYCN amplification and a poor prognosis (Hiyama et al. 1995; Krams et al. 2003). 
 
 
1.4.5.2. Angiogenesis-associated proteins 
 
Angiogenesis in neuroblastoma, as a partial consequence of vascular endothelial growth 
factor (VEGF), is beneficial for tumour progression and therefore associated with a poor 
prognosis (Fukuzawa et al. 2002). PI3K activation results in raised MYCN levels (due to 
protein stabilisation), with a consequent increase in VEGF secretion (Kang et al. 2008). 
MYCN also contributes to tumour vascularity through direct transcriptional repression of 
angiogenesis inhibitors Activin-A, LIF and IL-6 (Breit et al. 2000; Hatzi et al. 2000; Hatzi et al. 
2002). These factors normally modulate endothelial cell proliferation, so their inhibition 
results in less restricted blood vessel formation. 
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1.4.5.3. Trks 
 
For TrkB (whose expression is associated with MYCN amplification), TrkA and p75 (both 
repressed by MYCN), see section 1.3.4.7: “the Trk neurotrophin receptors”. 
 
 
1.4.5.4. Ndrg1 
 
Ndrg1 is a growth inhibitory gene induced by p53 and DNA damage that functions as an 
inhibitor of cell growth. It is transcriptionally repressed by MYCN, and low levels of the 
protein (found in MYCN-amplified neuroblastomas) are associated with a poor prognosis (Li 
& Kretzner 2003). 
 
 
1.4.5.5. Aurora kinase A 
 
Aurora kinase A (AURKA) is indirectly upregulated by MYCN, particularly in MYCN-amplified 
cells. It has been found to bind to and stabilise the MYCN protein, inhibiting its degradation 
(Otto et al. 2009). This group therefore propose that the elevated levels of Aurora A kinase 
which are commonly found in MYCN-amplified neuroblastomas, in stabilising MYCN, inhibit 
the cell-cycle exit of neuroblasts during development, resulting in a population of cycling 
cells that may contribute to the generation of neuroblastoma tumours. 
 
 
Mutations in, or atypical expression of, any of these genes involved in sympathetic nervous 
system development and/or maintenance could be implicated in oncogenic transformation 
(as secondary/passenger mutations) and development of neuroblastoma. As detailed above, 
altered levels/activity of many of these proteins have indeed been associated with the 
disease. 
 
 
1.4.6. Control of MYCN as a potential therapeutic target 
 
MYCN amplification and/or high expression correlates with poor patient prognosis in 
neuroblastoma, therefore control of this oncogenic product is an attractive therapeutic target. 
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As illustrated in Figure 1.10, stabilisation of the MYCN protein depends on phosphorylation 
at residue serine 62 (S62), which occurs in proliferating cells and is mediated by CDK1 
(Sjostrom et al. 2005). This phosphorylation then allows active GSK3β to phosphorylate 
MYCN at threonine 58 (T58). The S62- and T58-phosphorylated MYCN is stable and 
transciptionally active when bound to Max (Gustafson & Weiss 2010). Activity of GSK3β 
depends on upstream signalling. Receptor tyrosine kinases (potentially including ALK and 
the Trk neurotrophin receptors) activate phosphatidylinositol 3-kinase (PI3K), which in turn 
activates protein kinase B (Akt). Akt causes phosphorylation and hence inactivation of 
GSK3β, which has the consequence of stabilising MYCN by preventing phosphorylation at 
T58. The singly S62-phosphorylated protein is able to enter the nucleus and induce 
transcription. Although doubly-phosphorylated MYCN is also transcriptionally active, this 
protein can potentially be dephosphorylated at S62 by the phosphatase PP2A, which would 
result in ubiquitination and degradation. However, as an added complexity, Aurora kinase A 
(AURKA) can bind to and stabilise the T58-monophosphorylated and ubiquitinated MYCN, 
hence AURKA’s association with a poor prognosis (Otto et al. 2009). Akt also activates 
mammalian target of rapamycin (mTOR), which prevents dephosphorylation at S62 (and 
consequent degradation), allowing the stable, doubly-phosphorylated MYCN to enter the 
nucleus and induce gene transcription (Gustafson & Weiss 2010). 
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Figure 1.10. Depiction of signalling pathways involved in MYCN protein stability. Taken from 
Gustafson & Weiss 2010.  
 
 
In correlation with the above data, Chesler et al. (2006) used PI3K inhibitors to reduce both 
levels of phosphorylated Akt (pAkt) and MYCN proteins, with no significant decrease in 
MYCN mRNA levels. This observation was reproduced in the MYCN-amplified cell lines 
Kelly and LAN-1, and extended to demonstrate that MYCN protein degradation resulted in 
reduced levels of the MYCN targets MDM2 and MCM7 (Chesler et al. 2006). The reduction 
in proliferation and increase in apoptosis following PI3K inhibition was less pronounced in 
the non-MYCN-amplified SK-N-SH cell line compared to the Kelly and LAN-1. The effects of 
PI3K signalling inhibition were determined to be at least in part due to GSK3β, as MYCN 
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proteins lacking the GSK3β phosphorylation sites were stabilised and resistant to the effects 
of PI3K inhibition (Chesler et al. 2006). Since disruption of the MYCN phosphorylation 
pathway (by means of PI3K inhibition) halted growth of tyrosine hydroxylase-driven 
neuroblastoma tumours in vivo in mice, the potential of MYCN as a therapeutic target in 
neuroblastoma is substantiated, and therefore is an area that should be further delved into. 
 
 
1.5. Neuroblastoma diagnosis 
 
In a suspected case of neuroblastoma, levels of urinary catecholamine metabolites HVA 
(homovanillic acid) and VMA (vanillylmandelic acid) are generally analysed to confirm the 
adrenergic character of the tumour, as like the non-malignant sympathetic cells it arises 
from, neuroblastomas produce and secrete catecholamines (Berthold & Simon 2005). 
Histologically, the tumour tissue would typically appear somewhat heterogeneous, perhaps 
with regions of neuronal differentiation, as well as areas of densely packed, rapidly 
proliferating small round blue cells – the higher the proportion of the latter, the more 
aggressive the tumour. Immunohistochemisty is used to detect proteins which may help 
distinguish the disease from other tumours such as Wilm’s and pheochromocytoma. Protein 
markers suggestive of neuroblastoma include N-CAM (neural cell adhesion molecule), 
NB84, NSE (neuron specific enolase), synaptophysin, CGA (chromogranin A) and the GD2 
ganglioside. In addition, cytogenetic and genetic analyses to asses MYCN status, incidences 
of 1p deletion etc are performed to further support the diagnosis and determine treatment 
stratification (Brodeur et al. 1993). 
 
 
1.5.1. Staging Systems 
 
In order to distinguish between patients with low- or high-risk neuroblastoma, and determine 
the appropriate disease management, all tumours are placed in a particular “stage” bracket, 
the most commonly used being the International Neuroblastoma Staging System (INSS), as 
defined by Brodeur and colleagues in 1988, according to tumour location and spread (Table 
1.1). 
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Table 1.1. International Neuroblastoma Staging System (INSS). Adapted from Brodeur et al. 
1988. 
 
 
Although a universal staging system is extremely useful in a broad sense – for determining 
each patient’s likely prognosis and comparing the efficacy of various drugs in comparable 
groups of patients – for a disease which is extremely diverse in its nature, this alone is not 
enough to stratify tumour risk. With an increasing wealth of knowledge on the genetic 
aberrations, epigenetic modifications and chromosomal rearrangements that can be found in 
the tumour genome, and their prognostic impacts, the International Neuroblastoma Risk 
Group (INRG) Classification System was established in 2008, by carefully analysing the 
cases of 8,800 neuroblastoma sufferers in North America and Australia. The study 
concluded that “stage, age, histologic category, grade of tumour differentiation, the status of 
the MYCN oncogene, chromosome 11q status, and DNA ploidy were the most highly 
statistically significant and clinically relevant factors” (Table 1.2) (Cohn et al. 2009). They 
detailed that disease outcome worsens as patient age increases, and that those diagnosed 
before 18 months, and particularly in the first year of life, have a significantly better 
prognosis. The cohort with undifferentiated or poorly differentiated tumours had lower rates 
of event free survival (EFS) than those with differentiating neoplasms, and patients with 
primary tumours situated in the adrenal glands had the poorest prognosis. Although some of 
the listed factors were mutually dependent, in general, MYCN amplification, the presence of 
aberrations in chromosome 11q, and diploid tumour DNA, were all indicators of a poor 
prognosis. This classification system is now being used to allow all patients worldwide to be 
treated in a manner more suited to their specific tumour, and rather than a generic ‘one-size-
fits-all’ approach, therapy of an appropriate intensity can be employed. As well as the 
obvious benefits for the patient, this has the added advantage of improving the efficiency of 
data obtained from clinical trials, and is another step in the journey towards the eventual 
target of personalised medicine for cancer sufferers. 
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Table 1.2. International Neuroblastoma Risk Group (INRG) Classification System. GN, 
ganglioneuroma; GNB, ganglioneuroblastoma; Amp, amplified; NA, non-amplified. Taken 
from Cohn et al. 2009. 
 
 
It is evident that tumour stage is a huge prognostic factor, and from the Kaplan-Meier curves 
in Figure 1.11, one can deduce how heterogeneous the bracket of “neuroblastoma tumours” 
is, with recovery excellent in those patients with low stage tumours, but extremely poor in 
those with aggressive forms of the disease. 
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Figure 1.11. Kaplan-Meier curves to show A) event free survival, and B) overall survival in 
2779 neuroblastoma patients, staged according to the INSS. Taken from Berthold & Simon 
2005. 
 
 
1.5.2. Chromosomal aberrations 
 
1.5.2.1. DNA ploidy 
 
Ploidy is defined as the number of sets of chromosomes in each cell. Diploid is the normal 
occurrence of two copies of each chromosome: one maternal and one paternal. DNA ploidy 
of the tumour cells is an important prognostic factor in neuroblastoma. Tumours with 
hyperdiploidy/near-triploidy have the best prognosis, often with whole chromosome gains 
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rather than structural rearrangements (Brodeur & Nakagawara 1992). The near-diploid 
neuroblastomas have an poor prognosis, often encompassing several cytogenetic 
rearrangements, including deletions and translocation (Brodeur 1995). 
 
 
1.5.2.2. 1p deletion 
 
Around a third of neuroblastoma tumours have loss of heterozygosity (LOH) of chromosome 
1p (Maris et al. 2000). Outcome is worse in patients with the largest 1p deletions, and this is 
often associated with MYCN amplification and diploidy/tetraploidy (Schwab 2005). It is 
thought that at least one, possibly multiple neuroblastoma tumour suppressors are located 
within chromosome 1p, although the large size of the deletions in addition to the genomic 
complexity of the region make identification of such genes difficult. 
 
 
1.5.2.3. 11q deletion 
 
Deletions in chromosome 11q have been found in around 15% of neuroblastomas, usually of 
a high stage, but rarely coincides with MYCN amplification (Spitz et al. 2003; Van Roy et al. 
2009). 11q deletion is therefore sometimes considered to be an indicator of poor prognosis 
in non-MYCN-amplified tumours (Mertens et al. 1997). Loss of the whole chromosome 11 
seems to be associated with a better prognosis. 
 
 
1.5.2.4. 17q gain 
 
Comparative genomic hybridisation (CGH) experiments have shown that around half of 
neuroblastomas have an additional segment of chromosome 17q, making 17q gain the most 
common genetic aberration in the cancer. After 1p, 11q is the second most common partner 
for chromosome 17q translocations. 17q gain is most common in tumours of a high stage, in 
children older than one year, and in tumours with MYCN amplification and diploidy or 
tetraploidy (Maris 2004). 
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Figure 1.12. Kaplan-Meier curve displaying cumulative patient survival for 133 
neuroblastoma tumours with various genetic aberrations. Red line, chromosome segmental 
aberrations (not involving MYCN amplification, 11q deletion or 17q gain); Blue line, 
numerical changes only (whole chromosome loss and/or gain); Purple line, chromosome 17q 
gain (without MYCN amplification or 11q deletion); Yellow line, MYCN amplification (without 
11q deletion); Green line, 11q deletion (without MYCN amplification). Taken from Caren et 
al. 2010. 
 
 
1.6. Spontaneous regression 
 
Neuroblastoma has a “special” stage, termed “4S”, in which, following a period of aggressive 
disseminated growth (involving liver, skin or bone marrow in addition to the primary tumour), 
tumours spontaneously regress (diminish, disappear and/or differentiate) with little, or often 
no treatment. Such tumours have favourable histology, a single MYCN copy, and are 
generally classed as low-risk (Maris et al. 2007; Nickerson et al. 2000). Regression very 
rarely occurs in patients older than one year of age and usually occurs within the first six 
months after birth. However, it is extremely difficult to establish precisely what proportion of 
tumours undergo this phenomenon, particularly when one takes into account the results of 
neuroblastoma screening programmes performed in Japan, North America and Europe at 
the end of the last century. 
 
 
1.6.1. Screening 
 
Urinary catecholamine metabolites were analysed in infants up to one year of age, and those 
with elevated levels were investigated further for a potential neuroblastoma diagnosis. The 
three main trials took place in Japan (the most preliminary and least robust), Quebec and 
Germany, and although different in their designs, they all noted an increase in the incidences 
of neuroblastoma to almost double in the screened population compared to the control 
cohorts, regardless of age (≤6months, or 1 year), and this was coupled with no decrease in 
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mortality rates or the incidences of advanced stage disease at any age. These data led to 
two key outcomes: the determination that incidences of spontaneous regression may be 
much higher than previously thought, with many patients (in an unscreened population) 
never even presenting at the clinic; and the conclusion that the preclinical screening 
methods utilised were not beneficial and should be abandoned, as earlier detection made no 
difference to the mortality rates of patients with high risk disease (Woods et al. 1996). 
 
 
1.6.2. Possible reasons/mechanisms for spontaneous regression 
 
It has been established that a massive pre-programmed, regulated death of sympathetic 
neurons occurs around the time of birth, probably due to a lack of neurotrophins (particularly 
NGF). Exposure of TrkA-expressing neurons to NGF results in survival and differentiation, 
whereas NGF withdrawal leads to apoptosis, therefore the limited availability in the foetus 
permits only the survival of the required number of neurons (Oppenheim 1991). Nakagawara 
reported that this same apoptotic mechanism seemed to occur in neuroblastoma tumours in 
infants, potentially as the onset of spontaneous regression. He detailed that MYCN 
amplification inhibits spontaneous regression, but in tumours that do regress, caspases are 
induced and survivin, an apoptotic inhibitor which is overexpressed in advanced stage 
tumours, is downregulated (Nakagawara 1998). 
 
 
1.7. Neuroblastoma treatment 
 
Current treatment regimens for neuroblastoma range from surgical resection alone in some 
low risk cases, to intense multi-agent modalities in high risk patients. In advanced stage 
disease intensive chemotherapy is often the first treatment given, which is followed by stem 
cell collection and then surgery to remove as much of the tumour tissue as possible. Next is 
myeloablative therapy, which must be followed by autologous stem cell transplantation. This 
may then be followed by radiotherapy. In addition, some children are then given retinoid 
therapy to induce tumour cell differentiation (Bhatnagar & Sarin 2012). However, it is 
extremely difficult to eradicate all tumour cells in high risk patients, so in recent years 
immunotherapy has been used in combination with the retinoic acid treatment to target 
residual disease. GD2 is a ganglioside expressed on all neuroblastoma cells, but rarely on 
normal tissues, therefore is seen as an efficient way to target the cancer cells specifically. 
Monoclonal antibodies are administered to the patient and target GD2, leading to immune-
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mediated cell death. However, patient responses have varied, and unfavourable toxicities 
have been observed (Castel, Segura & Canete 2010). 
 
Chemotherapeutic drugs, still often the most effective treatment, usually cause severe 
toxicity and target all dividing cells in a non-specific manner, causing devastation to many 
body tissues. It would be favourable to kill neuroblastoma cells in vivo in a less destructive 
manner, whilst administering minimal toxicity. Since deregulation of MYCN contributes to 
tumourigenesis, not just in neuroblastoma but in a variety of tumours, selectively inhibiting 
MYCN is an attractive prospect. One way of doing this may be to find a way of 
reprogramming the cells, and encouraging them to either differentiate or undergo apoptosis 
of their own accord. 
 
 
1.8. Embryonic microenvironment reprograms tumour cells 
 
Numerous methods of experimentation have been underway for decades, attempting to 
transform various types of malignant cells to a more benign phenotype, by exposing them to 
assorted embryonic environments. In early experiments in 1975, Mintz & Illmensee injected 
malignant mouse teratocarcinoma cells into mouse blastocysts, which were then implanted 
into pseudo-pregnant mouse uteri. They discovered that the blastocyst microenvironment 
reversed the malignancy of the teratocarcinoma cells, and not only that, but in some of the 
mice that developed from said blastocysts, the formerly malignant cells had contributed to 
the make-up of many developmentally unrelated tissues, in what the authors termed “cellular 
genetic mosaics” (Mintz & Illmensee 1975). 
 
It had been documented that aggressive cancer cells (particularly relevant to the following 
experiments, malignant metastatic melanoma (MM)) share several characteristics with 
human embryonic stem cells (hESCs), most notably their multipotency. It was therefore 
proposed in 1982 that “an embryonic microenvironment capable of differentiating a stem cell 
lineage should be able to reprogram cancers derived from that lineage" (Pierce et al. 1982). 
Decades later, in 2006, Postovit and colleagues developed a system to determine the 
influence of a stem cell microenviroment on MM cells. They cultured hESCs on 3D matrices, 
before removing aforementioned stem cells and adding human MM cells to the culture 
system (i.e. the matrices had been conditioned by the hESCs’ secreted factors, but the 
complication of cell-cell interactions between them and the MM cells had been eliminated – 
the melanoma cells were effectively only exposed to the stem cells’ extracellular 
microenvironment). Morphologically, the MM cells grew as spheroids, reminiscent of the 
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colonies formed by hESCs. More remarkably, the conditioned matrices induced the 
expression of MLANA, a melanocytic marker that was absent from the malignant melanoma 
cells, and in addition reduced the invasive capacity of the MM cells in vitro and impaired their 
ability to form tumours in vivo, in nude mice (Postovit et al. 2006). All in all, proving an 
embryonic stem cell environment could have a dramatic effect on these multipotent 
melanoma cells. 
 
At around the same time, a paper was published using the zebrafish embryo as a model 
system, again attempting to reprogram MM cells (Lee et al. 2005). Five days subsequent to 
implantation into the blastula-stage zebrafish, the MM cells were found to be scattered 
throughout the embryo, and the expression of a pan-melanoma marker was found to have 
been downregulated. This de-differentiated phenotype was still apparent after three months 
of observation, by which time no tumours had been formed. This so-called “reprogramming” 
of the MM cells, was found to be critically time-dependent, when a different group injected 
MM cells into a zebrafish embryo 2 days post-fertilisation, and found that tumour-like masses 
developed, and within some of these, angiogenesis was beginning to occur (Haldi et al. 
2006). 
 
The first paper published transplanting melanoma cells into a chick embryo model was in 
2005. Melanocytes, of which melanoma is their malignant counterpart, originate from the 
neural crest. Since the dedifferentiated plastic/multipotent phenotype of melanoma cells, and 
the ability of an early embryonic environment to reverse their tumourigenicity had already 
been established, they reasoned that transplanting MM cells back into the neural crest 
environment from which they originally developed, may illicit a more pronounced response 
than had been seen in other model systems. SK-Mel28 cells, suspended in matrigel, were 
transplanted into the Hamburger and Hamilton stage (HH) 11-13 neural tube, and 48 hours 
later, HNK-1 negative, HMB-45 positive melanoma cells were discovered in the medial 
neural crest migratory stream, as well as in the sympathetic ganglia (Schriek et al. 2005). 
Kulesa et al., in 2006, then extended these observations further. They first injected DiI into 
the chick embryo neural tube to label the host neural crest cells, then transplanted blocks of 
around 1,500 aggressive MM cells into the neural tubes of chick embryos aged around HH9, 
the time when host NCCs are just about or beginning to emerge from the neural tube. These 
cells were analysed within the chick embryo 48h or 96h after transplantation. They were 
never found to form tumours, and instead, rather than lying dormant, a proportion of them 
migrated out into the surrounding chick tissues along with the chick’s endogenous NCCs, 
and were morphologically reminiscent of normal migrating neural crest cells. In addition, 
some MM cells were found to have invaded host NC target tissues, such as the branchial 
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arches, dorsal root ganglia and sympathetic ganglia. Not only this, but 34% of the migrating 
melanoma cells were found to express the melanocyte-specific marker MART-1, and 
another 13% of the migrating MM cells had been induced to express TUJ1, a neuronal 
marker (Kulesa et al. 2006). In contrast, when fibroblastic cells were transplanted into the 
neural crest cell migratory pathway, they remained intact at the graft sites, and did not 
migrate or invade the surrounding tissues (Erickson, Tosney & Weston 1980). 
 
This neural tube transplantation technique was utilised by another group, this time using only 
moderately aggressive murine B16-F1 melanoma cells, at HH12-12. Like the human MM 
cells, they migrated with the host NCCs, along both the ventral and lateral pathways, and 
colonised structures such as the sympathetic ganglia (Oppitz et al. 2007). However after 
48h, many cells were found to have undergone apoptosis rather than differentiation – the 
latter perhaps being a feature restricted to the most aggressive (and potentially most “stem”-
like) cells. To both check cell viability within the embryo, and prove that this tumour-reversing 
phenomenon was unique to cells transplanted back in to their environment of origin, they 
injected the same suspension into the eye cup of E3 (HH stage 20) embryos and observed 
that the melanoma cells’ tumourigenicity was maintained, as invasive melanomas formed, 
which were entirely comprised of murine cells (Oppitz et al. 2007). This group extended their 
observation further, after they reasoned that the melanoma cell migration may be due to 
endogenous BMPs – as normal neural crest cell migration is induced by BMPs and inhibited 
by noggin, but unlike transplanted neural stem cells (Busch et al. 2006), the melanoma cells 
did not require pre-treatment with BMP2 to migrate. Aggregates of B16 F1 mouse melanoma 
cells were cultured with either BMP2, noggin, or left untreated, and then implanted into the 
chick neural tube. Cells pre-treated with noggin did not migrate, and remained at the graft 
site. Those untreated and treated with BMP2 migrated through the embryo, but migration 
was enhanced, in terms of cell number and distance, in those BMP2-treated (Busch et al. 
2007). The neural crest-like migration of melanoma cells has also been recapitulated using 
mouse embryos (Diez-Torre et al. 2009). 
 
The chick-melanoma work was able to conclude, not only that an embryonic environment 
was capable of ablating the tumourigenicity of aggressive melanoma cells, but that following 
exposure to the microenvironment of their ancestral cell type, these so-called 
dedifferentiated cells were capable of responding to the signals they received, and behaved 
like normal NCCs, effectively going through the process of development a second time, this 
time differentiating into primitive neural-crest-derived tissues (albeit a small subset of the 
transplanted cells). 
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1.9. Hypothesis 
 
Since neuroblastoma can be a highly aggressive disease, and one that is still failing in terms 
of the treatment of high-risk patients, it is proposed that a similar outcome to the chick 
melanoma experiments described above could be achieved using neuroblastoma cells. Like 
malignant melanoma, neuroblastoma cells originate from the neural crest, but unlike 
melanoma, neuroblastoma is a paediatric cancer, so it is hoped that these comparatively 
immature cells may be more susceptible to signals within the neural crest embryonic 
environment. Coupled with the high incidence of spontaneous regression in neuroblastoma, 
in which cells in these usually young patients have been observed to differentiate and/or 
apoptose (Koizumi et al. 2006), it is hypothesised that reintroduction into their embryonic site 
of origin, i.e. the neural crest and its migratory pathways, may allow the neuroblastoma cells 
to respond to the environmental cues they encounter and behave in a similar manner to the 
endogenous neural crest cells – in effect, giving the cells a “second chance” at normal 
development. It is therefore expected that the tumour cells would thrive in an “inappropriate 
environment”, i.e. one in which neural crest developmental cues were absent, and proliferate 
to form microtumours. 
 
 
1.9.1. Aims 
 
• Establish a system, using the chick embryo as a model organism, for effective 
introduction of neuroblastoma cells into an “appropriate” environment (in which 
neural crest-related developmental cues are present) as well as into an 
“inappropriate” environment (devoid of neural crest signals). 
 
• Test methods of cell introduction: intra-ocular and intravenous injection. 
• Inject various cell lines: SK-N-BE(2)C, B16 F1 (mouse melanoma), SK-N-AS, SH-
SY5Y, Kelly, glioblastoma primary line, SH-EP. 
• Determine the most effective means of cell labelling. 
• Introduce cells at different chick embryonic ages: E3 and E6. 
 
 
• Determine the consequences of neuroblastoma cell targeting at E10. 
 
• E3 versus E6 injection. 
• Within neural versus non-neural tissues (E3). 
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• Proliferation 
• Differentiation 
• MYCN protein expression 
 
 
• Test the impact of the chick sympathetic ganglia microenvironment on the 
“reprogramming” of neuroblastoma cells. 
 
• Leave cells within the chick until E14. 
• Culture sympathetic ganglia containing Kelly cells in vitro: dissociated versus 
explanted. 
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2.1. Cell culture 
 
All experiments were performed using cells from the following cell lines: 
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Table 2.1. Information on the origins and culture conditions of the cell lines used in this 
project. 
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2.1.1. Cell line culture 
 
Cell lines were generally cultured as monolayers in 25cm2 or 75cm2 culture flasks (Sarstedt), 
in their appropriate media (see Table 2.1), at 37°C and 5% CO2, in a humidified incubator.  
When cells were approaching confluency, Ca2+- and Mg2+-free Hanks Balanced Salt Solution 
(HBSS) (Sigma-Aldrich) was used to wash the culture surface, following which 1ml 0.05% 
trypsin EDTA (Gibco) was added per 75cm2 flask. Following 5 minutes incubation at 37°C, 
9ml culture medium containing foetal calf serum (FCS) (Biosera) was added to the flasks to 
halt the action of the trypsin, and the resulting cell suspension triturated using a 10ml pipette 
(or blue tip, for the “clumpier” cell lines). Between 1x106 and 3x106 cells were replated per 
75cm2 flask, and the total volume made up to 12ml with the appropriate medium. 
 
Cell counts were performed by producing a single-cell suspension following trypsinisation, 
typically in a total volume of 10ml, and pipetting small volumes into a haemocytometer. The 
average number of cells was calculated from 5 counts, to give (average)x104 cells/ml. 
 
 
2.1.2. Primary neuroblastoma cell culture 
 
2.1.2.1. Primary tumour tissue 
 
Neuroblastoma samples termed NB16B, 17, 17B, 2C, 19B*, 20*, 20B*, 21**, 22***, 23*** and 
24*** were received as small tissue pieces in a 20ml tube of serum-free medium. These 
tubes were spun at 1000rpm for 5 minutes, for ease of removal of medium. The samples 
were then resuspended in 1ml 0.25% trypsin (Gibco), 100µg/ml collagenase (Sigma-Aldrich) 
and 100µg/ml DNase I (Sigma-Aldrich), and transferred to a 35mm dish. Tissue was cut into 
small pieces using sterile scalpels (size 10, Swann-Morton), and then incubated in the 
trypsin at 37°C for 30 minutes. Tissue was washed at least 3 times using HBSS, and then 1-
2ml culture medium: RPMI 1640 (Gibco) containing 20% FCS, 1% non-essential amino 
acids (NEAA) (Gibco), 100U/ml penicillin and 100μg/ml streptomycin (Gibco); was added, 
following which tissue was minced into yet smaller pieces using the two scalpels. This 
suspension was triturated using either a blue pipette tip or a glass Pasteur pipette, polished 
using a Bunsen burner to reduce the bore. The suspension was then filtered through a 40µm 
cell strainer, and the single cells transferred into one 25cm2 flask, and the tissue pieces/cell 
clumps remaining in the sieve transferred to a second flask. Cells were fed with fresh 
medium every 3 days, and once expanded, were frozen and stored in liquid nitrogen (see 
section 2.1.4). 
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* For samples NB19B, 20 and 20B, tissue was minced and filtered without the addition of 
trypsin, collagenase or DNase I, as this made little difference to the dissociation. 
 
** NB21 was prepared in the same way as tissues NB19B, 20 and 20B, i.e. without trypsin, 
DNase I or collagenase, but in addition explants of tumour tissue were plated onto 6 well 
tissue culture plates that had been coated with 10µg/ml Poly-L-lysine in 0.1M sodium borate 
pH8.3 for 1 hour. These explants, along with the dissociated tumour tissue, was cultured 
either in RPMI medium as detailed above, or in serum free medium: 3:1 DMEM:F12 (Gibco, 
Sigma-Aldrich respectively), 100U/ml penicillin and 100μg/ml streptomycin, 2% B27 
supplement (Gibco), 40ng/ml bBFGF (Gibco) and 20ng/ml EGF (Sigma-Aldrich) (Hansford et 
al. 2007). 
 
*** NB22, 23 and 24 were dissociated without trypsin, DNase I or collagenase, and cultured 
in serum-free medium (detailed above for NB21) – cells mostly grew as non-adherent 
spheres. 
 
 
2.1.2.2. Bone marrow samples 
 
Neuroblastoma samples NB22, 23 and 24 were accompanied by bone marrow aspirates, 
which were taken at the time of biopsy. Universal tubes containing the samples were 
centrifuged for 5 minutes at 1000rpm and the supernatant removed from the pellet of cells. 
The pellet was resuspended in serum-free medium (3:1 DMEM:F12, 100U/ml penicillin and 
100μg/ml streptomycin, 2% B27 supplement, 40ng/ml bBFGF and 20ng/ml EGF) and then 
sieved through a 40µm cell strainer. The single cells/smallest clumps that passed through 
the mesh were transferred to one 25cm2 flask, and the larger clumps washed from the mesh 
and cultured in a second 25cm2 flask. 
 
As the spheres increased in size in culture, they were passaged by mechanical trituration 
using a reduced bore Pasteur pipette (flamed over a Bunsen burner), and then passed 
through a 40µm cell strainer, before replating in new flasks. 
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2.1.3. Thawing of cells 
 
Upon removal from liquid nitrogen store, cryovials were placed in a warm waterbath until just 
thawed. The now liquid cell suspension (1ml) was transferred to a 10ml plastic tube, kept on 
ice to limit the damage caused by DMSO, and 1ml of the appropriate unsupplemented base 
medium (e.g. DMEM/RPMI 1640/etc.) added drop-wise over 30 seconds. A further 8ml 
medium was added over another 30 seconds, following which the diluted cell suspension 
was spun using a GLC-4 General Laboratory Centrifuge (Sorvall Instruments) at 1000rpm for 
5 minutes to remove the DMSO. The consequential cell pellet was then resuspended in 7ml 
fresh medium, and seeded in a 25cm2 flask. 
 
 
2.1.4. Freezing of cells 
 
Following trypsinisation (see cell culture), cells from a 75cm2 flask were diluted in their 
appropriate culture medium, up to a volume of 10ml. This cell suspension was then 
centrifuged at 1000rpm for 5 minutes, and the resulting pellet resuspended, on ice, in 
‘freezing medium’ – a solution of 90% FCS and 10% dimethylsulfoxide (DMSO). 1ml aliquots 
were transferred into cryovials (Sterilin) – a 75cm2 flask approaching confluency would 
typically produce 3 or 4 vials – and these cryovials placed in vapour phase over liquid 
nitrogen overnight to lower the temperature more slowly, limiting cell damage, and then 
transferred to the liquid nitrogen store the following day. 
 
 
2.1.5. Generation of a highly MYCN-expressing SH-EP-MYCN line 
 
In an attempt to produce a more stably MYCN-expressing line, SH-EP-MYCN cells were 
subcloned (see section 2.2.3.1.1) by plating at a density of one cell per well in a 96 well 
plate, in a volume of 50µl medium per well. The fastest-growing colonies were expanded 
and immunofluorescence stained for MYCN (see section 2.4.1.1), and the most consistently 
MYCN-expressing subclones expanded further into new cell lines. 
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2.2. Fluorescent cell labelling 
 
2.2.1. GFP cell transfection 
 
2.2.1.1. Plasmids used 
 
The two plasmids used were pEGFP-N1 (Clontech, USA) (Figure 2.1), from which 
successfully transfected cells could be selected by their resistance to the antibiotic G418, 
and a pBudCE4.1 vector (Invitrogen, UK) (Figure 2.2) containing GFP, cloned in under 
control of the human elongation factor 1α (EF-1α) promoter (by Dr Mohammed Akeel (PhD 
student, University of Liverpool, UK)), and contained a zeocin resistance gene. 
 
 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
http://www.human.cornell.edu/dns/qilab/images/pEGFPN11_1.jpg 
[plasmid map only] 
 
 
Figure 2.1. Vector map for pEGFP–N1. Adapted from 
http://www.human.cornell.edu/dns/qilab/images/pEGFPN11_1.jpg 
 
 
 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
https://products.invitrogen.com/ivgn/product/V53220 [a modified form of] 
 
 
Figure 2.2. pBudCE4.1 vector map, including GFP that was cloned in (by Dr Mohammed 
Akeel) under the EF-1α promoter. Adapted from Invitrogen. 
 
 
 
2.2.1.2. Killing curves 
 
“Killing curves” were performed as depicted in Figure 2.3, in which varying densities of the 
cells to be transfected were plated and these were cultured with varying concentrations of 
the appropriate antibiotic for the transfected plasmid. This was to discover the concentration 
of antibiotic required to kill the non-GFP-transfected cells at the various densities. Cells were 
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plated in 24 well plates at the densities shown in Figure 2.3, and 24 hours later, the 6 
different concentrations of antibiotic added. Cells were then monitored for survival/death for 
the following week, and an optimal plating density and antibiotic concentration deduced from 
these observations. 
 
      10% confluent 
      20% confluent 
      25% confluent 
      30% confluent 
100µg/ml 200µg/ml 400µg/ml 600µg/ml 800µg/ml 1mg/ml  
 
Figure 2.3. Illustration of a “killing curve”. Cells were seeded in a 24 well plate at various 
densities (detailed down the right hand side), and after 24 hours, a range of antibiotic 
concentrations added to their medium (shown along the bottom). 
 
 
 
2.2.1.3. ExGen500 
 
Transfection attempts were made using the pEGFP-N1 plasmid and transfection reagent 
ExGen500 (Fermentas) on B16 F1 cells. 24 hours after plating of the B16 F1 cells in a 
35mm diameter well, 3µg of plasmid DNA was mixed with 10µl ExGen500 in a total volume 
of 200µl 150mM sodium chloride, and was added to the melanoma cells and incubated for 
24 hours. 
 
 
2.2.1.4. TransIT-LT1 
 
The pEGFP-N1 and pBudCE4.1/EF-1α/EGFP were both transfected into B16 F1 cells, and 
pBudCE4.1/EF-1α/EGFP only into SK-N-BE(2)Cs, SK-N-AS and SH-SY5Y using TransIT-
LT1 (Geneflow). 2.5µg plasmid DNA was added to 7.5µl TransIT-LT1 reagent in 250µl total 
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volume of serum-free medium. This was added per well of cells that had been seeded on to 
a 35mm well 24 hours earlier, and incubated for 48 hours. 
 
 
2.2.1.5. JetPRIME 
 
The JetPRIME (Peqlab) reagent was used to transfect pBudCE4.1/EF-1α/EGFP into SK-N-
BE(2)C, SK-N-AS and SH-SY5Y cells. 2µg plasmid DNA was added per 35mm well 
alongside 4 or 6µl reagent in 200µl total volume of JetPRIME buffer, and incubated for 4 
hours. 
 
 
2.2.2. CFDA-SE labelling 
 
Following trypsinisation, 1x106 Kelly cells per ml of pre-warmed PBS containing 0.1% BSA 
were incubated with 2µM, 5µM or 10µM CFDA-SE (Invitrogen) for 10 minutes. Cells were 
washed four times in culture medium, and then plated at 20% confluency in 6 well plates. 
 
 
2.2.3. Lentiviral cell transduction 
 
2.2.3.1. Kellys 
 
Kelly cells, growing in a monolayer, were transduced with an EGFP-expressing lentivirus by 
Dr Sokratis Theocharatos (University of Liverpool, UK). EGFP was expressed constitutively 
under the control of the spleen focus-forming virus (SFFV) promoter (Demaison et al. 2002) 
(Figure 2.4) and the viral particles were pseudo-coated with a vesicular-stomatitis-virus 
glycoprotein (VSV-G) envelope (Aiken 1997). The Kellys were cultured in a 24 well plate, 
and the lentivirus was added to one well’s RPMI-based culture medium for 24 hours, after 
which time it was replaced by fresh, non-virus-containing medium. A proportion (≥80%) of 
the cells could be seen to be expressing EGFP 48-72 hours subsequent to lentivirus 
addition. Cells were expanded into a 6 well plate, then into a 25cm2 flask, and once thriving 
in a 75cm2 flask, were ready to be subcloned, in order to obtain a homogeneous strongly 
GFP-expressing cell line from this mixture of cells expressing GFP at varying levels, some 
not fluorescent at all. 
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2.2.3.1.1. Subcloning 
 
Cells were removed from their tissue culture flask using 1ml 0.05% trypsin EDTA at 37°C. 
When cells were seen to have lifted off the culture surface, 9ml of RPMI medium (the 10% 
FCS was important to counteract the trypsin) was added, and the cell suspension triturated 
using a blue pipette tip until a single-celled suspension was obtained. Cells could then be 
counted using a haemocytometer, and sequentially diluted with medium until a suspension 
of 20 cells/ml was obtained. The suspension was seeded at 50µl per well of a 96 well plate, 
i.e. an average of 1 cell per well, and fed every 2-3 days, in the hope that fluorescent 
colonies would form. Subcloning was also attempted a second time, using the same method, 
except the final cell suspension to be seeded was diluted in half fresh medium and half Kelly 
cell conditioned medium. The fluorescent colonies that eventually formed were transferred 
into a 4 well plate, up to a 6 well plate, then expanded into a 25cm2 and finally a 75cm2 flask. 
 
 
2.2.3.2. SH-EPs 
 
SH-EP and SH-EP-MYCN cells were lentivirally transduced in the same way as the Kellys 
(by Dr Anne Herrmann, University of Liverpool, UK), but instead of subcloning for the 
brightest GFP cells, they were selected using a FACS cell sorter (by Heba Karosh, MRes 
student, University of Liverpool, UK). 
 
 
2.2.4. Culture of GFP-labelled cells 
 
All GFP-expressing cell lines were cultured in the same medium, and using the same 
methods, as their non-GFP-labelled counterparts (see Table 2.1 and section 2.1.1). 
 
 
2.3. Chick embryo work 
 
2.3.1. Egg preparation 
 
Batches of (generally 18 or 24) fertilised white leghorn chicken eggs (obtained from Lees 
Lane Poultry, Wirral, UK) were incubated at 37°C and 35% humidity. The day the eggs were 
placed in the incubator was “day 0”. On embryonic day 2 (E2) or E3, i.e. Hamburger 
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Hamilton stage 12-18 (Hamburger and Hamilton, 1951), a small hole was poked in one end 
of the eggs, and a 19G gauge needle (Terumo) and syringe used to remove 3-4ml of 
albumin (dependent on the size of the egg), which resulted in the embryo and surrounding 
vessels being detached from the shell. A Power Craft PKW-160N Combitool was then used 
to cut a rectangular window (approximately 25x15mm) out of the shell, following which 
windows were resealed using Scotch Magic adhesive tape. Eggs were then re-incubated 
until injections at E3 or E6. 
 
 
2.3.2. Cell preparation 
 
2.3.2.1. For intravenous injections 
 
2.3.2.1.1. GFP-Kelly 
 
Prior to injection, cells were harvested from 75cm2 culture flasks using 1ml 0.05% trypsin 
EDTA, and following 5-10 minutes incubation at 37°C, diluted into 10ml total volume with 
RPMI 1640 medium containing 10% FCS, triturated using a blue pipette tip, and then 
counted using a haemocytometer. An appropriate number of cells (typically 5x106 cells for a 
batch of 24 eggs, of which 18-20 would be injected) were transferred into a sterile 10ml tube 
and centrifuged at 1000rpm for 5 minutes. The resulting cell pellet was then resuspended as 
single cells at a density of 1x105 cells/µl in RPMI 1640, containing 100µg/ml DNase I and 
0.05% fastgreen (i.e. in 50µl total volume, if preparing 5x106 cells). 
 
 
2.3.2.1.2. GFP-SK-N-BE(2)C 
 
Cells were harvested as above, with the exception that 0.25% trypsin was sometimes used 
instead of 0.05% trypsin EDTA, DMEM was used instead of RPMI 1640, and 1% 
collagenase was frequently added along with the 100µg/ml DNase I, to ensure the 
production of a single cell suspension, as the BE(2)Cs are particularly clumpy, and difficult to 
triturate. 
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2.3.2.1.3. GFP-SH-EP and GFP-SH-EP-MYCN 
 
Following trypsinisation, dilution in DMEM medium containing 10% FCS and centrifugation, 
cells were resuspended at a density of 1x105 cells/µl of DMEM containing 0.05% fastgreen. 
DNase was not added for these cells, as a single-celled suspension was easily achieved by 
mechanical trituration. 
 
 
2.3.2.1.4. GFP-TSIA (glioblastoma) 
 
Cells were prepared as for the Kellys, and following centrifugation, were resuspended at a 
density of 1x105 cells/µl in DMEM/F12 containing 0.05% fastgreen and 10µg/ml DNase I. 
 
 
2.3.2.1.5. Non-GFP-labelled cells 
 
In the earliest experiments, non-GFP-labelled SK-N-BE(2)C, SK-N-AS, SH-SY5Y and Kelly 
cells were all harvested as described for the GFP-Kellys, and following cell counts and 
subsequent centrifugation, resuspended in a solution of 500µl total volume of 40µM Vybrant 
DiI (Invitrogen) in the appropriate medium (see Table 2.1). Cells were incubated in the DiI for 
30 minutes, centrifuged for 5 minutes at 3000rpm, and then resuspended as single cells at a 
density of 1x105 cells/µl in the appropriate base medium (no FCS) containing 0.05% 
fastgreen. 
 
 
2.3.2.1.6. Fluorescent beads 
 
1µm diameter green fluorescent beads (Invitrogen) were washed in PBS, centrifuged at 
1000rpm for 5 minutes, and then suspended in PBS containing 0.05% fastgreen at a density 
of 1x105 beads/µl. 
 
 
2.3.2.2. Cells intended for eye cup injections 
 
SK-N-BE(2)C, B16 F1, Kelly (both non-GFP- and GFP-labelled) cells were prepared in the 
same way as the cells for intravenous injection (including DiI labelling for non-GFP cells), but 
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for these, resuspended 1x106 cells in a total volume of 50µl – sometimes made up mostly of 
the appropriate base medium (DMEM, RPMI or MEM, serum-free) with 0.2% fastgreen, and 
other times 1:1 base medium:matrigel (50µg/ml stock) (BD Biosciences). 
 
 
2.3.3. Chick injections 
 
Throughout the injection process, cells were kept on ice and occasionally re-triturated either 
by flicking the eppendorf or pipetting. Borosilicate glass capillary tubing (thin wall with 
filament, Warner Instruments) was pulled under heat to a thin taper (settings: heat 580, 
velocity 15, pull 130, time 15, pressure 20; Sutter Instrument Co.), and the resulting needles 
snapped using dissecting forceps to an appropriate diameter – thin enough for 
microinjection, but wide enough to allow entry of the cell suspension.  Suction was applied 
via mouth pipette (Sigma-Aldrich) to fill the needle with 2µl of the appropriate cell (or bead) 
suspension, and this was then injected, under a stereo microscope, into the extra-embryonic 
vitelline vein of each embryo at E3 (Figure 3.11 B+D) or E6, or, in the earliest experiments, 
into the E3 eye cup (either left or right, depending on which was up-facing) – as much cell 
suspension as could be injected, typically less than 0.5µl. Embryos were incubated until E10 
or, for some E3 injections, until E14.  To assess cell proliferation, typically 1µl of 20mM EdU 
(Click-iT EdU imaging kits, Invitrogen C10339) – roughly equivalent to a concentration of 
10µM, taking the embryo’s mass between E9 and E10 to be approximately 2g (Figure 2.4) – 
was injected into an extra-embryonic blood vessel at E9 for 24 hours (although 0.5 and 2 µl 
was injected with no appreciable difference in the percentage of cells labelled).  4µl of 20mM 
EdU was injected at E13. Embryos were then dissected 24 hours later (at E10 or E14), 
under a Leica M165 FC fluorescence microscope, and locations of GFP-labelled cells noted 
and photographed using a Leica DFC425C camera and Leica Application Suite V4.0 
software. Tissues containing GFP-Kelly cells were then fixed using 4% paraformaldehyde. 
 
 
 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
http://chickscope.beckman.uiuc.edu/resources/egg_to_chick/development.html 
[Figure 10] 
 
 
Figure 2.4. Average chick embryo masses for each day of gestation. (Taken from 
http://chickscope.beckman.uiuc.edu/resources/egg_to_chick/development.html. Illustration 
Copyright © 1998, Jill Hixon and the University of Illinois). 
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In each experiment, usually 18 eggs (but up to 24) were initially placed into the incubator. A 
small number of eggs may have been unfertilised, developing embryos were sometimes 
destroyed during the “windowing” procedure, or were occasionally deformed,  and some died 
for unknown reasons. Therefore between 12 and 18 embryos (in a typical experiment, 
approximately 15) were injected with malignant cells at E3. On occasion, all of the injected 
embryos would be alive on the day of analysis (E10 or E14), but usually a few would have 
died, either as a consequence of excessive bleeding after injection, or often with unknown 
cause slightly later in development. In a typical batch of 18 eggs, of which 15 had been 
injected with cells at E3, roughly 11 would have survived to the day of dissection (although 
this could be as low as 3 or 4 chicks, or as high as 14-15). In addition to the considerable 
variability described above, further inconsistency could sometimes be observed upon 
dissection – this would be usually down to a “poor” injections, perhaps because the cell 
suspension had become particularly clumpy, or the embryo was underdeveloped with 
smaller blood vessels and lower circulatory volume, both of which would have made it 
difficult to administer the usual number of cells. However, in a typical experiment, between 7 
and 10 embryos would usually contain sufficient numbers of fluorescently labelled cells to 
allow for analysis (and comparisons) to be performed.  
 
2.3.4. Tissue mounting for morphology studies 
 
Following fixation for the appropriate time (tissue-dependent, but generally 30-90 minutes) in 
4% paraformaldehyde, the small tissue pieces were washed in PBS, and then positioned in 
a drop of Dako fluorescence mountant on a glass slide, and a glass coverslip placed over 
the top. The sympathetic ganglia and meninges could be laid out and mounted without any 
problem. The gut was cut in half longitudinally using forceps and mounted luminal surface 
down. The tail tissue had to be forcibly “squashed” between the slide and coverslip. 
 
 
2.3.5. Tissue block preparation and frozen sectioning 
 
Tissues of interest were fixed in 4% paraformaldehyde, and then sequentially immersed in 
6%, 12%, then 18% sucrose for approximately 1 hour each, or until the tissue sank (this 
depended on the size of the tissue). The tissues were then mounted on 2cm diameter cork 
discs in Cryo-M-Bed embedding compound (Bright), orientated so the GFP cells were at the 
top, near the cutting surface, and frozen in isopentane cooled over liquid nitrogen to ensure 
more uniform and less rapid freezing through the tissue, thus causing less damage. Blocks 
were stored at -80°C. 10µm thick tissue sections were cut using a cryostat and collected 
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onto Menzel Gläser Superfrost Plus glass slides (Thermo Scientific). Those containing GFP-
labelled (or DiI-labelled) cells were then stained using the appropriate antibodies. 
 
 
2.4. Immunofluorescence staining 
 
2.4.1. Pre-fixed staining 
 
2.4.1.1. Cultured cells 
 
Cells that were to be stained for intracellular antigens had to be pre-fixed and permeabilised 
to allow entry (and exit) of the antibodies. Cells were plated at an appropriate density 
(typically 25-40%) on 13mm glass coverslips and cultured for 24-48 hours. Immediately 
following removal from the tissue culture plate, cells were fixed using 100µl 4% 
paraformaldehyde per coverslip, for 10 minutes at room temperature. Subsequent to 
paraformaldeyde removal, fixation was quenched with 50µl of 0.1M glycine pH7.4 for 15 
minutes at room temperature. Blocking was completed using 1% BSA, 0.1% Triton X100 in 
0.12M phosphate pH7.4, and 50µl per coverslip was incubated at room temperature for 15 
minutes. 50µl primary antibody (see Table 2.3) diluted in 1% BSA, 0.1% Triton X100 in 
0.12M phosphate pH7.4 (or diluent alone for secondary antibody controls) was added per 
coverslip and incubated at room temperature for 30-60 minutes. Following primary antibody 
removal, coverslips were dip washed 3 times in PBS (+Ca2+/Mg2+). 50µl of the appropriate 
secondary antibody (see Table 2.4) diluted in 1% BSA, 0.1% Triton X100 in 0.12M 
phosphate pH7.4, plus 0.1µg/ml DAPI (Sigma-Aldrich), was incubated for 30-60 minutes for 
each coverslip, at room temperature in the dark. Secondary antibodies were removed, and 
cells washed 3 times in PBS, once in distilled water, and then left to dry before mounting 
onto a glass slide with Dako fluorescence mountant. 
 
 
2.4.1.2. Frozen sections 
 
10µm thick frozen sections were cut, collected onto Superfrost Plus glass slides, and 
hydrophobic rings were drawn around those sections containing GFP-Kelly cells using a 
Dako pen, which were then allowed to dry. Tissue had been fixed prior to the production of 
frozen blocks, therefore the staining procedure began with the addition of 50µl of 0.1M 
glycine pH7.4 per section, and incubation at room temperature for 15 minutes. The staining 
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protocol then proceeded exactly as for “cultured cells” above, except for the washing steps, 
where slides were submerged in PBS (+Ca2+/Mg2+) for 10 minutes, before dip washing a 
further 2 times, and then allowing for drying of the hydrophobic ring before the addition of the 
next solution. See Table 2.3 for the primary antibodies used to stain frozen sections. 
 
 
Antibody Dilution Species raised in Clonality Cross reactivity Source 
Caspase 3 1:10 Rabbit Polyclonal Human, mouse, rat 
Millipore 
ab3623 
GFP 1:500 Rabbit Polyclonal - Abcam ab290 
HMB-45 1:5 Mouse Monoclonal Mouse, rat, human 
Abcam 
ab732 
Human 
nuclear 
antigen 
1:50 Mouse Monoclonal Human Chemicon MAB1281 
ki67 1:100 Mouse Monoclonal Human Dako F0788 
MYCN 1:20 Mouse Monoclonal Mouse, human Abcam ab16898 
NB84 1:200 Mouse Monoclonal Human Novocastra NCL-NB84 
N-CAM 
(CD56)* 1:2.5 Mouse Monoclonal Human 
Diaclone 
852.703.020 
Nestin 1:200 Rabbit Polyclonal Human, mouse, rat, hamster 
Abcam 
ab5968 
Phox2b 1:200 Rabbit Polyclonal Human, rodent Sigma-Aldrich P0371 
SMA 1:500 Mouse Monoclonal 
Rabbit, mouse, 
chicken, human, 
goat, sheep, rat, 
canine, bovine 
Sigma-Aldrich 
A2547 
Sox10 1:100 Goat Polyclonal 
Mouse, rat, 
human, equine, 
canine, bovine, 
porcine 
Santa Cruz 
sc-17342 
TH** 1:1000 Sheep Polyclonal Mammals Abcam ab123 
TUJ-1 
(β-III-tubulin) 1:500 Mouse Monoclonal 
“Multi-species” 
(including chick, 
human, rat) 
R&D 
mab1195 
Vimentin 1:200 Mouse Monoclonal Rat, human, avian, porcine 
Santa Cruz 
sc-6260 
 
Table 2.3. Details of primary antibodies used in pre-fixed staining of cultured cells and/or 
tissue sections. * Antibodies that detect cell surface antigens, therefore would ordinarily be 
used in live staining. However, since frozen sections were already fixed, they were used as 
per the pre-fixed protocol. **Detected (successfully) using goat-specific secondary. 
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Antibody Dilution Source 
Goat anti-mouse 
Alexa Fluor 488 (green) 1:500 Invitrogen, A11001 
Goat anti-mouse 
Alexa Fluor 568 (red) 1:500 Invitrogen, A11004 
Goat anti-rabbit 
Alexa Fluor 488 (green) 1:500 Invitrogen, A11034 
Goat anti-rabbit 
Alexa Fluor 594 (red) 1:500 Invitrogen, A11012 
Donkey anti-goat 
Alexa Fluor 488 (green) 1:500 Invitrogen, A11055 
Donkey anti-goat 
Alexa Fluor 594 (red) 1:500 Invitrogen, A11058 
 
Table 2.4. Details of secondary antibodies used in this project. 
 
 
2.4.2. Live staining 
 
Cells in culture that were to be stained for cell surface antigens were done so live. Cells 
were plated on 13mm glass coverslips and cultured for 24-48 hours. Following removal from 
the culture medium, 50µl primary antibody (see Table 2.5) diluted in 1% BSA in 0.12M 
phosphate pH 7.4 was added per coverslip and incubated at room temperature for 30 
minutes. 50µl diluent alone was added for secondary antibody controls. Coverslips were dip 
washed 3 times in PBS (+Ca2+/Mg2+) and then incubated with 50µl secondary antibody (see 
Table 2.4) diluted in 1% BSA in 0.12M phosphate pH 7.4 for 30 minutes at room temperature 
in the dark. Coverslips were dip washed 3 times in PBS, and then fixed using 50µl 4% 
paraformaldehyde for 10 minutes. Following fixation, coverslips were washed a further 3 
times in PBS, once in distilled water, and then left to dry, before mounting on a glass slide 
with Dako fluorescence mountant. 
 
Antibody Dilution Species raised in Clonality Cross reactivity Source 
CD133 1:100 Rabbit Polyclonal Human 
Autogen 
Bioclear 
abv-114 
CD24 1:50 Mouse Monoclonal Human Abcam ab76514 
HNK-1 
(CD57) 1:500 Mouse Monoclonal Human 
Diaclone 
853.463.020 
N-CAM 
(CD56) 1:2.5 Mouse Monoclonal Human 
Diaclone 
852.703.020 
 
Table 2.5. Primary antibodies used to live stain cultured cells. 
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2.4.3. Whole mount/explant staining 
 
Fixed tissue pieces were first placed in 0.25% Triton x100 in PBS (PBST) for 1 hour on a 
rocker to permeabilise the cells within the tissue, following which they were blocked in 3% 
BSA in PBST for a further hour. The tissues were then incubated overnight at 4°C in the 
appropriate primary antibodies, diluted in 3% BSA in PBST (see Table 2.6). The following 
day, tissues were first washed briefly in PBST to remove the majority of the antibody, and 
then washed more thoroughly, 3-4 times for at least an hour each in PBST on a rocker. 
Tissues were once again blocked in 3% BSA in PBST, and then incubated overnight at 4°C 
with the appropriate secondary antibodies (see Table 2.4) diluted 1:500 in 3% BSA in PBST, 
plus 0.1µg/ml DAPI. The next day, tissues were washed briefly in PBST, and then washed 3-
4 more times for at least an hour each in PBST on a rocker, covered in foil. They were then 
washed briefly in PBS before mounting between a glass slide and coverslip in Dako 
fluorescence mountant, ready for viewing. 
 
 
Antibody Dilution Species raised in Clonality Cross reactivity Source 
GAP43 
(chick-
specific) 
1:500 Rabbit Polyclonal Chick (Allsopp & Moss 1989) 
GAP43 
(human-
specific) 
1:1000 Rabbit Monoclonal Mouse, rat, human Abcam ab75810 
GFP 1:500 Rabbit Polyclonal - Abcam ab290 
MYCN 1:10 Mouse Monoclonal Mouse, human Abcam ab16898 
NF 70kD 1:500 Rabbit Polyclonal Human, chick 
Dr Diana Moss 
(University of 
Liverpool, UK) 
TH** 1:1000 Sheep Polyclonal Mammals Abcam ab123 
TUJ-1 
(β-III-tubulin) 1:500 Mouse Monoclonal 
“Multi-species” 
(including chick, 
human, rat) 
R&D 
mab1195 
 
Table 2.6. Primary antibodies used to whole mount stain chick tissue pieces. **Detected 
(successfully) using goat-specific secondary. 
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2.5. Cell proliferation detection 
 
2.5.1. ki67 
 
Following successful ki67 staining of cells in culture, yet no positive stain on frozen sections, 
various techniques were utilised in an attempt to optimise this antibody for use on tissue 
sections. 
 
 
2.5.1.1. Antigen retrieval 
 
An E11.5 mouse embryo was fixed in 4% paraformaldehyde for 1 hour, and then mounted 
as detailed in section 2.3.5, with the head in one block and the body in another, so that 
saggital sections could be taken. Antigen retrieval techniques were performed in the hope of 
a successful ki67 stain. 
 
 
2.5.1.1.1. Sodium dodecyl sulphate (SDS) 
 
Hydrophobic rings were drawn around each mouse tissue section using a Dako pen and 
allowed to dry. Slides were then washed 3 times for 5 minutes each in PBS (+Ca2+/Mg2+). A 
solution of 1% SDS dissolved in PBS was prepared, and 50µl added to each section and 
incubated at room temperature for 5 minutes. Following 3 5 minute washes in PBS, 50µl 
blocking solution (1% BSA, 0.1% Triton X100 in 0.12M phosphate pH7.4) was added per 
section for 10 minutes, and then 50µl ki67 antibody left on some sections for 1 hour at room 
temperature, and some sections overnight at 4°C – half at the usual dilution of 1:100 and 
half 1:50. Staining continued following the protocol in section 2.4.1.2. 
 
 
2.5.1.1.2. Citrate buffer 
 
Slides containing mouse embryo head or trunk tissue sections were washed 3 times for 5 
minutes each in PBS (+Ca2+/Mg2+). Citrate buffer was made by dissolving anhydrous citric 
acid in distilled water to a concentration of 10mM, adjusting the pH to pH6.0 with 1M NaOH, 
and adding 0.05% Tween 20. The citrate solution was heated inside a beaker, on a hot 
plate, to 100°C, and the slides were immersed in the boiling buffer for 10, 20 or 40 minutes. 
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After cooling, slides were washed in PBS 3 times for 5 minutes each. Slides were allowed to 
dry, and then hydrophobic rings were drawn around each section with a Dako pen. 50µl 
blocking solution (1% BSA, 0.1% Triton X100 in 0.12M phosphate pH7.4) was added to each 
section, and antibody staining then proceeded as detailed in section 2.4.1.2, except that the 
ki67 primary antibody was left on some sections for 1 hour at room temperature and others 
overnight at 4°C – half at the usual dilution of 1:100 and half at 1:50. 
 
 
2.5.1.2. Unfixed embryonic rat tissue 
 
Tissues from the brains and intestines of E21 rat embryos were mounted unfixed, i.e. 
dissected from the rats, washed in PBS, and positioned in the Cryo-M-Bed embedding 
compound (Bright). Blocks were then frozen as detailed in section 2.3.5. 10µM sections of 
both tissues were fixed with 4% paraformaldehyde for 10 minutes, which was then quenched 
with 50µl 0.1M glycine pH7.4. A third of sections were immersed in boiling citrate buffer for 
30 minutes, a third were treated with 1% SDS for 5 minutes, and the final third were stained 
without antigen retrieval. The ki67 antibody was used at a dilution of 1:50 and left on 
sections overnight. 
 
 
2.5.2. EdU 
 
The Click-IT EdU Imaging Kit was purchased from Invitrogen (C10339), and their protocol 
was either followed or adapted. 
 
 
2.5.2.1. Cells in culture 
 
At least 24 hours after seeding on 13mm glass coverslips, 5µM EdU was added to the 
culture medium, by producing a 2X (10µM) solution in the appropriate (fresh) medium and 
replacing half of the cells’ culture medium with this solution. 24 hours later, cells were fixed 
in 4% paraformaldehyde for 10 minutes. Following 2 washes in 3% BSA in PBS, 50µl of 
0.5% Triton X100 in PBS (PBST) was added to each coverslip and incubated for 20 minutes 
at room temperature. Since the Click-IT reaction cocktail used to detect the EdU results in 
the loss of GFP fluorescence, 50µl of an anti-GFP primary antibody (see Table 2.3) diluted 
in 3% BSA in PBS was incubated for 30 minutes at room temperature for those coverslips 
containing GFP-labelled cells. Following 3 washes in PBST, 50µl Click-IT reaction cocktail 
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(containing Alexa Fluor 594; see Invitrogen protocol) was added per coverslip and incubated 
for 30 minutes at room temperature in the dark. Following removal of the cocktail, cells were 
washed 3 times in 3% BSA in PBS. For coverslips containing GFP-labelled cells, the primary 
anti-GFP antibody was then detected using a goat-anti-rabbit Alexa Fluor 488 secondary 
(see Table 2.4) diluted in 3% BSA in PBS and incubating at room temperature in the dark for 
30 minutes – this step was emitted when testing the system on non-GFP Kellys. Following 2 
washes in PBST and 1 wash in PBS, 50µl Hoechst 33342, diluted 1:3000 in PBS, was 
incubated on each coverslip for 30 minutes at room temperature, protected from light. Each 
coverslip was then washed 3 times in PBS, once in distilled water, and once dry, mounted 
onto a glass slide using Dako fluorescence mountant. 
 
 
2.5.2.2. Frozen sections 
 
For chick tissue sections, EdU had already been injected into the chick embryos 24 hours 
prior to sacrifice, and tissues had been fixed before frozen blocks were produced. 
Hydrophobic rings were drawn around sections of interest using a Dako pen and once dry, 
sections were washed twice in 3% BSA in PBS, and then blocked for 20 minutes with 50µl 
0.5% Triton X100 in PBS (PBST). EdU detection then proceeded exactly as for cells in 
culture (section 2.5.2.1). 
 
 
2.5.2.3. Tissue pieces/explants 
 
Tissues were fixed in 4% paraformaldehyde and then washed in 3% BSA in PBST 3 times 
for 5 minutes each. Tissues were permeabilised using 50µl PBST per coverslip, or 500µl per 
well (of a 24 well plate) containing multiple tissue pieces, which was incubated for 20 
minutes at room temperature – each step in this protocol was completed on a rocker for the 
tissue pieces – before repeating twice more. 50µl anti-GFP primary antibody (see Table 2.3) 
per coverslip or 500µl per well, diluted in 3% BSA in PBST was incubated overnight at 4°C. 
Tissues were then washed for 3x1hour in PBST, following which 50µl Click-IT reaction 
cocktail (containing Alexa Fluor 594; see Invitrogen protocol) was added per coverslip/500µl 
per well and incubated for 90 minutes at room temperature in the dark. Following removal of 
the cocktail, cells were washed for 3x30 minutes in PBST. The GFP antibody was then 
detected using a goat-anti-rabbit Alexa Fluor 488 secondary (see Table 2.4) diluted in 3% 
BSA in PBST, incubated in the dark overnight. The next day, tissues were washed in PBST 
3 times for an hour each, once in PBS for 30 minutes, and once in distilled water for 30 
Chapter Two: Materials and Methods 
 
59 
 
minutes. Hoechst 33342 was not added as the confocal microscope did not have the 
appropriate filter. The tissues were then mounted onto glass slides using Dako fluorescence 
mountant. 
 
 
2.5.2.4. Cell proliferation quantification 
 
Following the detection of EdU incorporation into GFP-Kelly cell nuclei, the proportion of 
dividing cells was determined by counting EdU-labelled nuclei and calculating this as a 
percentage of all the GFP-labelled cells.  A minimum of 200 cells from at least two 
experiments, including tissue from at least three embryos per experiment was analysed. 
 
 
2.6. MYCN fluorescence analysis 
 
10µm frozen sections of E10 chick tissues containing GFP-labelled Kellys that had been 
immunofluorescence stained for MYCN were photographed using the Leica Application Suite 
software. Fluorescence intensity was measured using Image J software. In each 
photograph, the MYCN fluorescence intensity of every Kelly nucleus was measured 
individually. The “freehand selection” tool was used to demarcate an area that incorporated 
the majority of one Kelly cell nucleus (aided by the corresponding DAPI photograph), then by 
selecting “analyze” and “measure”, a mean fluorescence intensity value was obtained. An 
average background fluorescence value was calculated from the fluorescence intensity 
measurements for 6 individual chick nuclei per section, and this was subtracted from every 
single Kelly cell’s fluorescence value in that section. After accounting for background 
fluorescence, a mean was calculated from all of the individual Kelly values within a particular 
tissue, to obtain a quantitative MYCN fluorescence intensity value for that tissue. 
 
 
2.7. Confocal imaging 
 
Tissue pieces mounted onto microscope slides were viewed and photographed on a Zeiss 
LSM 710 confocal microscope. Images were processed using the Zeiss LSM Image Browser 
software. 
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2.8. E10 sympathetic ganglia and tail in vitro culture 
 
2.8.1. Dissociated tissue culture 
 
Following dissection of the E10 embryos, sympathetic ganglia and small pieces of tail tissue, 
both containing GFP-Kelly cells, were incubated for 30min at 37°C in 0.25% trypsin, washed 
3 times in Hanks, and then dissociated in 1ml of medium by mechanical trituration using a 
reduced bore Pasteur pipette (flamed over a Bunsen burner). The single-celled suspensions 
(chick SG plus the Kelly cells originating within them, and tail cells with their associated 
Kellys) were plated onto glass coverslips coated for 1 hour with 10µg/ml Poly-L-lysine and 
10µg/ml laminin in 0.1M sodium borate pH8.3. The volume of each well was made up to 
500µl total with L15 medium (Gibco), containing 0.5% methyl cellulose, 10% FCS, 100U/ml 
penicillin, 100μg/ml streptomycin, 0.3% glucose and 5ng/ml NGF (Sigma-Aldrich). 
 
 
2.8.2. Explant culture 
 
Kelly-containing sympathetic ganglia and tail tissues were torn into small pieces of roughly 
300-600µm diameter, and following confirmation that they contained GFP-labelled Kelly 
cells, were plated as explants onto Poly-L-lysine- and laminin-coated coverslips, in L15 
medium as described above. 3 or 4 tissue pieces were explanted per well. 
 
Both culture systems were incubated at 37°C in a CO2-free incubator in order to maintain the 
correct pH, in accordance with a previously published protocol for sympathetic neuron 
culture (Mains & Patterso.Ph 1973). After 48 hours, EdU was added to the culture medium in 
each well to a concentration of 5µM. Cells were then incubated for a further 24 hours before 
fixation in 4% paraformaldehyde. Dissociated cells were stained for MYCN as detailed in 
section 2.4.1.1 and EdU incorporation was detected as in section 2.5.2.1. Explants were 
stained for MYCN using the whole mount method detailed in section 2.4.3 and EdU detected 
using the method detailed in section 2.5.2.3. 
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3.1. Introduction 
 
Neuroblastoma, like melanoma, is a neural-crest-derived malignancy, and also resembles 
melanoma in that it has unusually high rates of spontaneous regression. Therefore it was 
reasoned that neuroblastoma was a prime candidate on which to test the previously 
published chick embryo model detailed in Chapter One. 
 
The chick embryo has long been used as a model system, in a multitude of different ways, to 
investigate phenomena such as neural crest development and diseases such as cancer. 
Although humans are closer to mice in the phylogenetic tree than chickens, embryonic 
development – particularly the early stages – is well conserved amongst all vertebrates. The 
chick embryo also has certain advantages over the mouse, in that it is significantly cheaper, 
and one has “easy access” to the developing embryo, for both manipulation and viewing, 
since it grows in ovo rather than in utero. In addition, chick development proceeds much 
more quickly than a mouse in its initial stages, as illustrated in Table 3.1. 
 
 
 
This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
Butler, H. & Juurlink, B.H.J. (1987) An atlas for staging mammalian and 
chick embryos, CRC Press Inc., Florida. 
 
 
Table 3.1. A comparison between the development of human, chicken and mouse embryos. 
Adapted from Butler & Juurlink 1987. 
 
 
Chick embryonic development has been well studied and well documented. Although aging 
the embryos according to their number of days of incubation is a perfectly acceptable and 
indeed useful developmental assessment throughout most of their gestation, for the first few 
days, further breakdown into more detailed developmental stages is needed. In a batch of 
eggs that all go into the incubator at the same time, there can be a huge variation in 
developmental stages between individual embryos, which is generally most pronounced up 
to E3/4. In 1951, Hamburger and Hamilton published a universal staging system for chick 
embryos, which is still used today and is detailed in Figure 3.1 and Table 3.2. 
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This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
http://www.docstoc.com/docs/91438835/HAMBURGER-POSTER 
 
 
Figure 3.1. Series of photographs documenting Hamburger Hamilton stages 1-35 of chick 
embryonic development. Adapted from 
http://www.docstoc.com/docs/91438835/HAMBURGER-POSTER, courtesy of Wiley Devel-
opmental Dynamics. 
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HH 
stage 
Time post 
fertilisation 
Brief 
description 
1   
2 6-7 h  
3 12-13 h  
4 18-19 h Primitive streak at maximum length 
5 19-22 h Head process visible 
6 23-25 h  
7 23-26 h 1 pair somites; neural folds in head 
8 26-29 h 4 pairs somites; neural folds meet at midbrain level; foregut formation begins; blood islands over yolk sac, dorsal aorta forming 
9 29-33 h 7 pairs somites; heart formation begins 
10 33-38 h 10 pairs somites; 3 primary brain vesicles; pronephric kidney formation begins 
11 40-45 h 13 pairs somites; anterior neuropore closing 
12 45-49 h 16 pairs somites; anterior neuropore closing; heart S-shaped, blood circulation begins; liver primordium visible 
13 48-52 h 19 pairs somites; neural tube closed down to posterior neuropore 
14 50-53 h 22 pairs somites; pharyngeal arches 1+2 distinct; hindgut present as simple tube 
15 50-55 h 24-27 pairs somites; optic cup completely formed 
16 51-56 h 26-28 pairs somites; tail bud present; extra-embryonic vasculature formation complete 
17 52-64 h 29-32 pairs somites; limb buds present; pancreas formation begins 
18 65-69 h 30-36 pairs somites; amnion closed, allantois obvious; gall bladder formation begins; tongue swellings appear 
19 68-72 h 37-40 pairs somites, extending into tail; eyes unpigmented 
20 70-72 h 40-43 pairs somites; body rotation complete, faint eye pigmentation 
21 3.5 d 43-44 pairs somites; primary sympathetic ganglia present 
22 3.5 d Somites extend almost to tip of tail; eye pigmentation distinct 
23 4 d Adrenal masses begin to form 
24 4 d  
25 4.5-5 d Elbow and knee joints distinct 
26 5 d Secondary sympathetic ganglia (“proper”) forms 
27 5-5.5 d  
28 5.5-6 d Beak outgrowth visible; future divisions of intestine recognisable 
29 6-6.5 d  
30 6.5-7 d Feather germs begin to form; chromaffin cells start to differentiate 
31 7-7.5 d  
32 7.5 d  
33 7.5-8 d  
34 8 d  
35 8-9 d Adrenal glands fully formed 
36 10 d Skull begins to ossify 
37 11 d  
38 12 d  
39 13 d Eyelids almost fully formed 
40 14 d  
41 15 d Metanephric kidneys fully functional 
42 16 d  
43 17 d Herniated intestine begins to be drawn back into abdomen 
44 18 d  
45 19-20 d  
 
Table 3.2. Table linking Hamburger Hamilton stages with incubation time. 
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Dhanya Mullassery (PhD thesis) injected a single-cell suspension of DiI-labelled SK-N-
BE(2)C neuroblastoma cells into the E2 neural tube, and found that after 48hr, the cells had 
segmented into clusters roughly at the levels of the intersomitic clefts, as was reported with 
the melanoma cells (Oppitz et al. 2007), and some were beginning to migrate with the host 
neural crest cells (Mullassery 2011). The neuroblastoma cells were behaving in a similar 
way to the melanoma cells and responding to their ancestral embryonic environment. 
Therefore the starting point for the project detailed in this thesis was effectively the positive 
control – do neuroblastoma cells proliferate to form a tumour in an inappropriate embryonic 
environment? Since the eye cup was a structure in which the injected cells could be nicely 
contained, yet would still have ample opportunity to invade, and an environment where the 
developmental signals found in the neural crest microenvironment would not be present, cell 
injections into this structure were attempted first. 
 
 
3.2. Aims 
 
To establish and optimise a new model system in which to study the effects of an embryonic 
microenvironment on neuroblastoma cells. 
 
• Determine the most appropriate technique for cell administration – test intra-ocular 
versus intravenous injection. 
• Test multiple neuroblastoma cell lines: SK-N-BE(2)C, SK-N-AS, SH-SY5Y, Kelly; and 
the mouse melanoma line B16 F12. 
• Attempt to characterise Kelly cells – the most promising cell line. 
• Determine the most effective cell labelling method – test DiI, CFDA-SE, GFP 
plasmids. 
• Analyse the behaviour of neuroblastoma cells within the chick embryo by means of 
immunofluorescence staining frozen sections. 
 
 
3.3. Results 
 
3.3.1. SK-N-BE(2)C eye cup injections 
 
Initial experiments used SK-N-BE(2)C neuroblastoma cell line, as it is MYCN-amplified, and 
therefore among the most aggressive lines. In addition, BE(2)Cs have been documented to 
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form tumours in nude mice  (Gaze, Hamilton & Mairs 1994), so it was assumed they would 
do the same in the chick. As in the Oppitz (2007) paper, cells were injected into the chick 
embryo eye on embryonic day 3 (E3), equivalent to HH stage 18, and then dissected at E7. 
The authors of the melanoma paper did not detail their cell preparation or the number of 
cells transplanted, but in this investigation <0.5µl was injected (limited to the volume each 
eye could hold) of a cell suspension of 106 cells in 50µl volume per eye. Initially the cells 
were suspended 1:1 in DMEM medium and ice-cold matrigel, with the idea that the matrigel 
would begin to polymerise within the 37°C chick eye and hold the cells in place, but it made 
no difference to whether the cells leaked out of the eye cup or remained inside, compared to 
DMEM alone. The cell suspension contained around 0.2% fastgreen to enable visualisation 
of the cell suspension in order to confirm they were being injected into the correct place 
(Figure 3.2 B, arrow), and the cells themselves were labelled with DiI to allow their 
identification under a fluorescent microscope (Figure 3.2. A). Intra-ocular BE(2)C injections 
were successfully performed on approximately 40 embryos (that survived with DiI 
fluorescence inside the eye), in 9 separate experiments. Upon dissection, clumps of BE(2)C 
cells were usually found within the retina, attached to the internal surface of the lens and in 
the space outside the vitreous humor (Figure 3.2 and 3.3). When the DiI-containing tissue 
pieces were dissected out, fixed in paraformaldehyde and mounted between a glass slide 
and coverslip, the BE(2)C cells were seen to be intensely fluorescent. This suggested limited 
cell division within the population, due to the lack of dilution of the fluorescent molecules. 
10µm frozen sections of the BE(2)C-containing eyes were stained with the ki67 antibody 
(Figure 3.3 G-I), and negative results implied that the neuroblastoma cells were not 
proliferating, however, subsequent experiments led to the conclusion that the ki67 antibody 
was ineffective when applied to frozen sections (see section 3.4. Discussion). Cells also 
failed to stain for caspase 3, a protein indicative of apoptosis. BE(2)Cs in culture stained 
positively for both ki67 and caspase 3, both when grown within matrigel and in normal 
medium alone (Figure 3.4), therefore at this time, a lack of staining for both of these proteins 
in the cells in vivo suggested that the cells were surviving, but not progressing through the 
cell cycle – in effect, just “sitting there” – as their rounded morphology made any attempts at 
differentiation seem unlikely. Sections were also stained with an antibody to the human 
nuclear antigen, to distinguish the human-derived neuroblastoma cells from the chick tissue, 
and confirm that the red fluorescence that presumably indicated the presence of DiI labelled 
cells was indeed the BE(2)C cells (Figure 3.3 A-F). This antibody had an extremely high 
background, and its results were variable – in some cases, a positive stain could be seen to 
stand out as more intense from the background (Figure 3.3 B, arrows), yet in other sections, 
no positive stain could be seen (Figure 3.3 E), even when I was relatively confident of the 
presence of cells. This antibody was not deemed to be particularly reliable. 
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Figure 3.2. <10,000 DiI-labelled BE(2)C cells were injected into the E3 chick eye. A, 
fluorescence and B, brightfield image of cells shortly after injection. Arrow points to 
fastgreen-labelled cell suspension. C-H, eye tissues from E7 chicks were dissected, and 
those containing BE(2)C cells were “squashed” between a slide and coverslip. C,D, retina; 
E-H lens. Scale bars A-B 100µm, C-H 50µm. 
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Figure 3.4. In parallel to the chick eye cup injections, DiI-labelled BE(2)C cells were 
“injected” by mouth pipette on to glass coverslips, grown in culture, then stained using 
antibodies as labelled. A-B, E-F, cells in a 1:1 matrigel:PBS suspension; C-D, G-H, cells 
suspended in PBS. Scale bar 50µm. 
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3.3.2. B16 F1 eye cup injections 
 
As the results of the melanoma eye cup injections had not been reproduced using 
neuroblastoma cells, the B16 F1 mouse melanoma cell line used by Oppitz et al. (kindly 
donated by Prof Dot Bennett, St George’s University of London, UK) were injected using the 
same methods as for our BE(2)C eye cup injections (Figure 3.5).  
 
 
 
Figure 3.5. <10,000 DiI-labelled B16 F1 mouse melanoma cells were injected into the E3 
chick embryo eye. Photographs show cells within the E4 chick eye, 24 hours after injection. 
Scale bars A-B, 500µm; C-D, 100µm.  
 
 
Approximately 40 embryos (from 8 separate batches) survived to E7, at which point the eyes 
were dissected. Upon dissection, the melanoma cells were easily identifiable, even without 
fluorescence, due to their obvious pigmentation (Figure 3.6). Like the BE(2)Cs, melanoma 
cells were found within the retina, on the back of the lens, and outside the vitreous humor 
(Figure 3.6). 
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Figure 3.6. Dissected A-D, E7; E-H, E10 chick eye tissues containing DiI-labelled B16 F1 
mouse melanoma cells that had been injected at E3. A-B,E-F, retina; C-D,G-H, internal view 
of the lens. Scale bars A-F, 500µm; G-H, 1mm. 
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Tissues were then mounted between a glass slide and coverslip and observed under a 
higher magnification than was permitted by the dissecting microscope. The cells were found 
to have a similar appearance to the BE(2)Cs, often residing in clumps and usually retaining 
their DiI fluorescence (Figure 3.7). In frozen sections, confirmation that the red DiI 
fluorescence belonged to B16 F1 cells was achieved by staining with the Human Melanoma 
Black antibody, HMB-45 (Figure 3.8 A-C). However, cell division was not detected with the 
ki67 antibody (Figure 3.8 D-F), again despite the fact that the B16 F1 cells in culture all 
stained brightly for this protein, when cultured with and without matrigel (Figure 3.9 E-H). 
Since caspase 3 is a protein involved in the apoptotic pathway, those cells that had already 
undergone the process may not have been identified by this antibody, plus even those that 
stained positively had an altered cell morphology, so although we were fairly confident of a 
tiny proportion of positively staining B16 F1 cells in culture (Figure 3.9 I-L), it was not clear 
whether the odd stained cell in the sections was authentic caspase 3 staining or an artefact 
(Figure 3.8 H, arrow). Nevertheless, it was clear that there were not vast numbers of these 
cells undergoing apoptosis. The apparent lack of cell proliferation was still a mystery, as the 
sheer size and appearance of the “tumours” seen in the Oppitz (2007) work suggested this 
to be the case. Further sections stained for HMB-45, showed corresponding green HMB-45 
melanoma-specific fluorescence over a clump of DiI fluorescent cells in the retina, but also 
identified an extension of this clump deeper into the tissue, which had lost most, if not all, of 
its DiI red fluorescence (Figure 3.10 A-D). This suggested that the cells had been 
proliferating, which had resulted in a dilution of the DiI (unfortunately these sections were not 
stained for ki67). Proliferation had been assessed using ki67 staining in early experiments, 
however subsequent results revealed that ki67 failed to stain frozen sections unlike cultured 
cells (see section 3.4. Discussion). The staining in Figure 3.10 A-D also implied that the cells 
had invaded further into the tissue (although this could not be confirmed, as it may well have 
been the route of injection at E3, and so the cells could have been deposited here as the 
needle was removed). The invasive nature of these cells when placed in the eye cup was 
substantiated by the finding of chains of single cells stained with HMB-45 (Figure 3.10 E-H), 
that were further along the section than the clump mentioned above, and appeared to be 
migrating through the chick tissue. This was deemed to be a somewhat successful 
replication of the published melanoma experiments, therefore focus was returned to the 
neuroblastoma cells. 
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Figure 3.7. Following injection at E3, DiI-labelled B16 F1 mouse melanoma cells were left to 
reside in the chick embryo eye until dissection at E7. Tissues found to contain DiI 
fluorescence were mounted between a glass slide and coverslip. A-D, retina; E-H, lens. 
Scale bar 50µm. 
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Figure 3.8. Following intra-ocular injection of DiI-labelled B16 F1 mouse melanoma cells at 
E3 and dissection at E7, E7 chick eye tissues containing DiI fluorescence were frozen and 
sectioned. 10µm sections were then stained using antibodies to the proteins as labelled. 
Scale bar 100µm.  
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Figure 3.9. B16 F1 mouse melanoma cells were plated within a cell suspension of PBS (left 
column) or matrigel (right column), cultured in appropriate medium for 24 hours, and then 
stained with antibodies as labelled. Scale bar 50µm.  
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Figure 3.10. Following intra-ocular injection of DiI-labelled B16 F1 mouse melanoma cells at 
E3 and dissection at E10, 10µm frozen sections of E10 eye tissues were stained with an 
antibody to HMB45 in order to conclusively identify the melanoma cells. Scale bar 50µm.  
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When additional BE(2)C eye cup injections failed to reproduce the melanoma results, the 
distinct possibility that the eye cup environment was not a suitable one to facilitate 
neuroblastoma growth led to a change in strategy. In accordance to the seed and soil 
hypothesis proposed by Stephen Paget in 1889, it was hoped that by introducing the cells by 
intravenous injection, the “seeds”, i.e. the cancer cells, would be carried around the chick 
embryo vasculature and locate to the appropriate “soil” – chick tissue microenvironment – in 
which conditions were favourable for said neuroblastoma cells to thrive. 
 
 
3.3.3. SK-N-BE(2)C intravenous injections 
 
Intravenous injections were carried out at E3 because this is the earliest point at which a 
complete circulatory system is present. This new method of administration meant that 
significantly more neuroblastoma cells could be introduced into the embryos. The volume 
that the E3 circulation is capable of holding was the limiting factor, and after several 
attempts, and depending on the stage of development of the embryo (E3 chicks can vary 
from around HH stage 16-20, but are usually around HH stage 18), it was concluded that the 
optimum injectable volume was around 2µl, generally not more than 3µl. A single-celled 
suspension of 100,000 DiI-labelled cells per microlitre was prepared, and injected into the E3 
extra-embryonic vitelline vein (Figure 3.11 B, D, arrows). The fastgreen allowed visualisation 
of the cell suspension being carried away by the chick circulation, straight into the heart and 
then around the body, and sometimes, as in Figure 3.11 D, the entire chick embryo turned 
green. Under fluorescence, the red BE(2)C cells could be seen throughout the entire chick 
embryos and in the extra-embryonic blood vessels (Figure 3.11 A, C), and as demonstrated 
in Figure 3.11 E-F and G-H, cells were passing through even the thinnest intersomitic 
vessels and those in the brain. 
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Figure 3.11. 200,000 DiI-labelled BE(2)C cells were injected into the extra-embryonic 
vitelline vein at E3. Chicks were photographed soon after injection. Some cells had settled 
within embryonic tissues, whereas others were still circulating. A-D, whole chick, open 
arrows (black) indicate sites of injection; E-F, DiI-labelled cells within the horizontal 
intersomitic vessels (closed arrowheads, white); G-H, brain. Scale bars A-D, 1mm; E-G, 
500µm. 
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These cells could still be visualised 24 hours later, at E4. However from E5/6 onwards, the 
increasing size of the embryos hence greater density of body tissues, as well as the 
overlying allantois, made it impossible to observe the DiI-labelled cells anywhere other than 
the extra-embryonic blood vessels and external body parts such as the eyes (when the 
embryos positioned themselves so that these came into view). The embryos were therefore 
left in a humidified incubator until E9 or E10, at which point they were dissected and the 
locations of fluorescence noted. Following 6 (E9) or 7 (E10) days in vivo, DiI fluorescence 
was observed throughout the majority of the embryonic tissues in every successfully-injected 
embryo (n = approximately 35 surviving embryos, 9 separate experiments). Interestingly, 
fluorescence (which was presumed to be an indicator of BE(2)C cells) was found within the 
sympathetic ganglia of almost all embryos, a structure in which neuroblastoma develops in 
humans. This fluorescence was present in two forms – as small “speckles” (Figure 3.12 
A+E), which may possibly have been DiI molecule incorporation into individual cells, and as 
larger patches of fluorescence that were somewhat “hazy” in appearance (Figure 3.12 C+G), 
it was considered that these may be small tumour-like masses of neuroblastoma cells. DiI 
fluorescence was also found in the gut – from the oesophagus down to the cloaca, including 
the gizzard (an organ unique to avians and known as the mechanical stomach) (Figure 3.13 
A-B), small intestine, caeca and colon. See Figure 3.14 for overview of the chicken’s 
digestive system. This DiI appeared more like flecks of fluorescence, as opposed to the 
clumps sometimes seen in the sympathetic ganglia. In the meninges, the DiI occurred both 
as tiny speckles – which may have been within the plasma membranes of individual cells, or 
may have been DiI molecules that had precipitated out of the cells – and as larger clumps of 
cells, roughly 25-100µm in diameter (Figure 3.13 C-F). 
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Figure 3.12. DiI-labelled BE(2)C cells within the chick sympathetic ganglia. Following 
intravenous injection at E3, chicks were dissected and photographed at A-D, E9; E-H, E10. 
Scale bars A-B, 500µm; C-H, 200µm. 
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Figure 3.13. DiI-labelled BE(2)C cells within the A-B, E10 gizzard; C-D, E9 meninges; E-F, 
E10 meninges. Cells were injected intravenously at E3, and chicks dissected and 
photographed when specified. Scale bars A-B, 200µm; C-F, 500µm. 
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This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
http://www.ca.uky.edu/poultryprofitability/Production_manual/Chapter3_Anatomy_and_
Physiology/Chapter3_digestive.html [Figure 3.2] 
 
 
Figure 3.14. Digestive system of adult chicken, dissected and laid out as organised in vivo. 
Photograph taken from 
http://www.ca.uky.edu/poultryprofitability/Production_manual/Chapter3_Anatomy_and_Physi
ology/Chapter3_digestive.html  
 
 
Particularly large clumps of cells were consistently observed in the tail regions of the 
embryos (Figure 3.15 A-B), ranging from around 30-300µm in diameter. Other organs, such 
as the heart (Figure 3.15 C-D), liver (Figure 3.15 E-F), kidneys (Figure 3.15 G-H), lungs and 
spleen had speckles of fluorescence throughout, which in the heart was always more 
concentrated in the conotruncal region (i.e. in the vicinity of the great vessels) and often at 
the apex, but in the other organs, was much more dispersed. 
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Figure 3.15. DiI-labelled BE(2)C cells were injected intravenously into E3 chick embryos. 
Upon dissection at E10, DiI fluorescence was observed within the A-B, tail; C-D, heart; E-F, 
liver; G-H, kidney. Minimal fluorescence was found in the adrenal glands (G-H). Scale bars 
A-B, 200µm; C-H, 1mm.  
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Following 6-7 days in the embryo, it was extremely difficult to confirm whether the 
fluorescence observed was due to the presence of BE(2)C cells, or molecules of DiI that had 
left the neuroblastoma cells and incorporated into the chick tissues. Therefore, two thin 
(hence easy to mount) tissues were chosen for increased scrutiny – the sympathetic ganglia 
and meninges – which both had speckles and clumps of fluorescence. The tissues were 
fixed and then “squashed” between a glass slide and coverslip within Dako fluorescence 
mountant, following which they could be observed under a x40 oil magnification lens. As 
shown in Figure 3.16 A, in certain areas of the sympathetic ganglia, speckles could be seen 
to define the outline of a small number of cells – seemingly the BE(2)C cells incorporated 
into the SG tissue. Upon inspection of the fluorescent clumps within the SG, although less 
clear, cellular outlines were still perceived, particularly within the area defined by the dashed 
lines in Figure 3.16 C. These areas were similar in appearance to those in the meninges, 
(Figure 3.16 E, G), which themselves were of various sizes. 
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Figure 3.16. Following E3 intravenous injection of DiI-labelled BE(2)C cells, chicks were 
dissected at E10, and tissues containing DiI fluorescence were mounted between a glass 
coverslip and slide. A-D, sympathetic ganglia; E-H meninges. Scale bar 50µm.  
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Being relatively confident that at least some of the fluorescence observed within embryonic 
tissues was incorporated into the external membranes of cells, the next task was to 
conclusively identify that these were the human neuroblastoma cells and not chick cells. In 
histopathology laboratories, identification of neuroblastoma is aided by a positive stain for 
the proteins NB84 and N-CAM (CD56). Frozen sections of chick tissues containing DiI-
labelled areas were stained for these human-specific antibodies, and a positive result led to 
the presence of BE(2)C cells being confirmed (Figure 3.17). 
 
 
Figure 3.17. DiI-labelled BE(2)C cells were intravenously injected into E3 chicks, which were 
then dissected at E10. A-C, meninges; and D-F, sympathetic ganglia containing DiI 
fluorescence were frozen and sectioned. 10µm sections were stained using antibodies as 
labelled, to aid in the identification of neuroblastoma cells. Scale bar 100µm.  
 
 
3.3.4. SK-N-AS and SH-SY5Y intravenous injections 
 
DiI labelled cells from the SK-N-AS and SH-SY5Y neuroblastoma cell lines were also 
(separately) injected into the chick bloodstream at E3, using the same method as for the 
BE(2)C cells, and then dissected at E10. Around 10 embryos containing DiI fluorescence, 
from 2 separate experiments, were dissected at E10 for each cell line.   Both SK-N-AS and 
SY5Y cells have a single copy of the MYCN gene and very low MYCN protein expression, in 
contrast to the MYCN-amplified BE(2)Cs. However, results were very similar to those 
obtained with DiI-labelled BE(2)Cs – for example, with speckles and clumps in the 
sympathetic ganglia and meninges, clumps in the tail, speckles around the great vessels of 
the heart, speckles in the liver, kidneys and spleen – observations were consistent in all 
embryos. A representation of these dissections can be seen in Figures 3.18 (SK-N-AS) and 
3.19 (SH-SY5Y). 
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Figure 3.18. DiI-labelled SK-N-AS cells were injected intravenously at E3, and then 
dissected and photographed at E10. DiI fluorescence was observed in the sympathetic 
ganglia, meninges, heart and kidney, as indicated. Scale bars A-B, 200µm; C-H, 1mm. 
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Figure 3.19. Following intravenous injection at E3 and dissection at E10, DiI-labelled SH-
SY5Y cells were discovered within the chick sympathetic ganglia, meninges, heart and 
kidneys, as labelled. Scale bars A-B, 200µm; C-H, 1mm. 
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3.3.5. Protein markers within SK-N-BE(2)C-injected cells 
 
To characterise the injected cells, in one E10 BE(2)C-injected chick heart, a large patch of 
DiI fluorescence was sectioned and stained for a variety of antibodies. DiI fluorescence 
sometimes (Figure 3.20 A+B), but not always (Figure 3.20 D+E) coincided with the presence 
of BE(2)C cells. Their presence was confirmed by a positive membranous stain for N-CAM 
(CD56) (Figure 3.20 A-C) and a nuclear staining for human nuclear antigen (Figure 3.20 D-
F). The vast majority of cells in the fluorescent heart patch stained positively for the 
proliferation indicator ki67 (Figure 3.20 G-I), and a small proportion stained for the 
intermediate filament protein vimentin (Figure 3.20 J-L). The most encouraging result from 
this experiment was the identification of a population of dividing neuroblastoma cells within 
the chick, as judged by successful ki67 (nuclear) staining, which had failed up until this point. 
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Figure 3.20. Following E3 intravenous injection and dissection at E10, frozen sections were 
taken of an E10 chick heart containing DiI fluorescence. 10µm sections were stained with 
antibodies to the proteins as labelled. hu. nu., human nuclear antigen. Scale bar 50µm. 
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3.3.6. Kelly cells 
 
Kelly cells were received as a kind donation from Dr Louis Chesler (The Institute of Cancer 
Research, Sutton, UK). Kellys are a MYCN-amplified and highly MYCN-expressing 
neuroblastoma cell line, with over 200 copies of the MYCN gene. They have been shown to 
form tumours in mouse xenograft models (Fichtner et al. 1997; Valentiner, Valentiner & 
Schumacher 2008). It was perceived that the BE(2)Cs had not been growing well in the 
embryos, therefore a more aggressive cell line was required. The Kelly cell line possesses 
the ALKF1174L mutation, is p53 mutated (suggesting the tumour of origin was a relapse), has 
chromosome 11q deletion (which is rare to occur alongside MYCN amplification), 9p deletion 
(which includes the tumour suppressor, and CDK inhibitor, p16), as well as 3p deletion 
(which includes receptor protein tyrosine phosphatase (PTPRD), a candidate tumour 
suppressor) – all suggestive of an aggressive tumour with poor patient prognosis (Akudugu 
et al. 2004; Caren et al. 2008; Caren et al. 2010; George et al. 2008). It was hoped that the 
Kelly cells would fulfil this criterion and form tumours in the chick embryos, which the 
BE(2)Cs did not seem to do. 
 
 
3.3.6.1. Kelly cell characterisation 
 
To characterise the Kelly cell line, cells were stained using a panel of antibodies. The first 
and most obvious immunofluorescence analysis needed was for the MYCN protein. 
Although individual cells expressed different levels of the protein, some considerably brighter 
than others (Figure 3.21, A-D), MYCN was detected in all of the Kelly cells. So although a 
heterogeneous population in terms of protein levels, their multiple copies of the gene meant 
that there was expression in every cell. In terms of neural crest markers, almost all of the 
cells (94%, n=240) displayed a membranous stain for HNK-1 (Figure 3.21 E-F), yet no 
staining whatsoever was found for Sox10 (Figure 3.21 G-H). The Phox2b protein, which is 
normally expressed in the sympathetic ganglia and adrenal and chromaffin cells, was 
detected in around 2% of Kelly cells (n=307), and although not so obvious in the photograph 
in Figure 3.22 A, the nuclei that stained positively were generally ones in which the 
chromatin stained most brightly, and appeared as if the cells were preparing to undergo 
mitosis. All of the Kelly cells stained for tyrosine hydroxylase (Figure 3.22 C-D), which is not 
surprising considering the increased catecholamine production and secretion found in 
neuroblastoma tumours. All of the cells also stained positively for CD24 (Figure 3.22 E-F), a 
cell surface protein expressed on differentiating neuroblasts. CD133 is a protein that has 
been documented as a marker of cancer stem cell in some malignancies (Baba et al. 2009; 
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Singh et al. 2004), and is expressed on the surface of various non-cancerous tissue-specific 
progenitor cells (Corbeil et al. 2000; Yin et al. 1997). Publications of expression in 
neuroblastoma have varied: aggressive bone marrow derived tumour initiating cell (TIC) 
spheres do not express CD133 (Hansford et al. 2007), whereas CD133 has been detected in 
some neuroblastoma cell lines, where it has been shown to regulate proliferation and 
repress differentiation (Takenobu et al. 2011).  A positive stain was observed in 17% of Kelly 
cells (n=264). Two proteins indicative of neuronal differentiation were also tested: the growth 
associated protein GAP43 (Figure 3.23 A-B) and NF70 (Figure 3.23 C-D), the lightest 
neurofilament subunit. Unsurprisingly, neither of these proteins were expressed in any of the 
cells – neuronal differentiation would mean that cells had dropped out of the cell cycle, 
hence were no longer contributing to the aggressive malignant nature of the tumour. 
Vimentin is an intermediate filament found in mesenchymally-derived cells, as well as those 
undergoing EMT, and was found to stain 22% of the Kelly cells (n=255) (Figure 3.23 E-F). 
Since neuroblastoma develops from neural crest cells, which undergo EMT in order to 
migrate, a lack of vimentin staining, particularly alongside a lack of neurofilament expression, 
suggests a possible de-differentiation in the majority of these cells, which would probably 
contribute to their aggressive phenotype. Smooth muscle actin (SMA) is documented as a 
marker for cancer-associated fibroblasts, which have a critical supporting role in the 
progression of tumours (Kalluri & Zeisberg 2006), and was seen to stain all of the Kelly cells 
(Figure 3.23 G-H). 
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Figure 3.21. Kelly cells in culture stained using antibodies as labelled. A-D, G-H, pre-fixed 
stain; E-F, live stain. Scale bar 50µm for all.  
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Figure 3.22. Kelly cells in culture stained with antibodies as labelled. A-D, pre-fixed stain; E-
H, live stain. Arrows identify Phox2b stained cells. Scale bar 50µm.  
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Figure 3.23. A-D, Kelly cells in culture stained with antibodies as labelled. All fixed prior to 
staining. Scale bar 50µm for all. 
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3.3.6.2. Kelly eye cup injections 
 
Kelly cells were injected into the E3 eye cup (Figure 3.24 A+B) to discover whether they 
would behave more aggressively than the BE(2)Cs – this was a distinct possibility, owing to 
their increased levels of MYCN protein. Successfully-injected eyes from 9 embryos, from 2 
separate batches were then dissected at E7. DiI fluorescence was observed on the posterior 
surface of the lens (Figure 3.24 C), attached to the vitreous humor and on the retina in the 
vast majority of eyes; all like the BE(2)Cs (Figure 3.2) and B16 F1s (Figure 3.6). In addition, 
speckles of DiI fluorescence were seen forming linear patterns along the folds of the ciliary 
muscle (Figure 3.24 E) – interestingly, a structure that is innervated by both the sympathetic 
and parasympathetic divisions of the autonomic nervous system. 
 
Sections of chick eyes containing DiI fluorescence were then stained successfully for N-CAM 
and NB84 (Figure 3.25 A-C and D-F, respectively), which confirmed that this fluorescence 
was definitely incorporated into the Kelly cells. However, even though a successful ki67 stain 
had been detected in BE(2)Cs within the E10 chick heart (Figure 3.20 H), this was not 
observed within the Kellys in the eye cup (Figure 3.25 G-I). A couple of Kellys seemed to 
stain for caspase 3 (Figure 3.25 J-L), but as the large nuclei of the Kelly cells can easily be 
distinguished from those of the surrounding chick cells via DAPI staining, it was clear that 
apoptosing cells were in the minority. 
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Figure 3.24. DiI-labelled Kelly cells were injected into chick eyes at E3. A-B, E4 eye, 24 
hours post injection, scale bar 100µm. Eyes were then dissected at E7, and any DiI 
observed was photographed. C-D, anterior half of E7 eye, viewed from interior, area inside 
white dashed line is the lens, scale bar 500µm; E-F, interior of E7 eye, DiI “speckles” – 
possibly cells – radiating along ciliary muscle, scale bar 200µm. 
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Figure 3.25. Following intra-ocular injection of DiI-labelled at E3, eyes were dissected at E7, 
and DiI-containing tissues mounted. 10µm frozen sections were taken of said DiI 
fluorescence, and stained with antibodies to the proteins as labelled. Arrows indicate single 
caspase 3-stained cells. Scale bar 100µm. 
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3.3.6.3. Kelly intravenous injections 
 
Intravenous injections of the DiI-labelled Kellys were also performed at E3, following which 
approximately 25 successfully-injected embryos from 4 separate experiments were 
dissected at E10. Results were very similar to the BE(2)C line – fluorescence was found 
throughout most regions of all embryos, including the sympathetic ganglia, in both speckles 
and clumpier-looking patches (Figure 3.26 A-D), the gut (Figure 3.26 E+F), meninges 
(Figure 3.26 G+H), spleen (Figure 3.27 A+B), heart (Figure 3.27 C+D), liver (Figure 3.27 
E+F) and kidneys (Figure 3.27 G+H)1. Overall, these results were almost indistinguishable 
from those of the BE(2)C cells. Kellys grown in culture had been shown to stain for the 
human-specific antibodies NB84 and N-CAM (Figure 3.28, A-D), and indeed when 
fluorescent patches in the E10 sympathetic ganglia were stained using these antibodies 
(Figure 3.28 E-H), it was confirmed that the DiI fluorescence was an indicator of the 
presence of Kelly cells. 
 
 
                                                          
1 It should be noted that the brightfield images in Figures 3.26 and 3.27 are not as clear as 
usual, as they were taken when the goose neck light source was broken, therefore a 
backlight had to be used for illumination. 
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Figure 3.26. DiI-labelled Kelly cells were injected intravenously at E3, and embryos 
incubated until E10. Upon dissection, DiI fluorescence was observed within chick tissues as 
labelled. Scale bars A-B, E-F, 500µm; C-D, 200µm; G-H, 1mm. 
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Figure 3.27. Following intravenous injection of DiI-labelled Kellys at E3 and dissection at 
E10, DiI fluorescence was observed within the chick tissues labelled. Scale bars A-B, 
500µm; C-H, 1mm. 
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Figure 3.28. A-D, Kellys in culture stained for A-B, NB84 (pre-fixed); C-D, N-CAM (live 
stained). E-H, frozen sections of DiI-labelled Kelly cells within E10 chick sympathetic 
ganglia, that had been intravenously injected at E3. Kellys can be identified by their large 
nuclei in the DAPI staining (B,D) and their corresponding immunofluorescence staining for 
NB84 (A) and N-CAM (C). Scale bars 50µm. 
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3.3.6.4. Kelly cell labelling 
 
3.3.6.4.1. Previous neuroblastoma cell line GFP transfection attempts 
 
Thus far a recurring problem had been the difficulty to be able to absolutely confirm the 
presence of neuroblastoma cells within both the dissected chick embryo tissues and the 
frozen sections without additional staining, due to the limitations of DiI described above. 
Several attempts were therefore made to transfect a GFP plasmid into various 
neuroblastoma cells, with the aim of producing a stable fluorescent line. 
 
Two different plasmids were transfected, using three different reagents, into four different 
cell lines. Killing curves were performed on each of the cell lines, using the antibiotic 
appropriate to the plasmid being transfected, to determine the concentration of antibiotic 
required to kill the non-GFP-transfected (therefore non-antibiotic-resistant) cells at various 
densities. In general, the higher the antibiotic concentration, the greater the cell death, but 
the higher the cell density, the more cells survive. This needed to be balanced out, so that 
the minimum possible concentration of antibiotic could be used (specific to each cell line), 
that would successfully kill the non-transfected cells, but not too quickly, as they play an 
important supporting role to those cells that incorporate the plasmid DNA, particularly in the 
initial stages. 
 
Transfection of the B16 F1 cells using pEGFP-N1 and the reagents ExGen500 and TransIT-
LT1 yielded initial transfection efficiencies of 5-30%, and over the following days, this 
reduced to much less than 5%, with only a couple of fluorescent cells in each well. 
Transfection of pBudCE4.1/EF-1α/EGFP proved this plasmid was far superior in terms of 
generating fluorescent cells. 
 
Since the main focus was on neuroblastoma cells, BE(2)C, SK-N-AS and SY5Y cells were 
transfected with pBudCE4.1/EF-1α/EGFP using TransIT-LT1 and jetPRIME (using various 
reagent:plasmid ratios), resulting in transfection efficiencies of between 15 and 40%. The 
SY5Y cells did not survive well following transfection with either reagent, even when the 
antibiotic concentration was reduced. Although the BE(2)C and SK-N-AS initially looked 
promising, with increasing time it was clear that the GFP-transfected cells would not form 
colonies – they were simply not dividing, yet not dying either. 
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3.3.6.4.2. CFDA-SE 
 
Lack of success with GFP plasmid transfection into neuroblastoma cell lines (section 3.3.6.) 
led to the consideration of an alternative fluorescent labelling technique. To be effective, this 
dye had to remain visible after multiple cell divisions, in order to be visible in the embryos. 
CFDA-SE (also known as CSFE) was added to Kelly cells in culture in 3 concentrations: 2, 5 
and 10µM, and subsequently observed alongside cells labelled with DiI. The 5 and 10µM 
concentrations of CFDA-SE were toxic to the neuroblastoma cells, and although the cells 
labelled with a 2µM concentration were almost all initially fluorescent, this label rapidly 
faded, even more rapidly than the DiI. 
 
 
3.3.6.4.3. GFP lentiviral transduction 
 
Neuroblastoma cells are notoriously difficult to transfect (Dr Louis Chesler, personal 
communication), but administration of plasmids using lentiviral transmission has been 
proven to be effective (De, Lewis & Gambhir 2003). The Kelly cells were infected with a 
lentivirus in which enhanced GFP (EGFP) was constitutively expressed under a spleen 
focus-forming virus (SFFV) promoter (kindly carried out by Dr Sokratis Theocharatos, 
University of Liverpool, UK). The lentiviral construct was added to the RPMI medium in one 
well of a 4 well plate containing Kelly cells at around 40% confluency. This virus-containing 
medium was removed after 24 hours, and a further 24-48 hours subsequent to this, more 
than 80% of the cells were seen to express the GFP protein. These cells were eventually 
subcloned at a density of average 1 cell per well of a 96 well plate, and after the first attempt 
it was feared that the fluorescent cells were not going to divide. However, since the non-
fluorescent cells were not dividing either, a second subcloning attempt was made, this time 
using half conditioned medium and half fresh medium, and in this case, a brightly fluorescent 
stable cell line was produced from subclone D4. 
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3.3.6.5. GFP-Kelly eye cup injections 
 
Once a stable GFP-expressing Kelly cell line had been established, the cells were injected 
into the E3 chick eye cup to recapitulate the melanoma experiments, and to validate that 
what had been observed with DiI was in fact neuroblastoma/melanoma cells. These eyes 
were left to develop until E9 or E10, and upon dissection of 14 embryos from 3 different 
batches, it was discovered that the DiI that had been seen within the retina, lens (Figure 3.29 
A+B) and vitreous humor (Figure 3.29 C+D) was reproduced by the GFP Kelly cells (in 
which no fluorescent molecules would have been able to precipitate out of the cells). 
However, the speckles of DiI radiating out along the ciliary muscle (Figure 3.24) was not 
observed to the same extent when the Kellys were GFP-labelled (Figure 3.29 E+F), 
indicating that the DiI seen here previously may not have been integrated into 
neuroblastoma cells. The GFP Kellys within the eye stained positively for N-CAM, NB84 and 
the neural crest marker HNK-1 (Figure 3.30). 
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Figure 3.29. GFP-labelled Kelly cells were intra-ocularly injected at E3, and following 7 days 
incubation, chick eyes dissected at E10, when any GFP fluorescence was documented. A-B, 
anterior half of eye, viewed from interior, area inside white dashed line is the lens, scale bar 
500µm; C-D, vitreous humor “bag”, cells attached to outside, scale bar 500µm; E-F, interior 
of eye, cells within ciliary muscle, scale bar 100µm.  
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Figure 3.30. Frozen sections of GFP-labelled Kelly cells within the chick eye, following intra-
ocular injection at E3 and dissection at E9. 10µm sections were stained using antibodies to 
the proteins labelled. Scale bar 100µm. 
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3.3.6.6. GFP-Kelly intravenous injections 
 
The GFP Kellys were DiI-labelled prior to E3 intravenous injections, so that a true 
comparison between the red DiI and green GFP fluorescence could be made. Figure 3.31 
shows the results of this one experiment, following dissection of 7 embryos at E10. On the 
whole, DiI fluorescence was a good indicator of the neuroblastoma cells – the areas with the 
most dense regions of red fluorescence in the sympathetic ganglia and gut were generally 
indicative of GFP Kellys, although, as expected, there were many red “speckles” that did not 
correspond to Kelly cells. In the meninges, however, many areas of DiI that had been 
assumed to be clumps of Kelly cells, were in fact merely DiI molecules that had dissociated 
from the cells – in the field shown in Figure 3.31 J-L, there was only one group of Kelly cells 
indicated by the GFP fluorescence, but looking at the DiI, one would have assumed there 
were several clumps. In the tail and heart, the DiI generally corresponded to GFP Kellys, 
although the cells were slightly more focussed than was suggested by the DiI. However, in 
organs such as the liver, kidneys and spleen that had previously been shown to have tiny 
speckles of DiI throughout the entire tissue (Figure 3.15 and 3.27), no GFP Kellys could be 
found, implying either that cells has initially located here and then died, leaving their DiI 
behind, or that DiI molecules had escaped from (either living, proliferating or dying) cells and 
then travelled to these organs via the bloodstream. 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________ 
Figure 3.31. (Over the page). GFP-labelled Kelly cells were also labelled with DiI, in order 
to distinguish where within the DiI “speckles” in chick tissues Kelly cells were really present. 
Cells were injected intravenously at E3, and chicks dissected at E10. Comparisons between 
the DiI and GFP fluorescence were noted in a number of dissected tissues. SG, sympathetic 
ganglia. Scale bars A-C,G-I,M-R, 500µm; D-F,J-L, 200µm. 
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3.4. Discussion 
 
The generation of a GFP-labelled Kelly cell line is ideal for identification of neuroblastoma 
cells upon dissection of the embryos. Although DiI labelling was a good tool for preliminary 
experiments in establishing the model system, a GFP line is preferable regarding long term 
behavioural studies of cells within the embryos, as no matter how many cell divisions are 
completed, the cells will continue to express the fluorescent protein. DiI, in contrast, is a 
lipophilic dye that inserts into the lipid fraction of the cell membrane, therefore its 
fluorescence is progressively diluted as a cell divides, and each of its daughters receives 
approximately half of the DiI molecules. An additional problem was that following dissection 
of chick tissues, a strong red speckled appearance to the surrounding tissue was noted 
where GFP-labelled cells were not present. This may have been due to one/a combination 
of: free DiI molecules being injected in the original cell suspension (washing will not have 
removed all excess dye); DiI molecules having precipitated out of the neuroblastoma cell 
membranes they labelled; or phagocytosis of DiI-labelled apoptotic fragments into 
neighbouring chick cells. Structurally, apoptosis begins with nuclear and cytoplasmic 
condensation, and is followed by fragmentation of the cell into membrane-bound apoptotic 
bodies (Kerr, Wyllie & Currie 1972). These may enter neighbouring cells by phagocytosis, 
and subsequently be degraded – in this scenario, transferring their fluorescent DiI molecules 
to the chick cells. The speckled appearance (when viewed under fluorescence) of almost the 
entire embryo made it difficult to identify the neuroblastoma cells within the chick tissues 
without immunofluorescence staining or prior GFP labelling. This was particularly evident in 
the liver, however, no GFP cells were ever seen there, so the abundance of DiI speckles 
here may have been due to rogue circulating DiI molecules that had been transported to the 
liver during blood detoxification. 
 
Assessment of cell proliferation was an ongoing problem. The ki67 antigen is present at all 
stages of the cell cycle, except from in resting cells (G0). Although the ki67 antibody worked 
well on cells in culture, it did not seem to work on frozen tissue sections. This was 
complicated by a positive nuclear stain of BE(2)C cells in the heart, which although never 
obtained in any other sections, implied that a successful stain of cells within tissues was 
possible. It was unknown whether cells simply did not proliferate within the chick embryo, or 
if there was a problem with the ki67 antibody. The combination of the DiI and HMB-45 stain 
of B16 F1 cells in chick eye sections made the latter possibility more likely. Therefore 
numerous methods of optimising conditions to lead to a positive ki67 stain were trialled, the 
most simple of which was using a different ki67 antibody. Fixation with agents such as 
paraformaldehyde preserve cell structure, but can form cross-links that obstruct the antibody 
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binding sites. Therefore antigen retrieval was performed using citrate buffer or 1% SDS on 
embryonic mouse heads.  In addition, embryonic rat tissue was mounted without prior 
fixation to prevent cross-linking, and paraformaldehyde was added to the sections for 10 
minutes, as was the case for the cultured cells. However no success was gained with any of 
the above mentioned techniques. 
 
From the outset, cells were “injected” into wells containing medium, and successful culture 
subsequent to this indicated that cells were entering (and leaving) the needle and surviving 
the injection process. Therefore any lack of survival should be as a result of the embryonic 
environment. 
 
A basic model system had now been established, in which neuroblastoma cells had been 
seen to localise to certain chick tissues and not others. Further investigation was necessary 
to assess their behaviour, and discover whether proliferating tumours were forming in vivo. 
 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter Four: 
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4.1. Introduction 
 
As a result of the preliminary work detailed in Chapter Three, the basic tools were now in 
place to begin to truly test the effects of an embryonic environment on the neuroblastoma 
cells. The DiI labelling used thus far was not ideal because as described previously, the DiI 
molecules had a tendency to leak out of the cells they had labelled, so locations of cells 
could not be irrefutably verified. However, following the establishment of a stably GFP-
transfected Kelly cell line, it would be possible to identify exactly where the neuroblastoma 
cells were locating to following intravenous injection, and make assessments from their 
morphology and protein markers as to their behaviour in various tissues. 
 
 
4.2. Aims 
 
To optimise the model system established in Chapter Three to be able to analyse the effects 
of different chick embryonic environments on the behaviour of MYCN-amplified Kelly cells. 
 
• Inject GFP-labelled Kellys into chick embryos, intravenously at different timepoints: 
specifically E3 and E6. 
• Confirm specific targeting by injecting fluorescent beads and a primary glioblastoma 
line (for contrast), as well as SK-N-BE(2)C cells (for comparison). 
• Analyse behaviour of Kellys within chick tissues, in terms of morphology, 
differentiation, proliferation and MYCN expression. 
 
 
4.3. Results 
 
4.3.1. Cell targeting 
 
4.3.1.1. GFP Kelly E3 intravenous injections 
 
The first objective was to assess the distribution of Kelly cells following E3 injection and 
obtain a more conclusive result via the GFP-labelled cells, compared to the DiI used in 
Chapter Three. Kellys were prepared as in section 2.3.2.1.1 (Chapter Two), and as for the 
DiI-labelled cells, approximately 2x105 were injected into the extra-embryonic vitelline veins 
(Figure 3.11 B+D). Embryos were incubated for a further 7 days and dissected at E10 – this 
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was conducted on approximately 35 batches of eggs (i.e. 35 independent experiments), with 
Kelly cell incorporation analysed in an excess of 250 dissected embryos in total. Within the 
E10 embryos, GFP Kelly cells were found in a number of body tissues. Kellys were routinely 
found in the sympathetic ganglia (Figure 4.1). As long as an embryo’s cell injection had been 
an efficient one, with a considerable number of cells observed within its dissected tissues, 
SG incorporation was evident almost every time –  in approximately a quarter of embryos, 
confined to a few individual (neighbouring) ganglia within the chain, but more often extending 
along most of the length. Injection of DiI-labelled cells had led to the conclusion that 
neuroblastoma cells often formed clumps in the sympathetic ganglia, reminiscent of micro-
tumours, however scrutiny of the GFP-Kellys revealed that the they frequently resided as 
single cells, sometimes grouped in slightly more dense patches, but there was little evidence 
of the neuroblastoma “tumours” that were suspected from the DiI experiments. 
Morphological observations were restricted, but the Kellys seemed to display a lengthened 
appearance, with chains of cells often orientated longitudinally along the length of the 
ganglia (Figure 4.1 E, G). Each sympathetic chain usually contained at least 50 Kelly cells, 
with some incorporating several hundred. 
 
GFP Kellys were also found within the chick digestive system (for overview of digestive tract, 
see Figure 3.14), where they appeared to be located relatively superficially. Kellys were 
rarely observed along the oesophagus or in the stomach, in around 10% of embryos were on 
the external surface of the gizzard (although relatively few cells), but were mostly 
concentrated along the small intestine (Figure 4.2 E-H), and to an even greater extent, the 
caeca and colon (Figure 4.2 A-D). This incorporation into the caeca/colon was observed in 
greater than 90% of surviving, efficiently-injected embryos, and cells were observed in the 
small intestine of around 80%. Their predominance in the hindgut suggests considerable 
migration by the Kellys, which must have entered the most rostral part of the gut 
mesenchyme, and followed the endogenous NCCs in their rostrocaudal along the length of 
the gut. Kellys appeared to be located mostly as single cells, although like in the sympathetic 
ganglia, they were often in patches of a few collective cells. But in neither of the formerly 
mentioned tissues did the fluorescent cells give the impression of a proliferating population – 
more that they were integrating into the chick tissues. 
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Figure 4.1. GFP-labelled Kelly cells were injected intravenously into E3 chick embryos, 
which were then dissected at E10. Cells were found to have incorporated into the 
sympathetic ganglia. Scale bars A-B, 1mm; C-D, 500µm; E-H, 200µm. 
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Figure 4.2. GFP-labelled Kelly cells were intravenously injected at E3 and dissected at E10. 
Cells were observed within the gut. E-F are a higher magnification of the area within the 
dashed boxes in C-D. Scale bars A-D, 1mm; E-F, 500µm; G-H, 200µm. 
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Posterior and slightly caudal to the colon, clumps of cells were found in the tail regions of 
almost all of the embryos (Figure 4.3). There were typically multiple clumps per embryo, 
which were of various sizes and often distributed down the length of the tail (Figure 4.3 E). In 
this region, the Kellys were not so incorporated into the chick tissue, instead forming clusters 
of cells that may well have been the tumour-like masses that were the original aim when the 
injection strategy was changed to an intravenous route. 
 
Upon dissection of the head, although GFP Kellys were never found within the brain tissue, 
they were always observed in the meninges (Figure 4.4 A-F). They appeared as numerous 
(at least 10, often up to 100 or more) “balls” of cells that were remarkably regular in size, at 
around 30-35µm in diameter, and spherical in appearance. Also in the head, cell clumps of 
similar spherical shapes were frequently witnessed inside the mouth – most often on the 
ventral surface of the tongue (Figure 4.4 G-H) and sometimes within the muscle forming the 
floor of the oral cavity. 
 
Injected neuroblastoma cells also targeted the heart – in a typical experiment, if 12 embryos 
had survived following successful injections (i.e. a sufficient number of cells had entered the 
embryos at E3), at least 10 would show cardiac incorporation of GFP Kellys. Of these, cells 
were almost always found in the conotruncal region (the area of the great vessels) (Figure 
4.5 A, E, G), often near the apex (Figure 4.5 A, E) and less often but still repeatedly (1 or 2 
embryos out of 12), along the interventricular septum on the posterior surface (Figure 4.5 C). 
Like those cells that located to the sympathetic ganglia and gut, the cells in the heart 
appeared to be integrated into the tissue rather than forming clumps of cells. 
 
Cells were usually found within the eyes – either in the sclera or uvea, but not the (internal) 
retina (Figure 4.6 E-F). In addition, they were found in around half of the parasympathetic 
ciliary ganglia examined (situated posterior to the eye, near the optic nerve) (n = 
approximately 45 ganglia from roughly 30 embryos), and within these structures the cells 
were seen to integrate into the tissue and extended processes, possibly indicative of 
neuronal differentiation (Figure 4.6 G). 
 
There were numerous areas of the embryos in which no cells were found to have invaded, 
such as the lungs, spleen, skin, liver (Figure 4.6 A-B), rarely to the kidneys, and surprisingly, 
never to the adrenal glands (Figure 4.6 C-D). 
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Figure 4.3. GFP-labelled Kelly cells were injected intravenously into E3 chick embryos. 
Following dissection at E10, cells were observed within the tail tissue. Scale bars A-F, 1mm; 
G-H, 200µm. 
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Figure 4.4. GFP-labelled Kelly cells were injected intravenously at E3, and chicks dissected 
at E10. Cells were observed within the A-F, meninges; G-H, tongue. C-D is a higher 
magnification of the area within the dashed box in B. Scale bars A-B, G-H, 1mm; C-D, 
200µm; E-F, 500µm. 
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Figure 4.5. GFP-labelled Kelly cells were injected intravenously at E3, and upon dissection 
at E10, were observed within the chick hearts. G-H is a higher magnification of area within 
dashed box in E. Scale bars A-F, 1mm; G-H, 200µm. 
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It was deduced that the tissues to which the Kelly cells located were either wholly neural 
crest-derived, or at least had a neural crest component to them. As discussed in Chapter 1, 
the sympathetic ganglia are formed entirely by cells that have migrated from the neural crest, 
whereas in the gut, the neural crest contribution is via the enteric nervous system (ENS). 
More puzzling was the recurrent appearance of GFP Kellys in the tail regions of the 
embryos. However, staining of frozen sections of tail tissue for the neuronal marker TUJ-1 
(which detects the protein β-III-tubulin) revealed a fine network of parasympathetic neurons 
(Figure 4.7) which are themselves derived from the neural crest. An additional 
parasympathetic structure targeted by the Kelly cells was the ciliary ganglion (Figure 4.4 G). 
 
 
 
 
Figure 4.7. E10 chicks (no previous injections) had their tails dissected, and the resulting 
tissues were whole mount stained with a TUJ-1 antibody (detecting β-III-tubulin). Confocal 
images were taken of the nervous tissues that had been revealed – those shown are 
compressed Z stacks. Scale bar 100µm.  
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4.3.1.2. GFP Kelly E6 intravenous injections 
 
For comparison, Kelly cells were injected at E6, when neural crest migration had been 
completed and neural crest-derived structures such as the sympathetic ganglia and adrenal 
glands had been formed, at least in a primordial form. An identical method of cell preparation 
and intravenous injection was employed to that utilised at E3, with approximately 200,000 
cells being introduced into each embryo. At E10, GFP cell location was markedly different to 
that following E3 injection (n = >70 embryos, 14 separate experiments). Cells were 
distributed more widely throughout the embryo, but were discovered predominantly as 
clusters of cells within the liver (Figure 4.8 A-D) and kidneys (Figure 4.8 E-H) in almost every 
embryo examined. The meninges continued to be a regular site of Kelly cell incorporation – 
like at E3, in small “balls” of cells (Figure 4.9). Again, these were somewhat regular in size, 
although understandably smaller than when cells were injected at E3, generally between 15 
and 20µm in diameter, likely owing to their reduced time within the embryo (4 days as 
opposed to 7). Cells were found in other locations such as the heart and lungs, and also in 
the gut – although the latter tissue contained considerably fewer neuroblastoma cells than 
the embryos injected at E3. Those cells within the gut may have colonised this structure 
along with the sacral component of the neural crest contributing to the formation of the ENS 
(Burns & Le Douarin 1998). 
 
In general, the Kellys discovered within chick tissues following E6 administration resided 
within small clumps of neuroblastoma cells, rather than fully integrating into the tissues as 
some of the cells injected at E3 had appeared to do in the sympathetic ganglia and gut. 
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Figure 4.8. GFP-labelled Kelly cells were intravenously injected into E6 chick embryos. 
Upon dissection at E10, small clumps of cells were observed within the livers and kidneys. 
Scale bars A-B, E-F, 1mm; C-D, G-H, 200µm. 
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Figure 4.9. GFP-labelled Kelly cells were intravenously injected at E6, and chicks dissected 
at E10. Cells were discovered within the meninges and gut, as labelled. Scale bars A-B, 
1mm; C-H, 200µm. 
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4.3.1.3. Fluorescent bead injections at E3 and E6 
 
To assess whether the differences in neuroblastoma cell targeting between E3 and E6 
intravenous injection could be attributed to changes in blood flow in the developing 
circulatory system between the two time points, 1µm diameter fluorescent beads were 
injected at both E3 and E6 and their locations noted at E10. The beads were diluted in PBS 
to a density of 1x105/µl, and as with the Kelly cells, 2µl of the suspension was injected into 
the extra-embryonic circulation either at E3 (n=10 surviving embryos) or E6 (n=11 surviving 
embryos). Upon dissection of the embryos at E10, beads were widespread throughout the 
entirety of the embryos, regardless of their time of injection (Figures 4.10, 4.11 and 4.12). 
The relative quantities of beads in each tissue were estimated very approximately: a value of 
1 equated to the presence of a small number of beads relative to the whole tissue, similar to 
that observed in the sympathetic ganglia (Figure 4.10 A), a value of 2 was given to the 
spleen (Figure 4.12 A), and a value of 3 meant there was an abundance of beads, such as in 
the meninges (Figure 4.10 G).  Figure 4.12 E shows a graph summarising the beads’ 
locations at E3 and E6. 
 
It was concluded that the differences in cellular integration observed between the Kellys 
injected at E3 and at E6 were due to tissue-specific targeting of the neuroblastoma cells. 
This was later substantiated by differential targeting of alternate cell types (Figures 4.13, 
4.14, 4.15, and summarised in Table 4.1). 
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Figure 4.10. 1µm diameter green fluorescent beads were injected intravenously into E3 
chick embryos. Upon dissection at E10, beads were observed within most chick tissues, 
including the sympathetic ganglia, tail and meninges. Scale bars A-B, G-H, 200µm; C-F, 
500µm. 
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Figure 4.11. 1µm diameter green fluorescent beads were injected intravenously into E3 
chick embryos. Upon dissection at E10, beads were observed within most chick tissues, 
including the skin, heart and liver. Scale bars A-B, G-H, 200µm; C-D, 500µm; E-F, 1mm. 
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Figure 4.12. Following the intravenous injection of 1µm green fluorescent beads into E3 
chick embryos, and subsequent dissection at E10, beads were observed within the majority 
of chick tissues, including the A-B, spleen; and C-D, mesenchyme within the body cavity. 
Scale bars 500µm. E, histogram to illustrate the distribution of fluorescent beads throughout 
the E10 chick embryos, following injection of beads at E3 (n=10) versus injection at E6 
(n=11). Relative fluorescence was quantified very approximately, by comparing all tissues 
with one another and assigning values of 0, 1, 2 or 3 to each structure. 
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4.3.1.4. GFP BE(2)C intravenous injections at E3 and E6 
 
Establishment of a GFP-labelled BE(2)C line by Dr Anne Herrmann (University of Liverpool, 
UK), meant that a second MYCN-amplified cell line could be injected intravenously at E3 and 
E6, to discover whether the targeting of neural crest derived tissues observed following E3 
injection was a phenomenon unique to Kelly cells or a feature common to multiple 
neuroblastoma cells. Dissection at E10 of roughly 35 embryos from 5 separate experiments 
revealed that the BE(2)C cells injected at E3 targeted exactly the same neural crest derived 
structures as the Kellys, including the sympathetic ganglia, gut, tail and meninges (Figure 
4.13), and like the Kellys, the BE(2)Cs were not observed in the chick adrenal glands. 
Similarly, following E6 injections, there was a total lack of neural crest specific targeting, with 
cells locating to tissues such as the liver, kidney and meninges (Figure 4.14), but never to 
the sympathetic ganglia (n = 14 embryos, from 3 separate batches). 
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Figure 4.13. GFP-labelled BE(2)C cells were intravenously injected at E3. Upon dissection 
at E10, cells were observed primarily within the sympathetic ganglia, gut, tail and meninges, 
as labelled. Scale bars: A-F, 200µm; G-H, 1mm. 
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Figure 4.14. Following intravenous injection at E6, and chick embryo dissection at E10, 
GFP-labelled BE(2)C cells were observed within the liver, kidney and meninges, as labelled. 
Scale bars 200µm.  
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4.3.1.5. GFP glioblastoma intravenous injections at E3 and E6 
 
The MYCN-amplified neuroblastoma cell lines had shown specific time-dependent targeting 
to neural crest derived structures. Therefore a different cancer line, from a glioblastoma 
tumour, was injected (in collaboration with Omar Pathmanaban, University of Manchester, 
UK) to determine whether it would also show patterns of targeting, and whether this would 
be similar to neuroblastoma or specific to its nature as a brain tumour. Glioblastoma 
multiforme is a brain malignancy, usually occurring in adults from a dedifferentiation of the 
cranial glial cells (typically astrocytes) and in which distant metastases are rare (Jellinger 
1978). It was anticipated that targeting would be different, as in stark contrast to 
neuroblastoma being an embryonic tumour of the PNS, glioblastoma is an adult cancer 
occurring in the CNS. 
 
GFP TSIA cells, a glioblastoma line derived from a primary tumour (by Omar Pathmanaban), 
were injected at the established E3 (n= 12 surviving embryos, 2 experiments) and E6 (n= 7 
surviving embryos, 1 experiment) time points and dissected at E10, both for comparison to 
the neuroblastoma cell lines. Although roughly 2x105 cells were injected per embryo, very 
few cells (difficult to quantify, but less than 100) were found to have survived in each embryo 
by E10, regardless of their injection time. Those cells that were alive were almost all found in 
CNS tissues – mostly the brain and sometimes the spinal cord - with a very small proportion 
also being discovered in peripheral neural tissues such as the dorsal root ganglia and 
sympathetic ganglia. This was the case for each one of the (albeit limited number of) 
surviving embryos. It may be hypothesised that survival was correlated with the cells’ 
invasiveness, in that only those able to extravasate and migrate into CNS tissue were able to 
sustain themselves within the embryo. As demonstrated in Figure 4.15, the GFP labelled 
glioblastoma cells observed within chick neural tissues had extended extremely long 
processes, strongly suggestive of them being neuronally differentiating cells – although they 
perhaps could have been astrocytic, but nevertheless were differentiating. This was 
surprising particularly in those cells injected at E6 (Figure 4.15 H-K), considering their short 
time within the chick embryos (4 days). 
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Figure 4.15. GFP-labelled glioblastoma cells within dissected E10 chick tissues as labelled, 
following intravenous injection at A-G, E3; H-K, E6. A-D, H-K, Images taken on Leica 
dissecting microscope; E-G, confocal microscopy, compressed  Z stack images. sc, spinal 
cord. Scale bars A-D, H-K, 50µm; E-G, 20µm. 
 
 
 
The targeting of the glioblastoma cells was substantially different from that of the Kellys, 
BE(2)Cs and fluorescent beads (Table 4.1), thus neural crest cell targeting was deemed to 
be a trait compatible with neuroblastoma being a neural crest derived tumour. 
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Chick 
tissue 
Kelly 
E3 
Kelly 
E6 
Fluo. 
beads 
E3 
Fluo. 
beads 
E6 
BE(2)C 
E3 
BE(2)C 
E6 
Glio-
blastoma 
E3, E6 
Sympathetic 
ganglia +++ - + + +++ - + 
Gut +++ + + ++ ++ + - 
Tail +++ + ++ ++ +++ + - 
Meninges +++ ++ +++ ++ +++ ++ + 
Heart ++ + +++ +++ ++ + - 
Eye ++ + ++ + ++ + - 
Adrenals - - + + - - - 
Dorsal root 
ganglia + - - - + - + 
Lungs - + +++ ++ - - - 
Spleen - - ++ +++ - - - 
Brain - + + + + ++ ++ 
Spinal cord - - - - - - + 
Liver - +++ +++ +++ - +++ - 
Kidneys + +++ +++ +++ + +++ - 
 
Table 4.1. Summary table of relative numbers of cells/beads discovered in various chick 
embryo tissues following intravenous injection at E3 or E6 and dissection at E10. Targeting 
was strikingly different, when neuroblastoma cells (Kelly, BE(2)C) were compared to 
fluorescent beads and glioblastoma. Quantification was subjective: -, no cells incorporated; 
+, contained cells, but very few and/or rarely; ++, usually contained a reasonable number of 
cells; +++, almost always possessed a relatively large number of injected cells. Shaded rows 
draw attention to those tissues with significant differences in targeting of neuroblastoma cells 
between E3 and E6 injections – the sympathetic ganglia, gut and tail displayed considerably 
more NB cell integration following E3 injection, and the liver and kidneys contained more 
cells when chicks were injected at E6. 
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4.3.2. GFP cells observed within E10 chick embryos were human neuroblastoma cells 
 
In order to ascertain that the GFP fluorescence detected within the E10 chick tissues could 
be attributed only to the GFP-labelled Kelly cells injected at E3/E6 and was not derived for 
example from chick macrophages that had ingested the Kelly cells, frozen sections of 
sympathetic ganglia, gut, meninges and tail containing GFP fluorescence were stained with 
antibodies to the proteins N-CAM (CD56) and NB84, which have been shown to stain the 
Kelly cells in culture (Figure 3.28) and are human specific. As shown in Figures 4.16 and 
4.17, there was a direct correlation between the GFP and the antibody staining, indicating 
that these were Kelly cells surviving within the various chick tissues. In addition, a lack of 
staining of the Kelly cells within the sympathetic ganglia, gut and ciliary ganglia, as well as 
the non-neural tail and meninges with a chick-specific antibody to GAP43 (Figure 4.18), 
demonstrated that the human neuroblastoma cells had not fused with chick cell nuclei. 
Histology of the GFP-containing livers, in addition to N-CAM staining (Figure 4.19, thanks to 
Andrew Dodson, University of Liverpool, UK) confirmed the lack of cell fusion and 
phagocytosis in tissues derived from E6-injected embryos. Cell clusters in the liver were 
usually located close to blood vessels/sinusoids, and their appearance following H&E 
staining was reminiscent of the small round blue cells observed in malignant primary 
neuroblastomas. 
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Figure 4.16. Frozen sections of GFP-Kelly cells within E10 chick A-F, sympathetic ganglia; 
G-L, gut; following intravenous injection at E3. Sections were stained for N-CAM and NB84 
as labelled. Scale bar 50µm.  
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Figure 4.17. Frozen sections of GFP-Kelly cells within E10 chick A-F, meninges; G-L, tail; 
following intravenous injection at E3. Sections stained for N-CAM and NB84 as labelled. 
Scale bar 50µm.  
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Figure 4.18. Confocal images, compressed from Z stacks, of GFP-labelled Kelly cells 
(green) within dissected E10 chick tissues, following intravenous injection at E3. Tissues 
were whole mount stained with chick-specific GAP43 antibody (red). A, sympathetic ganglia; 
B, gut; C,D, ciliary ganglia; E, tail; F, meninges. Scale bars 50µm.  
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Figure 4.19. Following E6 intravenous injection of GFP-labelled Kelly cells, a dissected E10 
liver was mounted in a paraffin block and sectioned.  A-C, N-CAM (CD56) staining of liver 
paraffin sections identifies the Kelly cells (brown); D, H&E stain shows the histology of the 
liver containing Kelly cells.  
 
 
4.3.3. GFP Kelly cell behaviour within chick tissues 
 
4.3.3.1. Morphology and differentiation 
 
Confocal microscopy of the GFP Kelly-containing E10 chick tissues revealed differing 
morphologies of the neuroblastoma cells depending on their environment. In neural tissues 
such as the sympathetic ganglia and gut (Figure 4.20 A and B, respectively), the Kellys were 
elongated in appearance and extended short processes, suggestive of cell migration or the 
beginnings of neuronal differentiation. In contrast to what was interpreted during dissection 
of the gut, cells were not located on the external surface, but were situated deeper within the 
tissue, integrated in two separate layers – the myenteric and submucosal plexuses of the 
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enteric nervous system (Figure 4.20 C). The Kellys in the two aforementioned tissues 
typically resided as single cells, or sometimes in groups of 2-5 loosely associated cells. This 
was in contrast to the appearance of Kellys in non-neural tissues such as the tail and 
meninges (Figure 4.20 D and E, respectively), where they were more rounded and tended to 
exist as clumps, which in the meninges were particularly tightly packed. This morphological 
state implied limited or no migration and/or cells undergoing proliferation. 
 
 
 
 
Figure 4.20. Confocal images, compressed from Z stacks, of GFP-labelled Kelly cells within 
E10 chick tissues. Kellys were intravenously injected at E3, chicks were dissected at E10, 
and tissues containing GFP cells were fixed and “squashed” between a glass slide and 
coverslip. A, sympathetic ganglia, white arrows indicate processes; B, gut (‘looking down’ 
onto the two layers of Kelly cells within the ENS); C, gut (image in B rotated though 90°, 
revealing the two plexuses of the ENS, identified by black arrows); D, tail; E, meninges. 
Scale bars A-C, 50µm; D-E, 20µm. 
 
 
Chapter Four: Results II 
 
142 
 
The morphologies observed for the Kellys were recapitulated using the BE(2)C cells; with 
cells extending processes in the sympathetic ganglia and gut and integrating into the two 
plexuses of the ENS, but forming more dense clumps in the tail and meninges (Figure 4.21). 
 
 
 
 
Figure 4.21. Confocal images of GFP-labelled BE(2)C cells within E10 chick tissues. 
BE(2)Cs were intravenously injected at E3, chicks were dissected at E10, and tissues 
containing GFP cells were fixed and “squashed” between a glass slide and coverslip. 
Images are compressed from Z stacks. A, sympathetic ganglia; B, gut (‘looking down’ onto 
the two layers of BE(2)C cells within the ENS); C, tail; D, meninges. Scale bars 25µm. 
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E10 chick tissues containing GFP Kellys were whole mount stained for the neurofilament 
70kD subunit, and the antibody was able to detect both chick and human antigens. Although 
none of the Kellys stained positively for this neuronal marker (Figure 4.22), the staining, 
along with the immunofluorescence for GAP43, revealed that the neuroblastoma cells had 
integrated well into the neuronal tissues and were closely associated with the chick neurons 
(Figure 4.18 A-D and 4.22 A-D), particularly in the ENS. In the tail the Kellys remained 
distinct from the chick tissue and its limited neuronal network (Figure 4.22 E). Similarly in the 
meninges, where no neural tissue exists, the Kellys existed as discrete clumps (Figure 4.22 
F). In all tissues, Kelly cells continued to stain positively for tyrosine hydroxylase, regardless 
of their morphology (Figure 4.23). 
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Figure 4.22. Confocal images, compressed from Z stacks, of GFP-Kellys (green) within 
dissected E10 chick tissues following intravenous injection at E3, and whole mount staining 
with an antibody to the neurofilament 70kD subunit (red). A-B, sympathetic ganglia; C, gut; 
D, ciliary ganglion; E, tail; F, meninges. Scale bars 50µm.  
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Figure 4.23. Confocal images, compressed from Z stacks, of GFP-Kellys (green) within the 
E10 chick A-C, sympathetic ganglia; D-F, gut: G-I, tail; J-L, meninges; all following 
intravenous injection at E3. Cells were whole mount stained for human-specific tyrosine 
hydroxylase (red). C,F,I,L are merged images. Scale bars 50µm.  
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Confocal analysis of E10 tissues of chick embryos injected at E6 confirmed the presence of 
small masses of rounded cells (Figure 4.24), which were of various sizes, particularly in the 
liver, where they could range from only a few cells, up to irregularly-shaped clumps with 
diameters of 300µm or more. Clumps in the kidneys were more regular in both shape and 
size; roughly 50µm in diameter, and those in the meninges were also regularly sized, at 15-
20µm. The morphologies of the cells within the tissues of E6-injected embryos were 
indicative of cells undergoing proliferation. 
 
 
 
 
Figure 4.24. Confocal images of GFP-labelled Kelly cells within dissected E10 chick tissues. 
Kellys were intravenously injected at E6, chicks were dissected at E10, and tissues 
containing GFP cells were fixed and “squashed” between a glass slide and coverslip. 
Images shown are compressed from Z stacks. A, liver; B, kidney; C, meninges. Scale bars 
20µm.  
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4.3.3.2. Proliferation 
 
Assessment of cell proliferation was crucial in determining the behaviour of the 
neuroblastoma cells within the chick tissues. However, as detailed in Chapter Three, the 
opportunity to quantify this had remained elusive, due to a lack of success with the ki67 
antibody on frozen sections. An alternative method was therefore tested. EdU (5-ethynyl-2’-
deoxyuridine) is a thymidine analogue that is incorporated into cellular DNA during the 
synthesis stage of the cell cycle, and can then be detected within cells that have divided, in 
these experiments using an Alexa Fluor 594 label. The EdU kit was initially trialled on Kelly 
cells in culture; adding concentrations of 15, 10 or 5µM to the culture medium and then 
uptake detected 24 hours later. The fluorescence emitted by the EdU-containing cells was of 
varying intensities, but was in general stunningly bright regardless of the concentration and 
was incorporated by almost all of the cells (Figure 4.25). Hence 5µM was deemed sufficient 
to label all cells in culture for a 24 hour time period. 
 
To test EdU within the chick “whole animal” model system, 0.5µl of a 20mM solution was 
calculated to be roughly equivalent to a concentration of 5µM within the embryo, taking its 
mass between E9 and E10 to be approximately 2g (Figure 2.4). Initially 0.5µl of the 20mM 
stock solution was injected into each E9 embryo, and this was subsequently changed to 1µl, 
roughly equivalent to 10µM, to ensure the amount of available EdU was not a limiting factor 
in the assessment of cell division. Cell proliferation rates were similar between the two EdU 
concentrations, but 10µM (i.e. 1µl injections) were routinely used, as an excess of EdU was 
preferable to a deficit. 
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Figure 4.25. EdU incorporation into cultured Kelly cells, following addition of 15, 10 or 5µM 
concentrations (as labelled) to the culture medium 24 hours prior to detection. Scale bar 
50µm.  
 
 
EdU integration was successfully detected in frozen sections of E10 tissues from EdU-
injected chicks. In all tissues tested, a significant proportion of cells had incorporated EdU, 
thus had divided within the 24 hours previous to sacrifice (Figure 4.26). 
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Figure 4.26. The equivalent of approximately 5µM EdU was intravenously injected into E9 
chick embryos. Following dissection at E10, EdU incorporation was detected in frozen 
sections of the tissues indicated. Scale bar 50µm. 
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To discover the extent of Kelly cell proliferation within the various embryonic locations, 1µl of 
20mM EdU solution was injected into each E3- or E6-injected embryo at E9 (roughly 
equivalent to a 10µM concentration). Results are summarised in Figure 4.27, from a total of 
9 different embryos, from 3 separate experiments: tissues analysed from 3 chicks per batch. 
In the sympathetic ganglia, only 15% of Kelly cells had divided between E9 and E10 (n=215 
cells). Host ganglion cells were also dividing, indicating proliferation as a normal 
physiological event in this tissue at this point in development (Figure 4.28). A similar result 
was observed in the gut, with the chick cells proliferating, but few EdU-labelled nuclei for the 
GFP Kelly cells (15%, n=210) (Figure 4.29). In contrast, within the clumps of Kellys in the tail 
and meninges, 50% and 53% respectively (n=534 and n=204, respectively) of the 
neuroblastoma cells had undergone division between E9 and E10 (Figure 4.30 and data not 
shown). Following E6 injection, 46% of Kelly cells within clumps in the liver (n=1008) (Figure 
4.31), 37% of Kellys in the kidney (n=307) (Figure 4.32) and 38% of Kellys in the meninges 
(n=209) (Figure 4.33) were seen to be actively proliferating within a 24 hour window. 
 
 
 
 
Figure 4.27. Summary of EdU incorporation into Kelly cells within E10 chick tissues, 
following cell injection at E3 or E6 as specified, and EdU injected to a concentration of 
approximately 10µM at E9. Error bars display standard deviation from the mean. 
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Figure 4.28. EdU incorporation into E10 sympathetic ganglia, containing GFP Kellys injected 
intravenously at E3. EdU was injected at E9, chicks dissected at E10, and detection 
performed on frozen sections. Scale bar 50µm. 
Chapter Four: Results II 
 
152 
 
 
Figure 4.29. EdU incorporation into E10 gut tissue, containing GFP Kellys injected 
intravenously at E3. EdU was injected at E9, chicks dissected at E10, and detection 
performed on frozen sections. Scale bar 50µm. 
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Figure 4.30. EdU incorporation into E10 tail, containing GFP Kellys injected intravenously at 
E3. EdU was injected at E9, chicks dissected at E10, and detection performed on frozen 
sections. Scale bar 50µm. 
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Figure 4.31. EdU incorporation into E10 liver, containing GFP Kellys injected intravenously 
at E6. EdU was injected at E9, chicks dissected at E10, and detection performed on frozen 
sections. Dashed lines in F roughly outline the clump of GFP Kelly cells. Scale bar 50µm. 
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Figure 4.32. EdU incorporation into E10 kidney, containing GFP Kellys injected 
intravenously at E6. EdU was injected at E9, chicks dissected at E10, and detection 
performed on frozen sections. Scale bar 50µm. 
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Figure 4.33. Confocal image, compressed Z stack, of EdU incorporation into E10 meninges, 
containing GFP Kelly cells injected intravenously at E6. EdU was injected at E9, chicks 
dissected at E10, and detection performed as a whole mount stain on meningeal tissue. 
Scale bar 20µm. 
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4.3.3.3. MYCN expression 
 
Kellys are a MYCN-amplified cell line and have been shown to express high levels of the 
protein in culture (Figure 3.22). MYCN amplification is a feature associated with high risk 
neuroblastoma tumours, with the protein encouraging progression of cells through the cell 
cycle and resulting in a population of aggressively dividing cells. Therefore, taking into 
consideration the differences in both morphology and proliferation between Kelly cells within 
neural crest-derived neural tissues (SG, ENS) and those in non-neural (tail, meninges) and 
non-neural crest-derived (liver, meninges) tissues, an investigation into whether the levels of 
MYCN had changed within the Kelly cells was deemed to be particularly interesting. 
 
The sympathetic ganglia and tail were selected as two contrasting regions in terms of Kelly 
cell incorporation, which could be tested in parallel with tissues having been derived from the 
same embryos, having experienced the same incubation conditions. Frozen sections were 
cut from each of the two tissues and stained with a monoclonal antibody to detect the MYCN 
protein. Looking down the microscope, it appeared that unsurprisingly, the cells in the tail 
had maintained their high MYCN levels (Figure 4.34 A-D and Figure 4.35 A-D), whereas in 
those in the sympathetic ganglia, no MYCN immunofluorescence could be detected by eye 
in any of the Kelly cells above the background fluorescence (Figure 4.34 E-H and Figure 
4.35 E-H). To confirm these observations, intensity of the red MYCN stain was measured 
within the GFP Kellys in both tissues (n=41 for SG, n=104 for tail), using Image J software. 
An average background fluorescence intensity measurement was taken from n=6 host nuclei 
per section, and subtracted from each Kelly cell’s measured fluorescence value in that 
frozen section. As shown by the graph in Figure 4.36, the mean fluorescence intensity of the 
MYCN stain in GFP Kelly cells within the E10 tail was quantified at 4.330 (standard deviation 
2.138), compared to 0.027 (standard deviation 0.397) for those in the sympathetic ganglia. 
This result reflected what had been seen by eye and conclusively proved that levels of the 
MYCN protein had been dramatically reduced to below detectable levels in the Kellys in the 
sympathetic ganglia compared to those in the tail. This was observed in all of the Kelly cells 
incorporated into the ganglia of at least 8 chicks in total, taken from 3 separate experiments. 
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Figure 4.34. MYCN expression (red, human-specific) in GFP Kellys (green) within frozen 
sections of the E10 A-D, tail; E-H, sympathetic ganglia, following intravenous injection at E3. 
Scale bar 50µm.  
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Figure 4.35. MYCN expression (red, human-specific) in GFP Kellys (green) within frozen 
sections of the E10 A-D, tail; E-H, sympathetic ganglia, following intravenous injection at E3. 
Scale bar 50µm. 
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Figure 4.36. Histogram displaying the average fluorescence intensity of MYCN staining in 
the nuclei of Kelly cells intravenously injected into E3 embryos, dissected at E10, and found 
to have located to the tail and sympathetic ganglia. Error bars display the standard error of 
the mean, calculated by dividing the standard deviation by the square root of the sample 
size. 
 
 
4.4. Discussion 
 
Prior to completing the intravenous injections, it had been expected that the neuroblastoma 
cells would locate to regions of the embryo where they would both survive and thrive, hence 
it was assumed that small proliferating tumour masses would be discovered upon E10 
dissection. It was essential to terminate experiments by E10.5 (halfway through gestation) 
according to Home Office guidelines, as a license to prolong these experiments was not 
possessed. Cells were injected at E3 because it is the earliest point in development that a 
fully-formed circulatory system is present, and having to dissect at E10, meant the cells 
could be left within the embryos for the maximum possible length of time. Unexpectedly, the 
cells responded to the guidance cues that direct neural crest cells along their migratory 
pathways, and following extravasation, incorporated largely into neural crest-derived tissues. 
This was a feature found consistently within the >250 embryos dissected, where cell 
integration was consistent in terms of both the organs targeted and cellular appearance. It 
had been presumed that targeting would occur following neuroblastoma implantation into the 
neural tube, but was surprising due to their ectopic site of introduction. Any uncertainty over 
whether cells had located to most tissues throughout the embryos, and apoptosed in some 
yet survived in others, was abated following the dissection of embryos at E7 (data not 
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shown), where Kellys were only observed in those structures found to contain the cells at 
E10.  
 
The targeting of cells to the parasympathetic ciliary ganglion and parasympathetic neuron-
containing tail, as well as non-neural tissues such as the meninges, indicated that the cells 
were not merely following the sympathetic nervous system developmental route, but the 
numerous different neural crest pathways. In the embryo, trunk neural crest cells migrate 
along two different pathways: the ventromedial route, which gives rise to cells of the DRG 
and SG; and the dorsolateral pathway, the cells from which form melanocytes (Henion & 
Weston 1997). Delamination and hence cell migration along the dorsolateral pathway is at 
least one day later than the NCCs travelling ventromedially (Erickson & Perris 1993; Henion 
& Weston 1997). Interestingly, the neuroblastoma cells seemed only to target the ventral 
neural crest migratory path, as cells were not found in the skin – even though neural crest 
delamination of cells destined to become melanocytes occurs at around HH17-18 in the 
chick (Kitamura et al. 1992), therefore migration would have been underway at the time of 
neuroblastoma cell injection. Perhaps the neuroblastoma cells have some kind of intrinsic 
epigenetic memory that resulted in them responding to factors along the neural crest 
pathway they would have originally followed in their pre-oncogenic state as neural crest 
cells. 
 
The formation of the primary sympathetic ganglia at HH21 (E3.5) in the chick embryo (Lallier 
& Bronnerfraser 1988), is near perfect timing to allow the neuroblastoma cells injected at E3 
to coalesce with the endogenous chick NCCs and participate in the formation of 
sympathoadrenal structures. This may be why the cells are fully integrated into the SG 
tissue. The earliest NCCs migrate between the neural tube and somites, and follow the 
routes of the intersomitic blood vessels (Kulesa & Gammill 2010), and immediately following 
injection, neuroblastoma cells are seen within these narrow vessels – therefore it may be 
postulated that the cells are attracted out of these small vessels to then aggregate with the 
sympathoadrenal precursors. However, this makes it even more intriguing that neither the 
Kellys nor BE(2)Cs were observed in the chick adrenal glands. Neuroblastoma tumours 
primarily occur in the sympathetic ganglia and the adrenal medulla, and both tissues are said 
to be derived from the same initial pool of sympathoadrenal precursors (Langley & Grant 
1999). It has been published that in mouse tail vein injections, neuroblastoma cells do locate 
to the mature adrenal glands (Engler et al. 2001), therefore targeting of the chick adrenal 
glands may be strictly time- and spatially-dependent – for example, by cells originating from 
a particular somitic level (18-24), in an embryo of a very specific age. It is also conceivable 
that the neuroblastoma cells locate to the primary sympathetic ganglia that form at around 
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E3.5, but do not migrate with the primitive adrenal cells (around E4); instead remaining with 
the cells that will go on to form the sympathetic ganglia at E5. It has been reported that 
neuroblastomas do not express phenylethanolamine-N-methyl transferase (PNMT), the 
enzyme involved in the conversion of noradrenaline to adrenaline which is expressed in the 
adrenal chromaffin cells (Hoehner et al. 1996). It has therefore been hypothesised that 
neuroblastomas occurring in the adrenal glands may arise from misplaced sympathetic 
ganglion cells rather than cells of the adrenal medulla (Pahlman et al. 2004), particularly as 
pheochromocytoma, a tumour derived exclusively from the adrenal chromaffin cells does 
express PNMT. If true, this would be a plausible explanation for neuroblastoma cells not 
targeting the chick adrenal glands following E3 intravenous injection. 
 
The targeting of the Kelly (and BE(2)C) cells to the gut following E3 injection may be 
explained by the contribution of chick neural crest cells to the enteric nervous system, which 
arises mostly from the vagal NCCs (at the level of somites 1-7). The endogenous NCCs 
collect in the caudal branchial arches, before entering the pharyngeal gut mesenchyme at 
around HH20 in the chick (Burns & Le Douarin 1998). The neuroblastoma cells injected at 
approximately HH18-20 may likely have located to the branchial arches along with the chick 
NCCs, and then followed them into the gut tissue at HH20. The neuroblastoma cells then 
presumably migrated rostrocaudally with the chick NCCs, which colonise the entire length of 
the gastrointestinal tract (Burns & Le Douarin 1998; Sasselli, Pachnis & Burns 2012). 
 
The ENS – specifically within the hindgut – has a sacral contribution from NCCs caudal to 
somite 28, which initially form the nerve of Remak, adjacent to the gut wall, from which the 
NCCs enter the hindgut upon arrival of the vagal NCCs at this region of the gut (Kapur 
2000). In the chick, sacral NCCs have been observed in the hindgut from E7 and 
colonisation is completed by E8.5 (Burns & Le Douarin 1998), and this may explain why a 
small number of Kelly cells injected at E6 are observed in the gut – the cells may have 
resided along with the endogenous NCCs in the nerve of Remak, before following them into 
the gut at E7.5. 
 
The meninges – particularly overlying the forebrain – have a neural crest contribution (Couly 
& Ledouarin 1987), and incidentally, it was primarily the forebrain meninges in which the 
Kelly cells were observed following E3 injection. Similarly in the eye, the cornea, sclera and 
uvea (consisting of the iris, ciliary muscle and choroid) all have a neural crest component 
(Johnston et al. 1979), and Kelly cells have been observed specifically in these locations. 
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In the heart, neuroblastoma cells displayed very specific homing to areas of cardiac tissue 
rather than the vasculature. One may have expected that, as the first organ the cells 
encountered following injection and the “key player” in the circulatory system the cells were 
initially contained within, the cells may have incorporated into the internal atrial/ventricular 
walls – these tissues being in the closest proximity. However, perhaps in part due to the 
magnitude of the contractional force, or maybe wholly due to the lack of neural crest 
contribution to this tissue, neuroblastoma cells were not observed in the inner heart muscle. 
They were instead discovered primarily in the conotruncal region and in the septa between 
the great vessels – it may be no coincidence that during development cranial neural crest 
cells have been demonstrated to contribute to the conotruncus and the septation of the 
outflow tract (Farrell et al. 1999; Jiang et al. 2000). 
 
The targeting of Kellys to the tongue seemed to be the exception to the rule, as this has no 
neural crest contribution, being derived from the somites and branchial arches (Bellairs & 
Osmond 1998). However, one possible explanation could be that if some NCCs did in fact 
locate to the branchial arches prior to gut colonisation (see above), there may have been a 
residual population that did not migrate with the prospective ENS, but remained in the 
branchial arches and incorporated into the tissue of the developing tongue from E4. 
 
The consistent appearance of neuroblastoma cells within the embryos’ tails was originally a 
mystery, but following immunofluorescence staining for TUJ-1 where they were shown to be 
loosely associated with the parasympathetic network of neurons, it was proposed that the 
cells followed the routes of neural crest cells destined to form parasympathetic structures, 
but once in the tail regions, the lack of dense nervous tissue for them to integrate into and be 
influenced by led to the formation of proliferating clumps of cells. 
 
Following injection at E3, cells were never/rarely found in structures such as the liver, lungs 
and spleen, which are not derived from neural crest cells. 
 
The targeting shown at E3 was in stark contrast to that seen following E6 injection, when the 
neural crest migratory cues were absent and the primordia of the resultant structures had 
already formed – very few cells were found in neural crest derived structures. Targeting was 
also considerably different following E3 injection of an alternative tumour line, glioblastoma, 
where the primary target for GFP cells was the CNS. In addition, when GFP-labelled SK-N-
AS neuroblastoma cells with a single copy of the MYCN gene were injected at E3 by Dr 
Anne Herrmann (University of Liverpool, UK), considerably fewer were observed within the 
E10 embryos than with the MYCN-amplified Kellys and BE(2)Cs. When GFP SH-EP 
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neuroblastoma cells, containing a single MYCN copy and negligible expression of the 
oncogene, were injected at E3 (by myself and Heba Karosh), no cells were found to have 
survived up to E10 within the embryos. A medulloblastoma cell line, D283, was injected by 
Haleh Shahidipour (technician, University of Liverpool, UK), and like the SH-EP, very few 
cells were observed in embryonic tissues at E10. Not only did neural crest targeting seem to 
be a feature compatible with neural crest derived neuroblastoma cells, but cell survival may 
possibly be confined to MYCN-amplified cells – particularly as MYCN amplification has been 
documented in medulloblastoma (Korshunov et al. 2012), but D283 are a non-MYCN-
amplified, non-MYCN-expressing cell line (Andrae et al. 2002). However more cell lines 
need to be tested before a firm conclusion can be reached. However, the observed 
differences in targeting meant that a useful model system had been established, in which the 
effects of various embryonic environments on tumour cells could be tested. 
 
The Kelly cells within chick tissues behaved differently depending on the site of 
incorporation. In neural tissues, the predominantly single cells displayed an elongated or 
“spread” appearance, which contrasted with the spherical, clumped appearances of Kellys 
within the tail, meninges, liver and kidneys. The clumps may have been a result of either 
clonal expansion (for example, in the relatively small, regularly-sized “balls” in the meninges) 
or aggregation and proliferation (one example may be the larger clumps of cells in the tail). 
In fact, observations on the various morphologies of the Kelly cells corresponded to the 
proliferation quantification data. For the generally single cells that extended processes within 
neural tissues, proliferation was restricted compared to the rounded cells residing in clusters 
within non-neural tissues, which were dividing more rapidly. The fact that a small proportion 
of Kellys in the sympathetic ganglia and ENS were dividing was less extraordinary, when it 
was taken into account that the endogenous chick cells in each of these structures were 
proliferating. For the sympathetic ganglia, particularly in Figure 4.29 A-D, there is a large 
blank space in the EdU photograph where the Kelly cells are located, with the surrounding 
chick SG cells showing evidence of proliferation. However in the tail and liver, the EdU-
containing nuclei are most abundant in the region of the Kelly cells, with what appears to be 
a much lower proportion of cells in the surrounding chick tissue dividing. This contrast 
between levels of proliferation in the Kellys and the surrounding chick cells in various 
locations, suggests that the Kelly cells do not seem to be influenced by the host tissue, in 
terms of reflecting the levels of proliferation of their surrounding cells. 
 
During ventromedial NCC migration, MYCN is expressed uniformly across the whole cell 
population. However, following aggregation at the primordial sympathetic ganglia, MYCN is 
switched off in all cells except those destined to become neurons (Wakamatsu et al. 1997). 
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The MYCN may have been downregulated in the Kellys soon after colonisation of the SG, in 
line with the non-neuronal host cells. It was not possible to detect MYCN levels in the chick 
SG cells as a chick-specific MYCN antibody is not commercially available. Regardless, the 
loss of MYCN expression in the Kellys implies that the cells are able to respond to the cues 
that downregulate MYCN during normal development. 
 
The fact that Kellys continued to express tyrosine hydroxylase in all tissues tested is perhaps 
unsurprising, as this enzyme is habitually expressed in normal developing neuroblasts, 
neuroblastoma tumours (which may be recapitulated to an extent by the MYCN-expressing, 
rapidly proliferating “microtumours” in the tail) and in sympathetic neurons (which the Kellys 
extending processes in the SG and ENS are reminiscent of). However, the cells in neural 
tissues did not appear to express the neuronal marker NF70 following analysis at E10, which 
may have been expected, thus left the fate of these cells slightly more unclear. 
 
When the morphological, proliferative and MYCN data were combined, it strongly implied 
that in the sympathetic ganglia the Kellys had been reprogrammed to a less aggressive 
phenotype. However, the reduction in MYCN expression made it intriguing that some of the 
cells within the sympathetic ganglia were still dividing. 
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5.1. Introduction 
 
The discovery that neuroblastoma cells were being influenced by the sympathetic ganglia 
environment in a favourable way (in the context of patient prognosis) was hugely exciting. It 
appeared that the majority of cells were being reprogrammed to a more benign phenotype, 
in that they had reduced rates of proliferation compared to those in non-neural regions such 
as the tail, and even more significantly, had lost any detectable MYCN expression. This was 
observed following 7 days in the embryos. MYCN immunofluorescence was not detected in 
any of the Kelly cells analysed, therefore it was surprising that 15% of the cell population 
continued to divide. A Home Office licence was obtained to allow incubation of the embryos 
past the previous restriction of E10.5. It was speculated that by leaving the GFP Kellys to 
survive within the chick tissues until E14, i.e. for 11 days in total, the proliferating fraction of 
Kelly cells in the sympathetic ganglia may decrease or disappear, presumably in parallel with 
those cells in the host tissue and also possibly as a result of the loss of MYCN in the whole 
cell population. 
 
 
5.2. Aims 
 
• To extend the duration of the Kelly cells’ subsistence within the different chick embryo 
environments in vivo, primarily to discover the effects on the Kellys following prolonged 
contact with and influence by the cells of the sympathetic ganglia. 
• To inject two SH-EP neuroblastoma cell lines: one with no MYCN expression and one 
with constitutive expression; to compare cell behaviour with the highly MYCN-
expressing Kelly cells. 
• To amass a selection of primary neuroblastoma cell lines, cultured from 
biopsies/resections of neuroblastoma tissue, for potential intravenous injection into the 
established chick embryo model system. 
• To establish an in vitro system in which to investigate the reliance of the Kelly cells on 
the sympathetic ganglia microenvironment for MYCN downregulation, and allow the 
identification of possible responsible factors. 
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5.3. Results 
 
5.3.1. GFP Kelly cells survive within chick embryos until E14 
 
5.3.1.1. Locations and morphology 
 
With the intention of investigating the behaviour of Kelly cells within E14 chick tissues 
compared to the results obtained at E10, GFP-labelled cells were injected intravenously at 
E3, as for the experiments detailed in Chapter Four; with 2x105 cells injected into the 
bloodstream of each embryo. Embryos were then incubated until E14, at which point 
experiments were terminated using a Schedule One procedure: decapitation. A total of 
approximately 45 chicks survived to E14, from 7 independent experiments. Dissection of the 
embryos showed that Kelly cell location was similar to that at E10, revealing that cells 
continued to survive in all locations. In the sympathetic ganglia (in all successfully injected 
embryos) and gut (at least 80-90% of embryos), Kellys remained elongated in appearance 
and existed mostly as single cells or in small loosely associated groups (Figure 5.1 A-B and 
C-D, respectively). Clumps of cells were still almost always found in the tail tissue (Figure 
5.1 E-H), and in this region, were also observed between the cloaca and cloacal bursa in 
almost every embryo (Figure 5.1 G-H), the latter being a structure which is a site of 
haematopoiesis, is considerably more pronounced at E14 than E10, and atrophies around 6 
months after hatching. The tightly packed groups of cells in the meninges were still present 
in large numbers in greater than 90% of E14 embryos (Figure 5.2 A-D) and were usually at 
least 50µm, often reaching 100µm in diameter. They were often located near to blood 
vessels (Figure 5.2 C-D), suggesting limited migration into the meningeal tissue following 
extravasation, possibly favouring proliferation. Cells remained integrated into predominantly 
the conotruncal region of the heart (Figure 5.2 E-F) in at least 6 or 7 of a typical batch of 10 
surviving embryos, and in the outer layers of the eye (Figure 5.2 G-H) in more than half. 
Kellys were also observed as clumps on the ventral surface of the E14 tongue (Figure 5.3 A-
B) in roughly a quarter of embryos dissected, and in 20-30% of cases were observed in 
major peripheral nerves, such as the sciatic, imaged in Figure 5.3 C-D. Like in the SG and 
ENS, cells appeared to be fully integrated into the nervous tissue and presented with an 
elongated morphology, reminiscent of cells undergoing neuronal differentiation. Interestingly, 
a small number of Kelly cell clumps were observed in the kidneys (Figure 5.3 E-F) of at least 
three quarters of the embryos. It was not unknown for a very small number of cells to appear 
in the kidneys at E10 (Table 4.1), but this was not found consistently enough, neither were 
there large enough numbers of cells in the organs, to be deemed particularly relevant 
compared to the other chick tissues. However, the appearance of groups of more than 1-3 
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cells at E14, suggested that the odd cells present at E10 had proliferated into small clusters. 
Once again, Kellys were not observed in the adrenal glands. 
 
Confocal microscopy revealed the Kellys’ morphology to be similar to, but a more 
exaggerated version of those in the E10 tissues – presumably owing to the prolonged 
influence of the various chick tissue microenvironments. In the E14 sympathetic ganglia, the 
majority of the Kellys had extended processes of roughly 30-70µm in length (Figure 5.4 A). A 
small proportion of the cells had processes in excess of 100µm (Figure 5.4 B, arrow), 
irrefutably representative of neuronal differentiation and axonal growth. Confocal imaging 
confirmed the observations made upon dissection, that the cells were often solitary within 
the ganglia, but also resided in small groups (Figure 5.4 B, arrow head). In the gut, like at 
E10, some cells existed singly, whereas many resided in ganglion-type groups (Figure 5.4 
C+D, arrow heads). Most of the cells extended processes, generally shorter than those from 
the Kellys in the sympathetic ganglia, but some more than 60µm long (Figure 5.4 C+D, 
arrows). It was once again confirmed that the neuroblastoma cells were integrated into the 
gut tissue in two separate layers, assumed to be the myenteric and submucosal plexuses of 
the enteric nervous system. In the tail, the cells were located in masses that were often more 
numerous and almost always of an increased size compared to those observed at E10, 
presumably due to the rapid cell proliferation by the cells in this region over the additional 4 
days. The cell clumps varied in size, but were often in excess of 200µm in diameter (Figure 
5.5 A+B). Similarly in the meninges the cells remained within compact clusters (Figure 5.5 
C+D), which were bigger in size than those witnessed within the E10 meninges. A notable 
increase in number of these clumps was not apparent. 
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Figure 5.1. GFP-labelled Kelly cells, following intravenous injection at E3 and incubation for 
a further 11 days prior to dissection, were found integrated into the E14 chick A-B, 
sympathetic ganglia; C-D, gut (C is a higher magnification image of the area within the 
dashed box in D); E-F, tail; G-H, caudal region (as labelled). Scale bars A-C, 200µm; D, 
500µm; E-H, 1mm. 
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Figure 5.2. GFP-labelled Kelly cells were intravenously injected into E3 chick embryos. 
Following dissection at E14, cells were discovered within the A-B, meninges in situ, over 
surface of brain; C-D, magnified area of the meninges, dashed lines in D indicate the 
positions of the clumps of Kelly cells in relation to the blood vessels; E-F, heart; G-H, eye, 
dashed line in G indicates the outer boundary of the eyeball. Scale bars A-B, E-H, 1mm; C-
D, 200µm. 
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Figure 5.3. GFP-labelled Kelly cells were injected intravenously into E3 chick embryos, and 
following dissection at E14, were found within the A-B, tongue, ventral surface; C-D, spinal 
nerve, possibly the sciatic, C is a magnified image of the area within the dashed box in D; E-
F, kidneys, but were not seen in the adrenal glands. Scale bars A-B, E-F, 1mm; C-D, 
500µm. 
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Figure 5.4. Compressed Z stack confocal images of GFP-Kelly cells within neuronal E14 
chick tissues, having been intravenously injected at E3. A-B, sympathetic ganglia; C-D, gut 
(ENS). Scale bar 50µm. Arrows identify long processes extended by the Kelly cells; arrow 
heads point to clumps of cells.  
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Figure 5.5. Confocal images (compressed Z stacks) of GFP-labelled Kelly cells that were 
injected intravenously into E3 chick embryos, and upon E14 dissection, were discovered 
within non-neuronal tissues, residing in clumps. A-B, tail; C-D, meninges. Scale bar 50µm.  
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The meninges data was analysed further, being the only tissue in which approximately 
regularly-sized “balls” of cells were consistently observed. Only meninges containing GFP-
labelled cells from the Kelly line were studied because data was available for all three 
injection/dissection time points. The BE(2)Cs were not included in the E3-E10 bracket 
because their meningeal clumps were considerably larger and much more variable in size 
compared to the Kellys – many reaching, and some exceeding, 100µm in diameter. As 
shown in Figure 5.6, the clumps in the embryos injected at E6 and dissected at E10 were the 
smallest in size, on average 15-20µm, having only been in the embryos for 4 days. Those 
embryos injected at E3 and dissected at E10 possessed meningeal clumps of Kelly cells that 
were intermediate in size, roughly 30-35µm in diameter. In comparison, those cells that had 
survived within the embryos for 11 days, from E3 to E14, were in by far the largest cell 
masses, generally between 50 and 100µm in diameter. Thus the size of the Kelly clumps 
increased with increasing time in the embryos and this, along with their relatively rounded 
form and regular size, suggested they had originated from single cells rather than 
aggregation and were actively proliferating, i.e. could be regarded as neuroblastoma micro-
tumours. 
 
 
 
Figure 5.6. GFP-Kelly cells within chick meninges; A+D, following intravenous injection at 
E6 and dissection at E10; B+E, E3 injection, E10 dissection; C+F, E3 injection, E14 
dissection. Note the difference in the length of the scale bar for F, showing a cell clump 
considerably larger than in D and E. Scale bars A-C, 200µm; D-F, 20µm. 
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5.3.1.2. Proliferation 
 
EdU was used to quantitatively assess the extent of proliferation of the Kellys in each of the 
four embryonic tissues analysed at E10: the sympathetic ganglia, ENS, tail and meninges. 
EdU was intravenously injected at E13, thus proliferation was measured over the 24 hours 
prior to sacrifice. The increased mass of the embryos was accounted for (see Figure 2.4), 
and 4µl of a 20mM solution was administered, roughly equivalent to a concentration of 10µM 
in an 8g embryo. Results are summarised in Figure 5.7, from Kellys within tissues from 6 
embryos, taken from 2 separate experiments, i.e. 3 per batch. In the sympathetic ganglia, 
the proportion of dividing Kelly cells was quantified at 22% (n=241) (Figure 5.8 A-D) – an 
increase from the 15% witnessed at E10. Of the Kelly incorporated into the enteric nervous 
system in the gut, 28% (n=200 cells) were proliferating (Figure 5.8 E-H), compared to 15% 
at E10. However, within the clumps of rounded cells in the tail and meninges, 49% (n=1247 
cells) (Figure 5.9 A-D) and 50% (n=660 cells) (Figure 5.9 E-G) respectively had divided 
between E13 and E14, which was almost identical to the results obtained at E10 – when 
50% of Kellys in the tail and 53% in the meninges were dividing. 
 
 
 
 
Figure 5.7. Histogram to show the proportions of proliferating Kelly cells between E13 and 
E14 within chick tissues as labelled. Error bars display the standard deviations from the 
mean values for each tissue. 
 
 
Although the increased rated of cell proliferation in the sympathetic ganglia and ENS was 
unexpected, the endogenous chick cells were still dividing in both of these tissues (Figure 
5.8), so perhaps the result was consistent with Kelly cells responding to their environment. 
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Figure 5.8. GFP-labelled Kellys were intravenously injected into E3 chick embryos. 4µl of a 
20mM solution of EdU was injected into E13 embryos, which were sacrificed and dissected 
24 hours later. E14 A-D, sympathetic ganglia; E-H, gut (ENS); were sectioned using a 
cryostat and EdU incorporation could then be detected. Arrows identify Kelly cells with 
nuclear EdU incorporation. Scale bar 50µm for all.  
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Figure 5.9. EdU incorporation into E14 A-D, tail; E-G, meninges; tissues containing GFP-
labelled Kellys that had been intravenously injected at E3. EdU was injected at E13, 24 
hours prior to dissection, and incorporates into all dividing cells – human and chick. A-D, 
frozen sections; E-G, whole mount stain. Scale bars 50µm.  
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5.3.1.3. MYCN expression 
 
At E10, the proliferating Kelly cells in the tail and meninges had continued to express MYCN 
at high levels, whereas in the sympathetic ganglia and gut, expression was downregulated; 
in the SG to below detectable levels in every Kelly cell. When assessed at E14, 
unsurprisingly, the Kellys in the tail and meninges still maintained their MYCN protein 
expression (Figure 5.10 and Figure 5.11). In the neural sympathetic ganglia and gut, results 
are different to those achieved at E10. In the Kellys located as single cells in the sympathetic 
ganglia, therefore mostly, if not completely, surrounded by chick cells, MYCN expression 
remained below detectable levels (Figure 5.12). However, there was an increased incidence 
of clusters of Kelly cells within the tissue, which were to some extent protected by each other 
from the chick host environment. Within these clusters, many of the Kelly cells had begun to 
re-express MYCN (Figure 5.13). There may have been very low levels of MYCN in some 
Kellys within the ENS, but many had undetectable MYCN (Figure 5.14). 
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Figure 5.10. MYCN expression in frozen sections of GFP-labelled Kelly cells, residing in 
clumps within the E14 chick tail. Kellys had been injected intravenously at E3. Scale bar 
50µm for all.  
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Figure 5.11. Confocal image (compressed Z stack) showing MYCN expression in GFP-
labelled Kelly cells in a clump within the E14 chick meninges. Kellys were injected into the 
chick intravenously at E3. Whole mount tisue stain. Scale bar 50µm.  
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Figure 5.12. GFP-labelled Kelly cells were intravenously injected into the E3 chick, and 
allowed to survive within the embryo for 11 days, until dissection at E14. Kellys were 
discovered within the sympathetic ganglia, which were frozen and sectioned. 10µm sections 
were stained for human-specific MYCN expression. Images shown are of Kellys located 
either as single cells or in small groups, and these do not express detectable levels of the 
MYCN protein. Scale bar 50µm for all. 
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Figure 5.13. GFP-labelled Kelly cells were intravenously injected into the E3 chick, and 
allowed to survive within the embryo for 11 days, until dissection at E14. Kellys were 
discovered within the sympathetic ganglia, which were frozen and sectioned. 10µm sections 
were stained for human-specific MYCN expression. Images shown are of Kellys located in 
more dense groups, in which some cells – particularly those shielded from the SG 
microenvironment – have re-expressed MYCN. Open arrows identify GFP-Kellys with MYCN 
expression, block arrowheads point to more singly-located Kellys with undetectable MYCN 
expression. Scale bar 50µm for all. 
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Figure 5.14. MYCN expression in frozen sections of GFP-labelled Kelly cells within the E14 
chick gut (ENS). Cells were injected intravenously at E3 and allowed to survive in the 
embryos for a total of 11 days. Some cells did not show detectable MYCN protein 
expression, however some may have low levels of expression (arrows). Scale bar 50µm. 
 
 
5.3.1.4. Differentiation 
 
Although over one fifth of the Kelly cells within the sympathetic ganglia were proliferating, 
and many of those shielded from the host environment had begun to re-express MYCN, the 
extension of significantly long processes by a proportion of cells prompted the completion of 
whole mount staining of the tissue for markers of neuronal differentiation. Tissues were 
stained using antibodies to the NF 70kD subunit (cross-reacts with both human and chick) 
and GAP43 (cross-reacts with human only). Although Kellys within the fluorescently 
neurofilament-stained chick neurons did not themselves stain positively for neurofilament, a 
small number of cells did express the GAP43 protein (Figure 5.15), revealing that the 
sympathetic ganglion environment was capable of inducing differentiation and hence a 
reversal in tumourigenesis of these MYCN-amplified neuroblastoma cells. 
 
 
Chapter Five: Results III 
 
185 
 
 
 
Figure 5.15. Following intravenous injection of GFP-labelled Kellys into E3 chick embryos, 
E14 sympathetic ganglia containing integrated Kellys were whole mount stained for MYCN 
protein expression and imaged using a confocal microscope. A small proportion of GFP-
labelled Kellys within the ganglia were found to express the neuronal lineage protein GAP43. 
Scale bar 20µm.  
 
 
5.3.2. GFP-labelled SH-EP injections 
 
5.3.2.1. SH-EP wildtype 
 
The SH-EP cell line is a non-MYCN-amplified neuroblastoma line, with no/negligible MYCN 
expression. It was intriguing to discover how these cells would behave in the chick embryos 
compared to the highly MYCN-expressing Kelly cells. A GFP-labelled SH-EP line was 
generated (with thanks to Dr Anne Herrmann, University of Liverpool, UK), and 2x105 of 
these cells were intravenously injected into E3 chick embryos, using exactly the same 
protocol as for the Kelly cells. As briefly mentioned in the Chapter Four Discussion, when 
embryos were dissected at E10, no SH-EP cells were found within any chick tissues (n=11 
embryos, 2 experiments). Following E3 injection, embryos had been examined under 
fluorescence, and GFP-labelled cells were observed throughout the circulation and within 
embryonic tissues, therefore cells must have undergone apoptosis at some point between 
E3 and E10. 
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5.3.2.2. SH-EP-MYCN 
 
The SH-EP-MYCN cell line (kindly donated (and produced) by Dr Louis Chesler, The 
Institute of Cancer Research, Sutton, UK) is one in which MYCN expression is driven by a 
human cytomegalovirus (CMV) promoter, resulting in the MYCN oncogene being 
constitutively expressed. Although this expression would probably not be as high as that in 
the Kelly cells, which have over 200 copies of the MYCN gene (Murphy et al. 2009), in 
theory, being under the CMV promoter, the MYCN would not be able to be turned 
off/downregulated in those cells within the sympathetic ganglia microenvironment. MYCN 
strongly induces cell proliferation, and rat embryo cells transfected with MYCN derived from 
Kelly cells have been shown to proliferate for at least 200 generations (Schwab & Bishop 
1988). Therefore it was considered to be of great interest how the cells would behave 
particularly in the sympathetic ganglia, where the stable MYCN expression could not be 
repressed by the as yet unidentified factor(s). Would SH-EP-MYCN cells form microtumours 
reminiscent of those occurring in the embryonic chick tail and meninges? 
 
The SH-EP-MYCN cells were stained in culture by Heba Karosh (MRes student, University 
of Liverpool, UK) to assess the MYCN protein levels. In this supposedly highly MYCN-
expressing line, only around half of the cells stained positively for the MYCN protein, 
therefore efforts had to be made to produce a more consistently MYCN-expressing line. 
After subcloning, although MYCN staining intensities still varied slightly, the subclones were 
initially much more uniform in terms of their expression than the original cell line. The most 
consistently highly MYCN-expressing subclone was GFP labelled by Dr Anne Herrmann 
(University of Liverpool, UK), and from the masterclone of cells with varying GFP 
fluorescence intensities, the brightest cells were selected by Heba Karosh using a FACS cell 
sorter. Thus a brightly GFP-expressing, constitutively highly MYCN-expressing SH-EP cell 
line was thought to have been produced. However, when this was later stained using a 
MYCN antibody, only 60-70% of cells stained positively, which although improved on the 
original cell line, was not favourable. 
 
The GFP-labelled SH-EP-MYCN subcloned cells were nevertheless injected intravenously: 
2x105 cells per E3 chick embryo. When these embryos were dissected at E10 (n=12 
embryos, 2 experiments), they were either completely devoid of neuroblastoma cells or 
found to contain less than 10 isolated SH-EP cells. The embryos had been examined under 
fluorescence at E3, 0-3 hours after injection, and every one had an abundance of cells within 
the chick tissues and travelling through the circulation, comparable in numbers to those 
typically seen following Kelly cell injection. When E3-injected embryos were then dissected 
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at E7 (n=4 embryos, 1 experiment), a greater number of SH-EP-MYCN cells were found, but 
this was still relatively few; less than 100 cells per embryo. These were mostly located in the 
internal heart tissue, plus single-figured numbers of cells were isolated in the gut (gizzard, 
intestine, colon), tail, meninges, eyes and body cavity – similar locations to the Kellys. In the 
four E7 embryos dissected, cells were not observed in the sympathetic ganglia, or adrenal 
glands. 
 
 
5.3.3. Moving forward with the chick intravenous injection model system 
 
Following the results obtained with the E3-injected Kelly cells, there are inevitably a 
multitude of questions to be answered and opportunity to pursue various routes of further 
investigation. Two different approaches on which work has commenced are the culture of 
primary neuroblastoma tissues, in the hope that these cells can be injected into the chick 
embryo, and in vitro culture of chick tissues containing neuroblastoma cells, to examine the 
dependence of the Kelly cells on chick tissues for maintenance of their phenotypes. 
 
 
5.3.3.1. Primary neuroblastoma cell culture 
 
Neuroblastoma primary tumour tissue was received from Alder Hey Children’s Hospital, 
Liverpool, UK – either from a biopsy at diagnosis or from a surgical resection. Eleven 
samples were received, and for the latter three (all biopsy tissues), they were accompanied 
by bone marrow aspirates. Images of cultured tissues are shown in Figures 5.16, 5.17 and 
5.20: those labelled with digits only (e.g. NB17) are from biopsy samples, i.e. pre-treatment, 
those labelled “B” (e.g. NB16B) are resected tissues, i.e. post-chemotherapy, and NB2C is 
from a relapse. 
 
Initially, for samples NB16B to 20B, tissue was dissociated as far as possible, and the single 
cells cultured along with small tissue pieces in serum-containing medium. The cells grew 
adherent to the culture surface, were usually large and flat displaying varying morphologies 
(Figure 5.16 A-D). However, some extended long processes (Figure 5.16 E and Figure 5.17 
C). All tumours behaved differently – some growing rapidly, and others taking weeks to 
expand. In general, the attachment of tissue pieces to the culture surface, as in Figure 5.16 
H and Figure 5.17 E, generally resulted in outgrowth of a large number of cells. However, for 
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many tumours, the tissue would not adhere, even if the culture surface was coated with 
Poly-L-lysine and/or laminin. 
 
 
 
Figure 5.16. Primary neuroblastoma tumour tissues received from Alder Hey Children’s 
Hospital. Tissues were mechanically dissociated and cultured in serum-containing medium. 
Single cells and tissue pieces adhered to the culture surface. Scale bars A-B, D, 20µm; C, 
E-H, 100µm. 
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Figure 5.17. Additional primary neuroblastoma tumour tissues received from Alder Hey 
Children’s Hospital, following tissue dissociation and adherent culture in serum-containing 
medium. Scale bars A-D, 20µm; E-F, 100µm. 
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The adherent cells of MYCN-amplified tumour NB19B were stained for the neuroblastoma 
protein markers MYCN and NB84 and the stem cell marker nestin (Figure 5.18). None of the 
cells expressed detectable MYCN or NB84, but the majority of cells did stain positively for 
nestin (Figure 5.18 G-L). Since this was a resected tumour and neuroblastoma patients often 
respond well to initial treatment, but succumb to a treatment-resistant relapse, it was 
possible that the cells being cultured were not malignant neuroblastoma cells. 
 
 
 
 
Figure 5.18. NB19B cells, following adherent culture in serum-containing medium, were 
trypsinised and cultured on 13mm glass coverslips. Cells were then stained using antibodies 
as labelled. Scale bar 50µm for all. 
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Methanol-fixed touchprints of MYCN-amplified tumour NB20 were received from the Alder 
Hey histopathologists, and these were stained for the stem cell markers CD133 and nestin to 
test the tumour’s aggressiveness. Like the cultured NB19B cells, the entire tumour region on 
the touchprint of MYCN-amplified NB20 stained for nestin, and the majority of the cells 
seemed to stain for CD133 – expression of both proteins is associated with MYCN 
amplification (Sartelet et al. 2012; Thomas et al. 2004a). 
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Following staining of adherent tumour cells by a number of group members, it was 
considered a distinct possibility that this culture method was not optimal for the culture of 
malignant neuroblastoma cells. Therefore future samples were cultured in serum-free “stem 
cell medium” as spheres (Figure 5.20). These spheres grew up to 500µm and following 
mechanical dissociation, further spheres were cultured for 1-3 passages before freezing. 
 
For samples NB22, NB23 and NB24, bone marrow aspirates (taken at diagnosis) were also 
received. Bone marrow samples may be the most effective in producing primary 
neuroblastoma lines, as most neuroblastoma cell lines were originally derived from bone 
marrow samples. Bone marrow cells were cultured in serum-free medium as spheres 
(Hansford et al. 2007) (Figure 5.20), and frozen after 1-2 passages. 
 
 
 
 
Figure 5.20. Neuroblastoma samples received from Alder Hey Children’s Hospital. A-B, 
primary tumour tissue following mechanical dissociation; C-D, bone marrow aspirates.  A, 
cultured in serum-containing medium, B-D, non-adherent culture in serum-free medium. BM, 
bone marrow. Scale bars all 100µm. 
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5.3.3.2. Establishment of an in vitro system to assess the effect of the sympathetic 
ganglia on neuroblastoma cells 
 
To test the influence and possible dependence of the Kelly cells on the sympathetic ganglia 
microenvironment for maintenance of a less aggressive phenotype, E10 sympathetic ganglia 
containing Kelly cells were dissected and placed into culture, either as dissociated cells or 
explants. E10 tissues were chosen because in their SG, the starting population of Kellys 
would all be MYCN deficient, therefore the effects of the ganglionic microenvironment could 
be efficiently tested. GFP-Kelly-containing tail tissue was cultured in parallel as a control. 
Following the discovery of MYCN re-expression at E14, the aim of these experiments was to 
investigate any differences between the behaviour of Kelly cells cultured with, but not 
necessarily in contact with SG cells, and Kelly cells integrated into explants, completely 
surrounded by and in contact with chick ganglion cells. 
 
Preliminary experiments were performed to investigate whether the Kelly cells would survive 
being cultured on poly-L-lysine- and laminin-coated coverslips, in L15 sympathetic neuron 
medium in a CO2-free incubator – the required SG culture conditions. Additionally, chick 
embryo tail cells were cultured on poly-L-lysine and laminin, in both L15 sympathetic neuron 
medium, cultured in a CO2-free incubator, and RPMI medium in a 5% CO2 incubator. EdU 
incorporation into both types of cells in all culture conditions indicated they were not only 
surviving, but proliferating in culture. Therefore sympathetic ganglia and pieces of tail tissue, 
both containing GFP Kellys that had survived in the embryonic tissues for 7 days, were 
either dissociated into single cells and placed into culture, or torn into small pieces and 
cultured as explants – all on coverslips coated with poly-L-lysine and laminin, in L15 medium 
and incubated at 37°C in 0% CO2 for 3 days. EdU was added to the culture medium after 48 
hours. These experiments were performed on two separate occasions, using tissues from at 
least 5 embryos each time. 
 
As expected, in dissociated tail tissue, the majority of GFP-expressing Kelly cells had divided 
in the 24 hours prior to fixation (87%, n=572) (Figure 5.21 A-F and Figure 5.22 D), and 
almost all showed clear retention of MYCN expression (94%, n=363) (Figure 5.21 G-L, 
Figure 5.22 E). The results for Kelly cells within the explanted tail tissue (photographed in 
Figure 5.22 A-B) were almost identical, with 86% (n=780) having EdU incorporation (Figure 
5.22 C+D) and 98% (n=373) displaying obviously high levels of the MYCN protein (Figure 
5.22 E). 
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In the E10 sympathetic ganglia, it had been found that only 15% of the Kelly population were 
undergoing cell division (Figures 4.29, 4.30) and MYCN could not be detected by 
immunofluorescence in any of the Kelly cells (Figure 4.36 E-H, Figure 4.37 E-H, Figure 
4.38). However, following dissociation of the tissue, meaning that the Kelly cells were not 
completely surrounded by SG cells, the proportion of proliferating cells had increased to 87% 
(n=377) (Figure 5.23 A-F, Figure 5.24 G), the same as those dissociated from the E10 tails. 
It was apparent from the E14 data that the loss of MYCN expression observed in the Kelly 
cells in the E10 SG was reversible, and this was also shown to be the case in the 
dissociated SG, where from an initial population of 0% MYCN-expressing Kellys, following 3 
days in culture, 75% of the Kellys were found to express MYCN (n=148) (Figure 5.23 G-K, 
Figure 5.24 H). The cells’ morphologies were similar to that observed for normal 
(undifferentiated) Kellys in culture. The sympathetic ganglion explants extended numerous 
axons, radiating out from the entire circumference (Figure 5.24 A-B), and some of the GFP 
Kellys within the explants also developed neurites which extended towards, and sometimes 
beyond, the edge of the SG tissue (Figure 5.24 C, arrows). Of the Kelly cells within the 
explants, 70% (n=248) had undergone cell division in the previous 24 hours (Figure 5.24 
D+G), and although this was considerably more than the 15% proliferating in the SG in vivo 
at E10, and even the 22% at E14, it was in keeping with the chick SG cells. Perhaps most 
interesting was the fact that MYCN immunofluorescence could not be detected in any Kelly 
cells in the SG explants (Figure 5.24 E-F+H). 
 
These results showed that the Kelly cells remained under the control of the sympathetic 
ganglia when put into culture, and implied that one or more factors within the sympathetic 
ganglionic environment were required for the maintenance of this downregulation. 
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Figure 5.21. Following E3 intravenous injection of GFP-labelled Kelly cells, dissected E10 
chick tail tissues containing GFP Kellys were dissociated into single cells and cultured on 
poly-L-lysine- and laminin-coated glass coverslips for 3 days. A-F, After 48 hours in culture, 
5µM EdU was added to the culture medium, then after a further 24 hours, cells were fixed 
and EdU incorporation detected; G-I, MYCN immunofluorescence staining, following 3 days 
in culture. Scale bar 50µm for all.  
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Figure 5.22. Tail tissue containing GFP-labelled Kellys (that had been injected intravenously 
at E3) was dissected from E10 embryos. This tissue was cultured in vitro as explants (A, 
fluorescence; B, brightfield) for 3 days. Tissues were then whole mount stained to detect 
EdU incorporation (C, compressed Z stack confocal image, green is anti-GFP antibody, red 
is EdU) and MYCN expression. Scale bars A-B, 200µm; C, 50µm. D-E, histograms to show 
the proportions of Kelly cells D, proliferating; E, expressing MYCN; in dissociated versus 
explanted tail tissue. Error bars display standard deviations from the mean value. 
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Figure 5.23. E10 chick sympathetic ganglia tissue, containing GFP-labelled Kellys that had 
been intravenously injected into the E3 embryos, were dissociated into single cells and 
cultured in vitro for 3 days. A-F, Following 48 hours in culture, 5µM EdU was added to the 
culture medium, then after a further 24 hours, cells were fixed and EdU incorporation 
detected; G-K, Following 3 days in culture, MYCN protein expression was detected by 
means of immunofluorescence. Arrows in I,J,K identify the individual Kelly cells. Scale bars 
50µm. 
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Figure 5.24. E10 chick sympathetic ganglia tissue containing GFP-Kellys (injected 
intravenously at E3) was  explanted; and cultured in vitro for 3 days (A, brightfield; B, 
brightfield and GFP merged image; C, magnification of the GFP-labelled Kellys within the 
dashed box in B, arrows identify processes extending from Kelly cells). The sympathetic 
explants were then whole mount stained to detect EdU incorporation (D, green is anti-GFP 
antibody, red is EdU) and MYCN expression (E, green, GFP Kellys; F, red, lack of MYCN 
stain in Kellys shown in E). Scale bars A-B, 200µm; C, 100µm; D-F, 50µm. G-H, histograms 
to show the proportions of cells G, proliferating; H, expressing MYCN; in dissociated versus 
explanted SG tissue. Error bars show the standard deviations from the mean. 
 
 
  
Chapter Five: Results III 
 
199 
 
5.4. Discussion 
 
5.4.1. Kelly cells within E14 chick tissues 
 
Following the discovery that Kelly cells were showing reduced proliferation rates and MYCN 
downregulation in the sympathetic ganglia at E10, cells were allowed to survive in the chick 
embryos until E14. The distribution of cells was equivalent to that seen at E10, implying a 
lack of apoptosis of the cells between E10 and E14. The morphological data was consistent 
with an increased time spent within the various chick microenvironments. The GFP Kellys in 
the tail and meninges displayed a rounded morphology indistinguishable to that seen at E10, 
but the cell clumps were considerably larger, which was seemingly indicative of a 
proliferating population of cells. Indeed, the EdU incorporation revealed that half of the Kelly 
cells in the tail and meninges had divided in the 24 hours prior to sacrifice; an almost 
identical result to that attained at E10. MYCN immunofluorescence staining showed that the 
Kelly population continued to express this oncogenic protein. Thus once the Kellys had 
located to these two tissues, they appeared to form a somewhat stable population of cells 
that whether studied at E10 or E14, are consistent in appearance, proliferation rates and 
continue to express high levels of MYCN protein. These data are reflective of a tumourigenic 
population of cells. 
 
In contrast, within the SG and ENS Kelly cells extended processes that were often much 
longer than those observed at E10, suggestive of cells proceeding further along the route of 
differentiation. Indeed, some of the cells expressed the neuronal protein GAP43. The 
proliferation data for Kellys in the sympathetic ganglia and gut showed cell division was 
markedly reduced compared to those cells in the tail and meninges, at 22% in the SG and 
28% in the ENS. However surprisingly, proliferation in these two neural tissues was 
considerably higher than it had been between E9 and E10. The reduction in cell division 
observed at E10 may have been a temporary cessation due to cell migration, or permanent 
because of cell differentiation. If the former were true (particularly because Kellys at E10 did 
not stain for markers of differentiation) the relevant increase at E14 could have been down to 
Kellys that had finished migrating and re-entered the cell cycle. However, a lack of 
proliferation in a proportion of cells at E14 will have been permanent because of 
differentiation. The chick cells within both the sympathetic and gut were still clearly 
proliferating, therefore Kelly cell proliferation may well have been in keeping with the 
behaviour of the host environment. In addition, when coupled with the results for MYCN 
staining, an alternative explanation is possible. The single Kelly cells within the sympathetic 
ganglia that were completely surrounded by chick ganglion cells continued to display 
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downregulation of the MYCN protein, but those that were situated within small groups and 
somewhat shielded from the sympathetic ganglia microenvironment did show re-expression 
of MYCN. Therefore the increased fraction of proliferating cells may have been due to a 
proportion of cells upregulating their MYCN expression, resulting in a more aggressively 
dividing phenotype. However it is equally feasible, possibly more likely, that although none of 
the Kellys were expressing MYCN at E10, 15% were dividing, and since there were few 
clusters of cells observed at E10, the appearance of these by E14 suggests the proportion of 
proliferating cells resulted in the formation of small closely-associated groups of cells. It is 
therefore possible that following a reduction in contact with the SG environment, MYCN had 
been re-expressed in the shielded cells. Either way, it seems apparent that particularly at 
E14, there are two populations of cells within the SG. 
 
 
5.4.2. SH-EP injections 
 
The SH-EP experiments were completed in order to make a comparison between the 
MYCN-amplified, highly MYCN-expressing Kellys and the non-MYCN-amplified, non-MYCN-
expressing wildtype SH-EPs, and also between the Kellys and the non-MYCN-amplified, yet 
MYCN-expressing SH-EP-MYCN cells – especially since the MYCN in the latter cells would 
not be able to be downregulated in response to the SG microenvironment. Since the 
wildtype SH-EPs were absent from the E10 embryos, even though large numbers of 
fluorescent cells were seen to be circulating following E3 injection, it was postulated that an 
initial lack of MYCN expression may have somehow prevented the cells’ survival and/or 
ability to extravasate within the chick embryo. This was made more likely considering that 
although SK-N-AS cells were found within E10 tissues (work completed by Dr Anne 
Herrmann, University of Liverpool, UK), they were considerably few in number when 
compared to the MYCN-expressing Kellys and BE(2)Cs. The SH-EP-MYCN cells, the 
majority of which expressed relatively high levels of MYCN were therefore expected to 
behave in a similar way to the Kellys and BE(2)Cs, particularly in terms of location and 
survival, however it would be intriguing to discover how the constitutive MYCN expression 
would affect the cells within the SG, particularly in terms of proliferation and differentiation. 
However, the SH-EP-MYCN cells did not survive within the chick embryos: very few were 
observed at E7, and these had declined to a negligible number by E10. 
 
The decrease in the proportion of cells expressing detectable levels of MYCN observed 
between subcloning of the SH-EP-MYCN cells and staining less than 10 passages later, 
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implies that although expression may be stable, it is definitely variable. The SH-EP-MYCN 
were not the constitutively highly MYCN-expressing line that had been hoped for. 
 
It may be proposed that the apparent reprogramming of neuroblastoma cells by the chick 
embryo microevironment may be restricted to MYCN-amplified and/or highly MYCN-
expressing cells. Particularly when it is considered that the Kelly and BE(2)C cell lines, both 
with high MYCN expression, exhibited good survival within the chick embryos, the SH-EP 
cells with little/no MYCN expression did not survive, and the SK-N-AS cells, with low-
medium levels of MYCN, demonstrated limited (a median level of) survival. Alternatively, the 
lack of SH-EP survival may be a feature of this cell line, or due to an alternate, as yet 
undetermined, cause. To aid in the answering of this question, it would be useful to inject 
non-MYCN-amplified, yet highly MYCN-expressing neuroblastoma cell lines, as well as other 
lines lacking in MYCN expression (invariably non-amplified cells). Video analysis of SK-N-AS 
cells in the hours following intravenous injection has shown that cells grown in hypoxia (1% 
oxygen) extravasate much more quickly than those cultured in 21% oxygen (Dr Anne 
Herrmann, personal communication). It may be the case that lower proportions of cells 
extravasate from the blood system into body tissues in the less aggressive cells (for example 
non-MYCN-amplified lines), leading to considerably fewer in chick tissues when dissected at 
E10. 
 
 
5.4.3. Primary neuroblastoma cell culture 
 
An additional route of interest would be the injection of neuroblastoma cells derived from 
primary tumours. Sample size is small, as neuroblastoma is a rare disease, and only 3-4 
samples are received on average each year from Alder Hey Children’s Hospital. Various 
culture techniques were used, but considerably more efforts need to be made in 
characterising the cells before attempts at in vivo experimentation can begin. Bone marrow 
samples would seem to be the most promising in terms of establishing primary lines 
(Hansford et al. 2007), as the majority of neuroblastoma cell lines originate from bone 
marrow metastases. However, patient bone marrow samples will not always be positive for 
neuroblastoma cells, but this is not known at diagnosis. So for some samples – NB23 being 
one example in which the marrow was subsequently found to be negative for neuroblastoma 
cells – non-malignant cells, maybe haematopoietic stem/progenitor cells, will have been 
cultured and frozen. These may be useful as “normal” human control tissue. 
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Positive staining of neuroblastoma samples with smooth muscle actin antibodies (performed 
by Dr Dhanya Mullassery, University of Liverpool, UK), may suggest that cancer-associated 
myofibroblasts (CAMs) have predominantly been cultured. High proportions of CAMs within 
tumour tissue has been associated with a poor prognosis and increased metastasis in adult 
cancers such as breast and colon (Nakagawa et al. 2004; Yazhou et al. 2004). In 
neuroblastoma, the incidence of CAMs has been associated with Schwannian stroma-poor 
tumours, which generally correlate with a poor clinical outcome, and CAMs may also aid in 
the process of angiogenesis (Zeine et al. 2009). If, following characterisation of the adherent 
cultures, it is discovered that mostly CAMs that have been cultured, it may be useful to mix 
these with neuroblastoma cell lines or neuroblastoma tumour initiating cells (TICs) (received 
from Prof. David Kaplan, University of Toronto, Canada), both in vitro and in vivo, to study 
their (possibly aggressiveness-enhancing) effect. 
 
 
5.4.4. Dissociation versus explant culture 
 
Following the results from Kelly cells within the E14 sympathetic ganglia, where an 
increased proportion showed evidence of proliferation and some had re-expressed MYCN, it 
was necessary to further investigate the importance for the Kelly cells of intimate contact 
with SG microenvironment for maintenance of a less aggressive phenotype. Kelly-containing 
tail tissue was used as a control, and whether dissociated or explanted, almost all of the 
Kelly cells were proliferating and expressing MYCN, regardless of whether they were in 
close contact with the chick tail cells. For the E10 Kelly-containing sympathetic ganglia, in 
which MYCN expression had been downregulated, dissociation of the tissue, i.e. 
reduced/loss of contact between the Kelly cells and the chick SG cells, resulted in increased 
proliferation and a large proportion of the Kellys expressing detectable levels of MYCN 
following 3 days in culture. When the tissue was cultured as explants for 3 days, proliferation 
of the Kellys did increase, albeit to a lesser extent than in the dissociated cells, but this may 
still have been due to chick SG environmental influence, as the chick cells were dividing 
much more than had been recorded in vivo. No MYCN fluorescence was detected in any of 
the Kelly cells within the sympathetic explants. Kelly cell clusters the size of those seen at 
E14 were not observed in the SG explants, therefore all of the cells appeared to have some 
level of contact with the SG microenvironment. It remains unknown whether the sympathetic 
ganglia tissue is sufficient to initiate MYCN downregulation, but it appears that it is required 
for maintenance of this downregulation. A useful in vitro system has been established which 
will henceforth be useful to investigate likely candidate factors responsible for this 
downregulation.
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6.1. The chick embryo intravenous injection model 
 
The chick embryo as a model organism has been invaluable in its contributions to furthering 
scientific knowledge in fields such as developmental biology: via gain- and more recently 
loss-of-function experiments using electroporation (Nakamura et al. 2004); neural crest cell 
fate maps, developed from imaging of labelled cells, allografts of NCCs from an alternate 
level, or grafting of exogenous cells, e.g. the creation of quail-chick chimeras (Burns & Le 
Douarin 2001; Erickson, Tosney & Weston 1980; Ezin, Fraser & Bronner-Fraser 2009); and 
has offered insights into the development of numerous body structures such as the limbs 
(Tickle, Summerbell & Wolpert 1975) and brain (Nico et al. 2001). In addition, the chick has 
had varied applications in the study of disease pathology, particularly tumour cell biology. In 
cancer research, the chick has aided numerous routes of investigation, including the study of 
medulloblastoma dissemination (Cage et al. 2012), glioma cell growth and invasion following 
injection into the brain ventricles (Cretu et al. 2005), and the use of the chorio-allantoic 
membrane (CAM) on which to grow cells from a variety of tumours such as colon carcinoma, 
squamous cell carcinoma and neuroblastoma, and analyse the extent of angiogenesis and 
metastasis (Cimpean, Ribatti & Raica 2008; Mangieri et al. 2009; Ossowski & Reich 1980; 
Stupack et al. 2006; Subauste et al. 2009). In terms of intravenous cell injection, the chick 
embryo has been published as a model for metastasis, following the injection of Lewis lung 
carcinoma cells into the chorio-allantoic vein at E12 (Bobek et al. 2004). However, 
intravenous injection at such an early time point and with the aim of reducing the 
tumourigenicity of neuroblastoma cells, such has been developed in this project, had never 
before been published. 
 
Previous attempts to investigate the influence of an embryonic environment on tumour cells, 
as detailed in Chapter One, had been performed on malignant melanoma cells (Busch et al. 
2008; Busch et al. 2007; Kulesa et al. 2006; Oppitz et al. 2007; Schriek et al. 2005). 
Although remarkable experiments which demonstrated that tumour cells can respond to an 
appropriate embryonic microenvironment and transform their behaviour and phenotype 
accordingly, the localised nature of the injections (into the neural tube or eye cup) meant that 
a relatively small number of cells could be administered (often less than 2000), and of these, 
only a small proportion responded to the environmental cues and migrated away from the 
neural crest. In comparison, the system of intravenous injection of single tumour cells at E3 
developed in this project, allows the introduction of a greater number of cells (≥200,000), and 
although cells were not placed directly into the neural crest migratory pathway, they still 
targeted neural crest-derived tissues. Hence it was an efficient way of getting a much larger 
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number of cells into structures of interest (such as the sympathetic ganglia) for further 
investigation. 
 
 
6.2. Brief overview of results 
 
When injected intravenously at E3, while neural crest cell migration is still underway, MYCN-
amplified neuroblastoma cells appeared to respond to guidance cues along the NC 
pathways and targeted specifically neural crest-derived tissues. Kelly cells integrated into 
neural tissues, i.e. the sympathetic ganglia and enteric nervous system within the gut, and 
showed reduced levels of proliferation compared to those situated within the non-neural tail 
and meninges – this was the case following analysis at both E10 and E14. In addition, 
expression of MYCN was downregulated in the SG – in all Kellys at E10 and in those in all-
round contact with the ganglion cells at E14. This suggestion of a dependence on close 
contact with the SG microenvironment for the downregulation of the MYCN oncoprotein was 
supported by the explants versus dissociation culture experiments. Kelly cells within 
sympathetic ganglion tissue had undetectable levels of MYCN, whereas those that were 
dissociated from the tissue, therefore not in intimate contact with SG cells, often began to re-
express MYCN. It was clear that the SG environment was critical for the maintenance of 
MYCN downregulation, however this was undoubtedly a reversible phenomenon, and it 
could not be determined from the experiments detailed in this project whether the 
sympathetic ganglia alone would be able to initiate this downregulation. 
 
 
6.3. Routes of further investigation 
 
The model established in this project provides opportunity to investigate the mechanism(s) 
by which MYCN is downregulated/controlled – both in normal development and in the Kelly 
cells – and also the consequences of this downregulation in the Kellys. Consequences 
would be expected to include alterations in neuroblastoma cell behaviour (potentially 
proliferation, apoptosis and/or differentiation), and the expression/repression of MYCN target 
genes.  
 
The targeting of the cells is a fascinating observation, and one that may deserve further 
investigation – particularly if it is discovered that the sympathetic ganglion environment alone 
is not sufficient for Kelly cell reprogramming (see section 6.5) and the route of transformation 
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begins immediately upon experiencing the E3 chick embryo. However, if proven that the 
chick SG are sufficient for reprogramming, then regardless of how the Kellys reached their 
targets, what is of prime importance is how and why this reprogramming occurs. The 
elucidation of the potentially multiple signalling factors involved in the loss of MYCN, and 
indeed their signalling pathways may provide new therapeutic targets for neuroblastoma 
treatment. In addition, discovery of whether MYCN is controlled at the transcriptional level 
would lead to an alternative avenue of investigation: attempting to discover whether all 
MYCN-amplified neuroblastomas contain the appropriate regulatory sequences that would 
allow for MYCN transcriptional repression during normal sympathoadrenal development, and 
hence allow for downregulation following exposure to the appropriate factors in the embryo. 
Since the Kelly cells in the SG downregulate their MYCN, it is evident that they must retain 
the regulatory sequences, but it is not known whether this is the case for other cell lines. 
Even more important is to elucidate what these regulatory sequences are. In a clinical 
context, being able to control MYCN expression, particularly in MYCN-amplified tumours, is 
an exciting prospect in terms of novel therapies. 
 
 
6.4. Consequences of MYCN downregulation 
 
Studying the consequences of MYCN downregulation could provide insight into how the cells 
respond to this repression, i.e. whether downregulation of MYCN is the key to controlling 
tumour growth. 
 
MYCN dowregulation has been studied by various groups on neuroblastoma cells in vitro. 
MicroRNAs (miRNAs) have been shown to be able to knock down endogenous MYCN 
protein levels, with the result of inhibition of proliferation and clonogenic growth in Kellys 
(Buechner et al. 2011). Short-hairpin RNA (shRNA) can also knock down MYCN expression 
in cultured MYCN-amplified cell lines following retroviral transmission. As a result of this, 
Kelly and SK-N-BE(2) cells differentiated into neurons, as judged by their morphology and 
staining for neurofilament and GAP43, and cell proliferation is also reduced by preventing 
transition of the cells from G1 to S phase of the cell cycle (Henriksen et al. 2011). The 
reduction of proliferation and induction of neuronal differentiation are both reflected in the 
results gained from the chick embryo injection model established in this project. In addition 
to the phenotypes mentioned above, an increase in apoptosis was observed in MYCN-
amplified cells transfected with MYCN-siRNA (Iraci et al. 2011; Nara et al. 2007). Cells also 
began to express the neurotrophin receptors TrkA and p75, which are associated with a 
good prognosis in neuroblastoma (Nakagawara et al. 1993; Suzuki et al. 1993). 
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It has been demonstrated that MYCN directly represses the expression of TrkA and p75 
when it forms a complex with Miz1 and SP1 and recruits the histone deacetylase HDAC1 to 
deacetylate the chromatin at the genes’ promoter regions. Subsequent knockdown of MYCN 
using siRNA resulted in re-expression of the aforementioned neurotrophin receptors (Iraci et 
al. 2011). In addition, the differentiating agent retinoic acid, which itself has been shown to 
downregulate MYCN expression, also increases the number of TrkA receptors in LA-N-1 
cells (Haskell et al. 1987). The prospect of TrkA and p75 being upregulated in response to 
the MYCN downregulation in the Kelly cells observed in our chick model is an exciting one, 
because of the possible consequences of expression of these proteins. 
 
When neuroblastoma cells expressing high levels of TrkA (low stage and 4S) were grown in 
vitro in medium containing NGF, the result was enhanced survival as well as neuronal 
differentiation, but when these cells were cultured in the absence of NGF, many underwent 
apoptosis (Brodeur et al. 2009). These results were consistent with the behaviour of normal 
sympathetic neurons cultured with or without NGF (Oppenheim 1991). Advanced stage 
tumours with low TrkA expression did not undergo differentiation in response to NGF 
(Nakagawara & Brodeur 1997). However, in contrast, neuroblastoma cells initially lacking 
TrkA and p75 but then induced to re-express the receptors by MYCN knockdown, were 
exposed to NGF and this resulted in mass apoptosis (Iraci et al. 2011). This is supported by 
work in which MYCN-amplified neuroblastoma cells were induced to express TrkA, and this 
induced apoptosis by affecting levels of p53, caspase 3 and Bcl-2 (Lavoie et al. 2005). A 
possible explanation to these opposing behaviours is that the sudden induction of TrkA 
expression and shock of massively increased NGF detection led to the dramatic cellular 
response of apoptosis. An alternate explanation could involve the protein CCM2, as this has 
been shown to mediate TrkA-induced cell death (Harel et al. 2009), so the TrkA-expressing 
neuroblastoma cells that underwent differentiation in response to NGF may have been 
lacking CCM2. Whether the Kellys whose MYCN has been knocked down by the chick 
embryo sympathetic ganglia express CCM2 or not, the possibility of them being induced to 
express TrkA is exciting, as the prospect of them consequently undergoing either 
differentiation (as a small number did by E14) or apoptosis – possibly depending on the 
availability of NGF – are both appealing. 
 
Following on from this project, it would be useful to first establish the response of Kelly cells 
to MYCN downregulation in vitro, which could be achieved by siRNA transfection. 
Expression of TrkA and p75 would be analysed, and in the event of a positive result, 
differentiation and apoptosis would be tested for, with and without the addition of NGF. 
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These data could then be used as a control, against which to compare the behaviour of Kelly 
cells in vivo. Kellys within the SG (whose MYCN has been downregulated) should be tested 
for TrkA and p75 expression at both E10 and E14, and perhaps in the explanted SG pieces 
after 3 days in culture. The next question would be, if the cells do express TrkA, do they 
respond by differentiation or apoptosis? A small proportion of Kellys at E14 have already 
been shown to express the neuronal protein GAP43, but since a wave of apoptosis of 
endogenous sympathetic neurons occurs around the time of hatching, likely in response to 
an abundance of neurotrophins, and for which the low affinity neurotrophin receptor p75 has 
been implicated (Bamji et al. 1998; Huang & Reichardt 2001), the same may occur in the 
Kelly cells expressing TrkA and p75. 
 
As well as affecting the expression of neurotrophin receptors, loss of MYCN may result in a 
reduction of other MYCN targets which had previously contributed to an aggressive 
phenotype. Such genes may include hTERT (involved in cellular immortalisation), proteins 
involved in cell cycle progression such as cyclin D2, CDK4 and SKP2, the p53 inhibitor 
MDM2, Bmi-1 (involved in the self-renewal of cells and contributes to the prevention of 
apoptosis) and ODC1 (involved in polyamine synthesis) (Bell, Lunec & Tweddle 2007; 
Cetinkaya et al. 2007; Huang et al. 2011; Knoepfler, Cheng & Eisenman 2002; Lutz et al. 
1996; Slack et al. 2005) . MYCN knockdown by siRNA in MYCN-amplified IMR-32 and 
BE(2)C cells has indeed been shown to modulate the expression of cell cycle related genes: 
SKP2 levels were reduced, whereas expression of DKK3 (a Wnt antagonist), p53 and 
TP53INP1 (a p53-inducible protein) increased (Bell, Lunec & Tweddle 2007). Another group 
have shown that loss of MYCN as a result of shRNA decreased Bmi-1 expression (Huang et 
al. 2011). 
 
Downregulation of MYCN by antisense RNA constructs has been associated with a 
decrease in the levels of the Multidrug Resistance associated Protein (MRP) – a protein 
correlated with poor clinical outcome in neuroblastoma due to its inferred resistance to 
cytotoxic drugs (Haber et al. 1999; Norris et al. 1996). Therefore a therapeutic agent that 
effectively targeted MYCN would potentially be beneficial if used in conjunction with 
chemotherapeutic drugs. 
 
Although the primary long term aim is to discover precisely what reduces MYCN levels in the 
chick embryo, it is important to assess the response of Kelly cells to a downregulation of 
MYCN, as this may be an indication of how MYCN-amplified primary neuroblastomas would 
respond to MYCN-reducing therapy. 
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6.5. Potential causes of MYCN downregulation 
 
To be able to translate this research into the clinic, it is vital that the factors that prompt 
downregulation of MYCN in neural tissues are elucidated. In order to attempt this, one must 
examine genes upstream of MYCN that potentially control either transcription of the 
oncogene or stabilisation of its mRNA/protein product. Control of MYCN is however 
extremely complicated. 
 
To begin to narrow down the potential regulators of MYCN expression in the chick embryos, 
it would first be helpful to answer the question of whether the SG alone can cause 
downregulation of MYCN. A relatively simple experiment could be performed entailing the 
dissociation of chick sympathetic ganglia into single cells and mixing with a small proportion 
(1-5%) GFP-Kelly cells, before culturing as “hanging drops” (Banerjee & Bhonde 2006) to 
allow close association of the cells. Staining of either frozen sections or whole mount 
staining of the entire resultant spheres with a MYCN antibody (alongside Kellys cultured in 
hanging drops with tail tissue as a positive control) may provide an indication of whether 
sympathetic ganglia alone are sufficient to knock down MYCN expression. If this culture 
system proves successful, the Kellys could be cultured with embryonic adrenal cells to 
discover the effect of these on the neuroblastoma cells’ behaviour. In addition, success with 
this technique would allow for easier analysis of both the consequences and causes of 
MYCN downregulation. In permitting greater numbers of Kelly cells to be “reprogrammed” 
(compared to the relatively few in each sympathetic chain in the chick embryos), qPCR could 
be performed as a more sensitive detection method than immunofluorescence. If, via the 
hanging drop method, MYCN downregulation was discovered to be a direct consequence of 
contact with the SG and/or alternative chick tissues, this would go some way to restricting 
the number of possible instigators of MYCN downregulation. In either case, future 
experiments should test the addition of activators and inhibitors of signalling pathways 
implicated in MYCN expression to identify the key pathways involved in our model system. 
 
 
6.5.1. MYCN gene transcription 
 
During normal embryonic development, MYCN is crucial, particularly for the developing 
nervous system (both CNS and PNS), lung, gut heart, liver and mesonephros. However, 
MYCN expression is completely repressed in almost all adult tissues (Stanton et al. 1992). 
This occurs epigenetically, at the transcriptional level, and this is likely to be the reason 
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behind the decrease in MYCN protein levels observed in Kelly cells within the chick SG. In 
MYCN-amplified neuroblastoma cell lines, induced differentiation results in a reduction of 
MYCN mRNA levels (Thiele, Reynolds & Israel 1985). The results obtained from Kelly cells 
in the E10 chick sympathetic ganglia reflect those obtained from cell lines in vitro, where 
inhibition of MYCN protein expression in MYCN-amplified LA-N-5 neuroblastoma cells 
resulted in reduced proliferation alongside a progression towards cellular differentiation 
(Negroni et al. 1991). In contrast, MYCN overexpression results in increased proliferation 
and cells being unable to differentiate in response to retinoic acid (Peverali et al. 1996), 
which could be considered to recapitulate the effects of the MYCN oncogene in highly 
MYCN-expressing tumours (Nara et al. 2007; Schweigerer et al. 1990). 
 
Although some consideration should be given to proteins involved in activation of MYCN 
gene expression, such as E2F, SP1 and SP3 (Kramps et al. 2004; Strieder & Lutz 2003), in 
the context of this work, and considering that inhibition of a single protein with multiple 
cellular functions is unlikely to have a prolific effect on MYCN, it may be more appropriate to 
consider what may be actively downregulating the oncogene. Factors known to negatively 
modulate MYCN expression include BMPs, retinoic acid (RA), nitric oxide (NO) and 
vasoactive intestinal peptide (VIP), (Alvarez-Rodiguez et al. 2007; Chevrier et al. 2008; Ciani 
et al. 2004; Thiele, Reynolds & Israel 1985), all of which will have been encountered by the 
Kelly cells in the chick embryo. Retinoic acid is already used in neuroblastoma therapy as a 
differentiating agent, which also acts to reduce levels of MYCN in neuroblastoma cell lines 
(Messi et al. 2008; Thiele, Reynolds & Israel 1985). Using the in vitro explants culture 
system optimised in this project, or if successful, the hanging drop co-culture technique, it 
will be possible to investigate the effects on MYCN expression and cell behaviour of 
inhibiting these proteins 
 
Sonic hedgehog (Shh) signalling has been shown to upregulate MYCN expression, with a 
resultant increase in proliferation in cerebellar granule precursors (Kenney, Cole & Rowitch 
2003). BMP2 opposes Shh’s activity by preventing MYCN expression via KLF10, with a 
consequent decrease in proliferation and promotion of differentiation (Alvarez-Rodiguez et 
al. 2007). The Kellys would have been exposed to BMPs released by the dorsal aorta upon 
aggregation in the primary sympathetic ganglia at E3.5 in the chick, but are unlikely to have 
been exposed later in development, therefore MYCN downregulation may have been 
initiated almost immediately upon sympathoadrenal targeting in the embryos. Nevertheless, 
a potential role for BMPs could be tested by the addition of a BMP antagonist such as 
noggin to the in vitro culture systems, to discover whether the subsequent loss of BMPs 
results in MYCN expression being upregulated. 
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Nitric oxide reduces proliferation in multiple cell types, including neuroblastoma, without 
affecting cell viability or apoptosis (Murillo-Carretero et al. 2002). It acts on several signalling 
pathways by activating transcription factors such as NF-κB and AP-1, which has the 
consequence of regulating a wide range of genes (Kroncke 2003). NO has been shown to 
inhibit MYCN expression, in turn reducing proliferation and promoting differentiation (Ciani et 
al. 2004). NO, as a result of its MYCN downregulation, reduces the levels of those ATP 
binding cassette (ABC) drug transporters under transcriptional control of MYCN – key 
proteins involved in chemotherapeutic drug resistance (Porro et al. 2010). It is not clear 
whether NO affects transcription of the MYCN gene, stability of its mRNA, or results in 
degradation of the protein. The neuronal form of nitric oxide synthase (nNOS) may be 
present in the chick SG (Bennett 1994; Domoto et al. 1995; Modin et al. 1994), therefore NO 
can be considered a candidate factor for MYCN downregulation in the Kellys. It would 
therefore be interesting to test nNOS inhibitors such as L-NAME in our in vitro culture 
systems (Kelly-containing sympathetic ganglia explants or hanging drops), to discover 
whether the loss of NO causes re-expression of MYCN. A positive result would go some way 
to confirming that NO is at least partly responsible for MYCN downregulation in the SG. 
 
The sympathetic ganglia consist of both noradrenergic and cholinergic neurons. The former 
are characterised by their expression of tyrosine hydroxylase and dopamine-β-hydroxylase, 
and produce the neurotransmitter noradrenaline. Cholinergic neurons release the 
neuropeptide VIP, which acts as a vasodilator (Fahrenkrug 1989). Cholinergic neurons 
develop from noradrenergic sympathetic neurons which lose expression of TH and DBH. In 
the chick, they begin to express the cholinergic genes ChAT and VAChT from E7, with VIP-
positive cells being detected at E10 (Duong, Geissen & Rohrer 2002). VIP induces 
differentiation of neuroblastoma cells (Pence & Shorter 1990), and also acts to reduce 
MYCN mRNA and therefore protein levels, particularly in MYCN-amplified cell lines 
(Chevrier et al. 2008). This effect is potentiated when added to cells in conjunction with RA, 
following which MYCN target genes SKP2 and TP531NP1 are downregulated (Chevrier et 
al. 2008). VIP inhibition would determine whether this peptide is contributing to maintenance 
of MYCN downregulation of Kellys in the sympathetic ganglia. However, its expression from 
E10 onwards makes it unlikely that VIP is one of the initiators of MYCN downregulation in 
the Kellys, which already have undetectable levels of MYCN when dissected at E10. 
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6.5.2. MYCN mRNA stability 
 
It is also possible that the loss of MYCN observed in Kellys is due to mRNA instability. 
MYCN’s mRNA stability is known to be affected by proteins such as MDM2, p53, p73 and 
HuD, as well as various microRNAs (miRNAs). Stabilisers of MYCN mRNA include MDM2, 
which increases stability in a p53-independent manner, resulting in an increase of protein 
translation and an abundance of MYCN in the cell (Gu et al. 2012). HuD, an RNA-binding 
protein specific to neurons, also stabilises MYCN mRNA, thereby inhibiting its decay 
(Manohar et al. 2002; Ross et al. 1997), and consequently contributing to neuroblastoma 
malignancy. 
 
Overexpression of p53 has been shown to reduce MYCN protein levels, and this is proposed 
to be via destabilisation of the mRNA, which is then directed to the proteosome for 
degradation (Torres et al. 2010). The p53-related protein p73, despite inducing transcription 
of MYCN, also negatively regulates mRNA stability, leading to a reduction in protein levels 
(Horvilleur et al. 2008). 
 
On the opposite strand to MYCN, an antisense gene has been discovered, N-cym, which is 
highly expressed only in MYCN-amplified cell lines, suggesting co-amplification with MYCN. 
The N-cym RNA has the potential to regulate the stability of MYCN mRNA (Scott et al. 
2003). 
 
MicroRNAs are endogenous short non-coding RNA molecules that bind (imperfectly) to 
complimentary nucleotide sequences within mRNA gene transcripts, with the consequence 
of preventing protein translation (Lewis et al. 2003). miR-34a is classed as a tumour 
suppressor, directly targeting, and preventing translation of MYCN. It has been mapped to 
chromosome 1p36, a region commonly deleted particularly in MYCN-amplified 
neuroblastomas, and the loss of miR-34a is likely to contribute to the malignant phenotype 
(Wei et al. 2008). Several other miRNAs have been identified as targeting MYCN, including 
miR-34c, -449, -29a, -29b, -29c, -101, -202 and -let-7e. These all reduce levels of MYCN 
protein when overexpressed in Kelly cells (Buechner et al. 2011). However, it is not known 
whether endogenous levels of any of the above miRNAs are sufficient to downregulate 
levels of MYCN protein, although this may be an interesting area for investigation. 
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6.5.3. MYCN protein stability 
 
MYCN protein degradation as a result of phosphorylation is required for cell cycle exit and 
differentiation in cerebellar granule neuron precursors (Kenney, Widlund & Rowitch 2004). 
MYCN protein stability is directly influenced by glycogen synthase kinase 3 β (GSK3β), and 
indirectly via upstream PI3K/Akt signalling that converges on GSK3β (illustrated in Figure 
1.10). Activation of this pro-survival pathway is associated with a poor prognosis in 
neuroblastoma (Opel et al. 2007). 
 
PI3Ks are a family of lipid kinases that transmit signals from cell surface receptors such as 
Trks and ALK (Gustafson & Weiss 2010). Activating mutations in ALK, for example, may 
result in increased PI3K/Akt signal transduction, and therefore increased aggressiveness of 
neuroblastoma. PI3K phosphorylates PIP2 to PIP3, which allows translocation of both Akt 
and PDK1 to the plasma membrane, following which Akt is activated by phosphorylation at 
two distinct sites, by PDK1 and mTOR complex 2 (mTORC2) (Segerstrom et al. 2011). 
Active Akt then in turn activates mTOR which prevents MYCN S62 dephosphorylation (which 
may have otherwise been followed by ubiquitination and degradation), and Akt also blocks 
GSK3β-induced T58 phosphorylation of MYCN, which results in increased stability and 
transcription of growth-inducing target genes. 
 
The tumour suppressor gene PTEN is able to dephosphorylate PIP3, thereby halting the 
PI3K/Akt/mTOR signalling cascade (Yin & Shen 2008). PTEN deletion may be expected to 
result in vastly increased pro-survival signal transmission, hence propagation of various 
cancers. However deletion of PTEN is rare in neuroblastoma, although inactivation of the 
gene by hypermethylation is much more common (Hoebeeck et al. 2009). Akt 
phosphorylation is associated with decreased survival in neuroblastoma, as well as often 
occurring alongside MYCN amplification (Opel et al. 2007). In addition, it has been shown 
that activated Akt and mTOR are found in neuroblastoma tumours, but not in normal adrenal 
medullas (Johnsen et al. 2008). It would be interesting to examine the activity of proteins 
along this pathway in Kelly cells in culture, compared to those within the E10 sympathetic 
ganglia with reduced levels of MYCN protein. For example, using an antibody that 
exclusively detects the phosphorylated Akt protein (pAkt), one may expect to find increased 
levels in MYCN-expressing Kellys in vitro or in the E10 chick tail, but reduced levels in the 
non-/low-MYCN-expressing cells within the SG. 
 
Control of MYCN protein stability is clearly complex. However, a recent study using PI3K 
inhibitors reported degradation of MYCN protein resulting in “decreased angiogenesis and 
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improved survival” in mice with neuroblastoma (Chanthery et al. 2012). This demonstrates 
the potential of the PI3K/Akt/mTOR pathway as a therapeutic target in neuroblastoma, and 
suggests this may be an area worthy of further investigation. 
 
Although testing the effects of inhibitors of various proteins along these pathways on the 
Kelly+SG in vitro systems, seems an obvious route of investigation, one would have to 
dissect the other pathways converging on these proteins, to ensure no adverse effects on 
fundamental cellular processes that may be assumed to be due to MYCN loss, but in fact 
because of disruption of vital signalling pathways. 
 
 
6.6. Identification of MYCN regulatory DNA sequences 
 
The amplified region of the MYCN gene in Kelly cells must contain the regulatory DNA 
sequences required to downregulate MYCN expression in response to SG environmental 
cues. Recently, MYCN amplicon sizes and positions were assessed in several MYCN-
amplified neuroblastoma cell lines and a number of MYCN-amplified primary tumours 
(Blumrich et al. 2011). Amplicons ranged from 0.1 to 2.8Mb in size: for the Kellys it is roughly 
1Mb (Figure 6.2). Although both the BE(2)C and IMR-32 lines’ amplicons overlap with the 
Kellys’, their overlap with each other’s is only around 47kb. Therefore it would be useful to 
inject both of these cell lines at E3 to discover whether either (or both) responds to the 
sympathetic ganglia microenvironment by downregulation their MYCN expression. It has 
already been shown in this project that the BE(2)C cells target the same tissues and display 
the same morphologies as the Kelly cells at E10. However, cell proliferation and most 
importantly MYCN detection should be carried out on these cells, as well as the IMR-32. The 
results obtained could potentially narrow the specific region(s) of the MYCN amplicon 
required to allow cells to downregulate MYCN in response to factors within the SG 
environment. This region could be narrowed even further with the injection of additional cell 
lines. Injection of multiple cell lines would also be informative as to whether all/most MYCN 
amplicons contain the appropriate regulatory sequences to enable them to respond to 
signals within the embryo and downregulate MYCN. 
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This text box is where the unabridged thesis included the following 
third party copyrighted material: 
 
Blumrich, A., Zapatka, M., Brueckner, L.M., Zheglo, D., Schwab, M. & 
Savelyeva, L. (2011) 'The FRA2C common fragile site maps to the 
borders of MYCN amplicons in neuroblastoma and is associated with 
gross chromosomal rearrangements in different cancers', Human 
Molecular Genetics, vol. 20, no. 8. [Figure 3 B] 
 
 
Figure 6.1. Illustration of MYCN amplicons (blue) in MYCN-amplified neuroblastoma cell 
lines and primary tumours. Chromosomal gains are represented by red bars, chromosomal 
losses by green bars, and no change left blank. Attention is drawn to the Kelly cell line by a 
purple box. Adapted from Blumrich et al. 2011. 
  
 
Potential repressor sequences may be able to be identified using the information gained 
from the experiments detailed immediately above, in conjunction with bioinformatics analysis 
and/or data gained from experiments to determine the cause of MYCN downregulation. A 
reporter gene, for example the dTomato plasmid, could then be inserted into the Kelly 
amplicon, placed under control of the proposed regulatory sequence, and tested by 
intravenous injection at E3 in the hope that in the sympathetic ganglia, tomato fluorescence 
would disappear along with the MYCN, but in the tail, the red fluorescence is still expressed. 
This reporter gene analysis could allow the identification of the appropriate enhancer and 
repressor sequences involved in the control of MYCN expression – in neuroblastoma cells 
and in embryonic development. 
 
 
6.7. Concluding remarks 
 
A new model system has been developed, in which MYCN-amplified neuroblastoma cells 
show neural crest targeting, and once incorporated into the sympathetic ganglia, are 
reprogrammed to a more benign phenotype. Repression of MYCN observed in the SG may 
be process involving multiple steps that also requires signals from the neural crest migratory 
stream, as well as those in the sympathetic ganglia. Factors from the migratory pathway only 
are likely to be inadequate, as MYCN expression is seen in the Kelly cells within the 
meninges and tail. 
 
The ultimate aim is to decipher the mechanism(s) of MYCN downregulation, so that this 
could provide new therapeutic targets to control MYCN expression in MYCN-amplified 
neuroblastomas. The ideal scenario would be the ability to replicate the developmental 
Chapter Six: Discussion 
 
216 
 
signals (still to be identified) in the chick model and persuade aggressively dividing tumour 
cells within patients to differentiate or apoptose without harming healthy tissues in the 
process. This would be a much less destructive treatment than is currently administered with 
cytotoxic drugs. However, any new druggable targets that can be translated into novel 
therapeutic agents would be a welcome discovery, for a disease in which despite intensive 
research, treatment is still failing high risk patients. 
 
(Morales, Barbas & Nieto 2005) 
(Jessen & Mirsky 2005) 
(Caren et al. 2010) 
(Schmidt et al. 2009) 
(Berthold & Simon 2005) 
(Butler & Juurlink 1987) 
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